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ABSTRACT 
Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder during pregnancy, and 
it occurs in 1% of pregnancies in Finland. In recent years, attention has been paid to 
the long-term effects of ICP. However, there is little information on the long-term 
health of women with a history of ICP. ICP has been found to be associated with 
an increased risk of liver, pancreatic and biliary disorders. One study found an 
association between ICP and liver and biliary tree cancer, autoimmune diseases, and 
cardiovascular diseases. In a questionnaire study, women reported higher frequencies 
of hypothyroidism and breast cancer. However, there are no previous studies on 
mortality and causes of death associated with previous ICP. 
To investigate the long-term aspects of ICP, a cohort was collected for a period 
of 20 years. The cohort comprised all ICP pregnancies at Tampere University 
Hospital, Finland, between 1969 and 1988. For every ICP labour, previous and 
subsequent deliveries were obtained to form a control group. Altogether, the cohort 
comprised 571 women with ICP and 1,333 women as a reference. 
The aim was to examine the health of Finnish women with a history of ICP using 
registries. To study the association between ICP and co-morbidity, the cohort’s 
hospital discharge diagnoses were examined. The diagnoses were obtained from the 
Finnish Hospital Discharge Register, and the registry data included in this study 
contain all hospital discharge diagnoses in Finland from 1969 up to the end of 2013 
as well as diagnoses from specialized outpatient care from 1998 to 2013. Women in 
the ICP group were diagnosed more with hypothyroidism and diseases of the 
digestive system, and the risk for hepatobiliary diseases and diseases of the pancreas 
in particular was increased. Arterial diseases were less common in the ICP group 
compared to the control group. Regarding other diseases, there were no differences 
in morbidity between the ICP and control groups. 
The study included all reported cancers between 1953 and 1960 and all registered 
cancers – including the location and malignancy – between 1961 and 2013 for the 
cohort. The data were collected from the Finnish Cancer Registry. No significant 
differences between the ICP and control groups were found. 
To study the association between ICP and mortality and survival, the cohort’s 
deaths and causes of death were accessed for 1971–2015. The data were obtained 
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from Statistics Finland. Women with a history of ICP do not appear to have an 
increased overall mortality. However, deaths from gastrointestinal diseases were 
overrepresented among women with a history of ICP. In terms of survival from 
birth or ICP delivery, no differences were found between the ICP and control 
groups.  
To investigate what kind of guidelines have been given to the physicians who 
treat women with ICP, a literature review was performed. This review was published 
in a Finnish medical journal. 
A postal questionnaire was carried out to study the subjective health of the sons 
of mothers in the ICP group. There were no remarkable differences in terms of 
health between the sons of the ICP group and the sons of the control group. 
This thesis confirms the results of previous studies and also brings new insights 
to the long-term aspects of ICP. Intrahepatic cholestasis of pregnancy seems to be 
associated with gastrointestinal diseases and hypothyroidism. Based on the literature 
and this study, the risk for hepatobiliary diseases and diseases of the pancreas is 
especially increased. It is no doubt a relief for women with a history of ICP that 
based on the registries, no associations were found between ICP and breast cancer. 
Based on this study, the risk for hepatobiliary cancer was not found to be increased 
among women who had experienced ICP. Nevertheless, a gastrointestinal disease 
was more often the cause of death among women with a history of ICP than it was 
among the controls.  
It is commonly noted that autoimmune pathogenesis has a remarkable effect on 
hypothyroidism. There might also be an autoimmune aspect in the pathogenesis of 
ICP. Mutations in gene ABCB4 in ICP and cholelithiasis might be an example of the 
shared risk factors that may influence the pathogenesis of ICP and other diseases of 
the digestive system. 
In primary health care, attention should be paid to certain illnesses when 
encountering women with a history of ICP later in their life. This study does not 
investigate whether women with a history of ICP should be screened for 
gastrointestinal diseases or hypothyroidism. However, it confirms the importance of 
anamnesis in guiding the conclusions of the clinician. 
In the future, even longer follow-up studies are required to study the association 
between ICP and mortality and co-morbidity. New guidelines for clinicians should 
be considered, as there is growing evidence of the long-term effects of ICP. 
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TIIVISTELMÄ 
Raskaushepatoosi on raskauden aikainen sapen salpaus, johon sairastuu noin 1 % 
suomalaisista synnyttäjistä. Siihen liittyy monia sikiön riskejä ja vasta viime vuosina 
on huomiota kiinnitetty raskaushepatoosin pitkäaikaisvaikutuksiin.  
Raskaushepatoosin pitkäaikaisvaikutuksia naisen terveyteen on tutkittu vasta 
hyvin vähän. Raskaushepatoosiin on havaittu liittyvän suurentunut riski maksa-, 
sappi- ja haimasairauksille. Yhdessä tutkimuksessa havaittiin raskaushepatoosin 
sairastaneilla naisilla lisääntynyt riski maksa- ja sappisyövälle sekä autoimmuuni- ja 
sydän- sekä verisuonitaudeille. Suomalaisessa kyselytutkimuksessa raskaus-
hepatoosin sairastaneet naiset ilmoittivat enemmän rintasyöpää ja kilpirauhasen 
vajaatoimintaa kuin verrokit. Raskaushepatoosin sairastaneiden naisten pitkäaikaista 
kuolleisuutta ja kuolinsyitä ei ole aiemmin tutkittu. 
Väitöskirjatyössä tutkitaan raskaushepatoosin pitkäaikaisvaikutuksia 20 vuoden 
ajalta kerätyn tutkimusjoukon avulla. Tutkimusjoukkoon kerättiin kaikki Tampereen 
yliopistollisessa sairaalassa raskaushepatoosin sairastaneet naiset vuosien 1969 ja 
1988 väliltä. Jokaiselle naiselle otettiin verrokki edeltävästä ja seuraavasta synnytyk-
sestä. Siten tutkimusjoukossa oli 571 raskaushepatoosin sairastanutta naista ja 1333 
verrokkia.  
Tutkimuksen tarkoituksena oli tutkia raskaushepatoosin sairastaneiden naisten 
terveyttä rekistereitä käyttäen. Raskaushepatoosin ja sairastavuuden yhteyden tutki-
miseksi tutkimusjoukolta kerättiin tiedot hoitoilmoitusrekisteristä. Tämän rekisterin 
avulla tutkimusjoukolta kerättiin tieto kaikista sairaaloiden hoidonpäättödiagnoo-
seista vuosilta 1969–2013 ja erikoissairaanhoidon poliklinikkakäyntien diagnoosit 
vuosilta 1998–2013. Raskaushepatoosin sairastaneet naiset näyttävät kuitenkin 
sairastavan muuta väestöä enemmän kilpirauhasen vajaatoimintaa ja ruuansula-
tuselinten sairauksia, erityisesti riski maksa- ja sappisairauksille sekä haiman 
sairauksille on suurentunut. Valtimotauteja raskaushepatoosin sairastaneet naiset 
sairastavat vähemmän kuin verrokit. Suurimmassa osassa diagnoosiryhmiä ei 
raskaushepatoosin sairastaneiden ja verrokkien välillä ollut eroa. 
Väitöskirjatyöhön sisältyy kaikki tutkimusjoukon syöpärekisteriin ilmoitetut syö-
vät vuosien 1953 ja 1960 väliltä ja kaikki syövät vuosilta 1961–2013. Todetuista syö-
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vistä selvitettiin sijainti ja pahanlaatuisuus. Merkittäviä eroja syöpäsairastavuudessa ei 
raskaushepatoosin sairastaneiden ja verrokkien välillä havaittu. 
Kuolleisuuden ja elossa olon tutkimiseksi kerättiin tutkimusjoukolta tieto kaikista 
kuolemista Tilastokeskukselta. Kuolinsyyt ja -päivät kerättiin vuosien 1971 ja 2015 
väliltä. Raskaushepatoosin sairastaneilla naisilla ei ole kohonnutta kokonais-
kuolleisuutta verrokkeihin nähden. Kuitenkin ruuansulatuselinsairauksien osuus oli 
kuolinsyissä suurempi raskaushepatoosin sairastaneilla naisilla kuin verrokeilla. 
Elossa olossa ei ryhmien välillä ollut eroa tarkastellen joko iän tai 
raskaushepatoosisynnytyksen suhteen.  
Hoitosuosituksien kartoittamiseksi kirjoitettiin katsaus raskaushepatoosista 
Suomen Lääkärilehteen. Yhtenä väitöskirjan osatyönä suoritettiin postikysely 
raskaushepatoosin sairastaneiden naisten ja verrokkien poikalapsille. Näiden miesten 
terveydessä ei vaikuta olevan eroa. 
Väitöskirjatyö vahvistaa aiempaa tutkimustietoa, mutta tuo myös uusia 
näkökulmia raskaushepatoosin pitkäaikaisvaikutuksiin. Raskaushepatoosi näyttää 
olevan yhteydessä ruuansulatuselinten sairauksiin ja kilpirauhasen vajaatoimintaan. 
Tutkimuksen ja kirjallisuuden perusteella erityisesti riski maksa-, sappi- ja 
haimasairauksille on suurentunut. Raskaushepatoosin sairastaneet naiset kuolevat 
useammin ruuansulatuselinten sairauksiin kuin muu väestö. Tutkimus ei vahvista 
aiempaa havaintoa raskaushepatoosin ja rintasyövän yhteydestä. Tutkimuksessa ei 
havaittu yhteyttä maksa- tai sappiteiden syövälle ja raskaushepatoosille.  
Autoimmuniteetin merkitystä pidetään selvänä kilpirauhasen vajaatoiminnan 
kehittymisessä. Myös raskaushepatoosin kehittymisessä sillä saattaa olla vaikutusta. 
ABCB4-geenin mutaatiot raskaushepatoosissa ja sappikivitaudissa ovat esimerkki 
mahdollisesta jaetusta riskitekijästä, joka voi vaikuttaa sekä raskaushepatoosin että 
muiden ruuansulatuselinten sairauksien riskiin. 
Perusterveydenhuollossa tulee kiinnittää huomiota raskaushepatoosin 
sairastaneeseen naiseen. Erityistä huomiota tarvitaan tutkimuksessa havaittuihin 
lisääntyneisiin riskeihin ja lisäsairastavuuteen naisen myöhemmän elämän aikana. 
Tässä tutkimuksessa ei selvitetty hepatoosin sairastaneiden naisten seulontaa. 
Tutkimus vahvistaa käsitystä anamneesin tärkeydestä ohjaamassa kliinikon 
päätelmiä. 
Tulevaisuudessa vieläkin pidempiä seurantatutkimuksia tarvitaan, jotta voidaan 
vahvistaa raskaushepatoosin ja sairastavuuden sekä kuolleisuuden yhteyksiä. Uusia 
hoitosuosituksia tulisi pohtia, kun lisääntyvästi saadaan tietoa raskaushepatoosin pit-
käaikaisvaikutuksista terveyteen. 
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1 INTRODUCTION 
Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder during pregnancy in 
which bile flow is diminished. It usually manifests during the third trimester of 
gestation. Pruritus, especially on the palms and soles, is the leading symptom. 
Additionally, liver transaminases and/or bile acids are elevated. 
In recent years, there has been a growing interest in the long-term health of 
women who have experienced ICP. Nevertheless, there is a need for reassess the 
findings, as little is known about the mortality or survival of women with a history 
of ICP.  
This study investigates the long-term health women with a history of ICP using 
an objective methodology: registries. In addition, a questionnaire study for the sons 
of such women was carried out to investigate their long-term health. Furthermore, 
knowledge about intrahepatic cholestasis of pregnancy was spread to Finnish 
doctors via a review in a national medical journal. 
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2 REVIEW OF THE LITERATURE 
2.1 Terminology of intrahepatic cholestasis of pregnancy 
In 1883, F. Ahlfeld described intrahepatic cholestasis of pregnancy as recurrent 
jaundice in pregnancy that resolved following delivery (Geenes and Williamson 
2009). In the 1950s, case reports mentioned pruritus with or without jaundice 
completely resolving after delivery and noted high recurrence rates in following 
pregnancies (Svanborg 1954, Thorling 1955). 
 Earlier ICP has been addressed as jaundice in pregnancy, recurrent jaundice in 
pregnancy, idiopathic jaundice of pregnancy, obstetric hepatosis, hepatosis 
gestationalis and obstetric cholestasis (Geenes and Williamson 2009). Nowadays, 
obstetric cholestasis is used to describe ICP. 
2.2 Epidemiology 
The incidence of ICP varies extensively based on ethnicity and geographic location. 
In the 1970s, the overall prevalence was 10% in Chile and as high as 28% among 
Araucanian Indians (Reyes et al. 1978). Thereafter, the prevalence of ICP in Chile 
has decreased to 1.5–4% of all pregnancies (Reyes 2008). In parts of Europe, the 
incidence is 0.1–0.2%, but a higher prevalence has been reported in the Scandinavian 
countries (Lammert et al. 2000, Ozkan et al. 2015). In Finland, the ICP incidence is 
approximately 1.0–1.5% (Ropponen 2006).  
The risk for obstetric cholestasis seems to depend on age and parity. The risk has 
been shown to be three-fold higher in women over 39 years old compared to women 
under 30 years old (Ropponen 2006). Another study found an increased risk for ICP 
among women over 35 years (Heinonen and Kirkinen 1999). By comparison, 
teenage pregnancy was not associated with ICP in a large population-based study 
(Raatikainen et al. 2006). Nulliparous women were found to have an increased 
incidence of ICP, at 1.24%, compared to the incidence of multiparous women, at 
0.80% (Ropponen 2006). Maternal age and parity were consequently found to 
interact with multiple pregnancy to increase the risk for ICP (Ropponen 2006). 
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However, multiple pregnancy has been found to act independently and elevate the 
risk for ICP (Ropponen 2006). The incidence has been found to be nearly 17% in 
the first multiple pregnancy of women over 39 years (Ropponen 2006). Additionally, 
in vitro fertilization seems to increase the risk for ICP nearly four-fold (Koivurova 
et al. 2002), and serum bile acid levels have been found to be higher in IVF than in 
spontaneous pregnancies with ICP (Bolukbas et al. 2017). ICP has been found to 
recur in 40–70% of subsequent pregnancies (Reyes 1997, Hay 2008). 
2.3 Aetiology and pathogenesis 
The aetiology of intrahepatic cholestasis of pregnancy is multifactorial. Aetio-
pathology is influenced by environmental factors, hormonal factors and genetics. 
Estimates are that 10–15% of ICP cases can be explained by known genetic variation 
(Geenes et al. 2016).  
Environmental factors seem to interact in the pathogenesis of cholestasis of 
pregnancy. Selenium deficiency and reduced glutathione peroxidase activity are 
associated with its aetio-pathogenesis (Kauppila et al. 1987, Reyes et al. 2000). This 
may be due to their effects on bile formation and secretion, as bile enzymes need 
selenium to work properly. In winter, the incidence of ICP has been shown to be 
increased (Berg et al. 1986), and women with a history of ICP have been shown to 
have a lower vitamin D status at mid-gestation or delivery compared with controls 
(Dror 2011). A major indicator of foetal distress, meconium staining, is inversely 
correlated with lower 1,25-D3 levels in ICP (Wikström, Shemer and Marschall 2010). 
Two hours after breakfast and supper, greater glucose concentrations in serum 
samples were reported among women with ICP when compared with healthy 
controls (Wojcicka-Jagodzinska et al. 1989).  
Metabolic markers are related in the pathogenesis of obstetric cholestasis. 
Postprandial plasma glucose levels have been found to be higher in women with ICP 
than in controls when using a continuous glucose monitoring system at home 
(Martineau et al. 2015). The same study revealed a 30% incidence of gestational 
diabetes after the ICP diagnosis. The association between ICP and gestational 
diabetes has also been observed before (Baliutaviciene et al. 2011, Martineau et al. 
2014, Wikström Shemer et al. 2013). Elevated serum levels of triglycerides and total 
and LDL cholesterol, as well as a decrease in HDL cholesterol, have been associated 
with the disease (Martineau et al. 2015, Dann et al. 2006, Nikkilä et al. 1996, Johnson 
1973). Lipoprotein lipase expression has been shown to be increased limitedly in 
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maternal plasma, and disturbances in lipid profiles were reported among women 
with ICP (Hao et al. 2016). 
The association between cholestasis of pregnancy and changes in lipid and 
glucose metabolism may be augmented by a decline in the activity of the bile acid 
receptors FXR and TGR5, which are associated with lipid and glucose metabolism 
(Fiorucci et al. 2009, Sharma et al. 2011). A rise in sulphated progesterone 
metabolites is associated with ICP pregnancies (Glantz et al. 2008). The rise includes 
the 3β-sulphated progesterone metabolite epiallopregnanolone sulphate, which has 
been shown to antagonize FXR (Abu-Hayyeh et al. 2013). Gluconeogenesis has been 
shown to be weakened by the bile acid activation of FXR (Ma et al. 2006, Y. Zhang 
et al. 2006, Yamagata et al. 2004) and to induce the insulin-regulated glucose 
transporter GLUT-4 (Shen et al. 2008). Thus, the rise in blood glucose levels 
observed in ICP may be explained by disruption in these homeostatic pathways. 
Glucose and bile acids have been reported to act synergistically to stimulate insulin 
release through FXR-mediated pathways (Renga et al. 2010, Seyer et al. 2013, Dufer 
et al. 2012). TGR5 is promoted by enteric bile acids and results in GLP-1 release and 
the promotion of pancreatic β-cell function (Thomas et al. 2009, Parker et al. 2012, 
Jansen 2010). In the condition, the insulinotropic effect of prandial bile acid release 
might be both directly and indirectly attenuated due to disruption of the 
enterohepatic circulation. Postprandial concentration of GLP-1 has been reported 
to be lower among women with ICP (Martineau et al. 2015). The possibly 
reproductive hormone-related antagonism of FXR is a result of a fall in the levels of 
HDL cholesterol and apolipoprotein A1 in pregnant women with ICP (Dann et al. 
2006). 
The inheritance of ICP is under considerable research. It is assumed to run 
dominantly in an autosomal or X-chromosome-linked fashion (Holzbach et al. 1983, 
Hirvioja and Kivinen 1993). Several genes or their mutations have been proposed to 
be associated with the condition. For Finnish patients, a mutation of chromosome 
region 2p13 is reported to indicate maternal susceptibility (Heinonen et al. 2001). 
The association of canalicular transporter ABCB4 with ICP has been studied. 
Firstly, homozygous mutations of this gene were identified in progressive familial 
intrahepatic cholestasis (de Vree et al. 1998). Secondly, an ICP pedigree with a 
segregating mutation in the absence of progressive familial intrahepatic cholestasis 
was identified (Jacquemin et al. 1999). Thirdly, the first sporadic case of ICP caused 
by a heterozygous mutation was identified (Dixon et al. 2000). Thereafter, several 
studies have investigated the range of mutant alleles in this gene associated with ICP. 
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In recent studies, a vital role for common variation around the ABCB4 and ABCB11 
loci has been noted (Dixon et al. 2014, Anzivino et al. 2013, Dixon et al. 2009).   
Mutations in transporter ABCB11 have been noted to play a role in ICP. Both 
novel and recurrent mutations have been recognized in ICP cohorts (Pauli-Magnus 
et al. 2004). In addition, many other canalicular transporters affect bile formation 
and membrane stability in hepatocytes. ATP8B1 mutations have been suggested to 
play a possible role in some cases (Painter et al. 2005, Müllenbach et al. 2005). In a 
South American cohort, ABCC2 was suggested to affect ICP (Sookoian et al. 2008), 
although the finding could not be replicated in a larger European cohort (Dixon et 
al. 2014). 
The aetiology seems to be related to the cholestatic effect of reproductive 
hormones in genetically sensitive women (Williamson and Geenes 2014). 
Progesterone and oestrogen have been shown to be associated with the pathogenesis 
of ICP. ICP typically manifests in the third trimester of pregnancy when oestrogen 
levels are at their maximum (Ozkan et al. 2015). This finding suggests that oestrogen 
takes part in ICP’s pathogenesis. Higher level of oestrogen is associated with multiple 
pregnancy, and the risk for a multiple pregnancy is 2.5- to five-fold higher with ICP 
(Gonzalez et al. 1989, Turunen et al. 2010). Orally administered progesterone used 
to prevent preterm labour was associated with pruritus or jaundice and elevated 
fasting serum levels of total bile acids (Bacq et al. 1997). This indicates that 
progesterone plays a role in the pathogenesis of obstetric cholestasis. Further 
supporting the hypothesis, some women with a history of ICP have had a recurrence 
of symptoms and biochemical abnormalities with oral contraceptives (Williamson et 
al. 2004). Additionally, the role of prolactin is under study (Bulaeva et al. 2017). 
There have been studies suggesting an association between cholestatic liver 
disease and inflammatory processes (Kosters and Karpen 2010, Allen et al. 2011). 
There has also been a study suggesting that dendritic cells participate in damaging 
maternal-foetal immune tolerance, and this might be associated with the 
differentiation of T helper 17 and regulatory T cells, causing ICP (Kong et al. 2018). 
2.4 Diagnosis 
The diagnosis of intrahepatic cholestasis of pregnancy is based on maternal pruritus 
and raised levels of liver enzymes and/or serum bile acids. To diagnose ICP, other 
possible reasons for pruritus and biochemical abnormalities must be excluded. 
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Pruritus itself is common in pregnancy, as it occurs in nearly one in four pregnancies 
(Kenyon et al. 2010). 
Approximately 80% of ICP cases present after 30 weeks of gestation (Kenyon et 
al. 2002, Geenes et al. 2014). However, the onset of ICP has been reported even at 
8 weeks of gestation (Berg et al. 1986). Thirty-four weeks is suggested to be the cut-
off time for the diagnosis of early-onset ICP (Lin et al. 2017). 
2.4.1 Symptoms 
Pruritus is the key symptom in the diagnosis of ICP. It is presented typically on the 
palms and soles, but it can be generalized (Bacq and Sentilhes 2014, Ozkan et al. 
2015, Williamson and Geenes 2014). In one study, 86% of women with ICP had 
generalized pruritus (Sharma et al. 2016). Many women experience worsening 
symptoms at night, and thereafter sleep is disturbed (Geenes et al. 2016, Ahmed et 
al. 2013). As liver function may deteriorate, pruritus often worsens as the pregnancy 
advances (Geenes et al. 2016). ICP is characterized by the pruritus of otherwise 
healthy skin. However, secondary excoriation marks, pigmented lesions, friction 
blisters and abrasions may be present (Geenes et al. 2016).  
Symptoms of cholestasis may occur. Dark urine, pale stools and right upper 
quadrant pain may be present (Geenes et al. 2016). In addition, steatorrhea, mal-
absorption of fat-soluble vitamins and weight loss may occur (Ahmed et al. 2013). 
However, less than 10% of women with ICP have jaundice (Geenes et al. 2016). 
2.4.2 Biochemical abnormalities 
Normal pregnancy seems to be mildly cholestatic (Castano et al. 2006, Pascual et al. 
2002). Bile acids are toxic, so their homeostasis needs to be strictly regulated (Geenes 
et al. 2016). In clinical practice, it is important to remember that pruritus may precede 
biochemical abnormalities (Kenyon et al. 2001). If the unexplained pruritus 
continues, laboratory markers should be taken repeatedly every one or two weeks. 
Usually, alanine aminotransferase (ALAT) and bile acids are used in the 
diagnostics. It has been suggested that the upper limit of the normal reference range 
for ALAT should be reduced 20% during pregnancy (Girling et al. 1997). During 
ICP, ALAT levels may rise two- to ten-fold (Geenes and Williamson 2009), and it is 
considered a sensitive test for ICP (Bacq et al. 1997). Increase in total bile acids 
(TBA) is a highly sensitive marker of the disease (Heikkinen et al. 1981, Shaw et al. 
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1982, Bacq et al. 1997, Lunzer et al. 1986). The generally accepted upper limit of 
normal TBA in the serum is 10 μmol/L. Some studies also use the limit of ≥6 the 
threshold value of bile acids (Joutsiniemi et al. 2014). TBA may rise to 100 times the 
upper limit of normal (Sjövall and Sjövall 1966, Heikkinen et al. 1981). Taurocholate 
is the main bile acid to increase in ICP (Pataia et al. 2017). 
Other liver function tests may also be used. Glutathione S-transferase alpha 
(GSTA) is reported to be a more sensitive and specific marker of hepatic damage 
than other liver function tests (Knapen et al. 2000, Hayes et al. 1988, Beckett and 
Hayes 1993). GSTA has been reported to rise in cases of ICP, and it has been 
proposed to be used for the early diagnosis of cholestasis of pregnancy (Joutsiniemi 
et al. 2008, Dann et al. 2004). 
Not all liver function tests can be used to diagnose ICP. Alkaline phosphatase 
(AFOS) typically rises during pregnancy (Bacq et al. 1996). The rise is usually of 
placental origin, so AFOS cannot be used for the diagnosis of ICP (Geenes and 
Williamson 2009). Bilirubin is not used for diagnostic purposes because it is at a 
normal level in the majority of ICP cases. If abnormally high levels of bilirubin are 
detected, it is conjugated hyperbilirubinemia (Heikkinen 1983). 
In the future, some new biochemical markers might become useful in the grading 
and early diagnosis of ICP. Increased white blood cell counts, mean platelet volume, 
the platelet-to-lymphocyte ratio and decreased red blood cell distribution have been 
associated with ICP (Yayla Abide et al. 2017). Mean platelet volume was found to 
increase with the severity of ICP, but clinical use for predicting the severity of ICP 
needs further research (Yayla Abide et al. 2017). High red cell distribution width has 
been associated with the incidence of meconium staining in women with ICP (Vural 
Yilmaz et al. 2017). This is a potential novel laboratory test marker, which indicates 
a meconium staining risk in labour. Matrix metalloproteinase-2 and -9 might become 
useful in diagnosing and grading ICP (Chen et al. 2017). 
2.4.3 Differential diagnostics 
Other reasons for cholestasis should be sought out. The most important ones are 
hepatitis and cholelithiasis. In patients who have a high increase in ALAT levels, 
current viral hepatitis should be ruled out (Bacq et al. 1997). The incidence of 
cholelithiasis is suggested to be 0.5–2% among pregnant women (Ko et al. 2005, Ko 
2006), and pregnancy is considered a risk factor for it (Jorge et al. 2015).  
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Other diseases may cause an increase in liver function tests, but the following 
diseases do not typically cause pruritus. Pre-eclampsia and acute fatty liver of 
pregnancy may rarely be associated with ICP, as they all occur during the last 
trimester of pregnancy (Bacq 2011). Additionally, hyperemesis gravidarum may 
result in an abnormal liver function test, but this normalizes as the pregnancy 
continues (Williamson and Geenes 2014). 
Moreover, cytomegalovirus, Epstein–Barr infection and drug-induced liver injury 
may cause challenges in differential diagnostics (Bacq and Sentilhes 2014, Royal 
College of Obstetricians & Gynaecologists 2011). Cholestasis can also be caused by 
a urinary tract infection, and it may associate with ICP (Bacq and Sentilhes 2014). 
During pregnancy, existing chronic liver disease may worsen (Bacq and Sentilhes 
2014) and be unmasked (Pataia et al. 2017). Examples of this include primary biliary 
cirrhosis and primary sclerosing cholangitis (Williamson and Geenes 2014). 
There are pregnancy-specific causes of pruritus. One similar presentation of 
pruritus other than ICP is pruritus gravidarum, although there are no biochemical 
abnormalities (Williamson and Geenes 2014). Furthermore, pruritus may be caused 
by atopic eruption of pregnancy, polymorphic eruption of pregnancy or pemphigoid 
gestationis (Williamson and Geenes 2014). Prurigo of pregnancy and pruritic 
folliculitis of pregnancy are also possible causes of pruritus (Williamson and Geenes 
2014). 
2.5 Risks of ICP for the mother and foetus at the time of 
delivery 
In a recent study, maternal deaths were investigated during hepatic dysfunction in 
pregnancy. In the study, there were no maternal deaths after delivery (Suresh et al. 
2017). Postpartum blood loss was no different compared to controls in the women 
with ICP who were treated with ursodeoxycholic acid (UDCA) and women who had 
a planned delivery (Furrer et al. 2016).  
In a meta-analysis, elevated maternal bile acids were significantly associated with 
increased risks of overall adverse perinatal outcomes, preterm birth, meconium-
stained amniotic fluid, asphyxia or respiratory distress syndrome (Cui et al. 2017). 
ICP has been linked to 2–4% of foetal deaths (Fisk and Storey 1988, Alsulyman et 
al. 1996), although not all studies confirm such a high foetal mortality (Turunen et 
al. 2010, Sharma et al. 2016, Wikström Shemer et al. 2013). 
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Maternal serum bile acid levels could be used as a predictor for the risk of adverse 
perinatal outcomes (Cui et al. 2017). When maternal bile acid concentrations are ≥40 
μmol/l, the risk for adverse foetal outcome has been found to be increased (Geenes 
et al. 2014, Glantz et al. 2004). Recently, the increased risk of stillbirth was shown to 
be higher in singleton ICP pregnancies at bile acids concentrations ≥100 μmol/l. 
The risk of stillbirth in ICP pregnancies with bile acids <100 μmol/l seems to be 
similar to the risk of the general population (Ovadia et al. 2019). The risks for the 
foetus seem to be caused by increased bile acids in the foetus. Normally in 
pregnancy, the bile acid (BA) gradient ensures that BAs are transported from the 
foetus to the mother. In intrahepatic cholestasis of pregnancy, the gradient has been 
shown to be reversed (Geenes et al. 2014). 
The underlying mechanisms of foetal complications are not fully known. High 
BA levels seem to have a harmful effect on cardiomyocytes, causing arrhythmia 
(Gorelik et al. 2004, Gorelik et al. 2002, Williamson et al. 2001). The increased 
incidence in stillbirths could possibly be explained by this phenomenon if these 
potentially lethal arrhythmias also occur in the foetus. Regarding adult 
electrocardiographs, the PR interval is reported to be a potential marker of 
arrhythmia development, such as atrial fibrillation, heart block and tachyarrhythmias 
(Schnabel et al. 2009, Simpson et al. 1982). During the second and third trimester, 
foetal supraventricular tachycardia and atrial fibrillation has been shown to occur in 
ICP (Shand et al. 2008, Al Inizi et al. 2006). The foetuses of mothers with ICP have 
been reported to have a higher PR interval (Strehlow et al. 2010), which might be 
linked to foetal arrhythmias. 
Placental chorionic veins are reported to be influenced by the vasoconstrictive 
effect of bile acids (Sepulveda et al. 1991), which may explain foetal distress, asphyxia 
and mortality. Additionally, oxytocin receptor expression and sensitivity in the 
human myometrium is reported to increase because of BA (Germain et al. 2003, 
Israel et al. 1986). This may be the mechanism of spontaneous preterm delivery in 
ICP. Maternal cholestasis may also have an impact on neonatal lung surfactant and 
cause atelectasis for the foetus in women with ICP affected by a genetic mutation 
(Zhang et al. 2015). 
Studies investigating the association between foetus size and intrahepatic 
cholestasis of pregnancy have been performed. An association between the incidence 
of infants being large for gestational age (LGA) and ICP was found even after 
excluding women with gestational diabetes (Wikström Shemer et al. 2013). 
Independently of glucose levels, elevated serum triglycerides have been suggested to 
promote foetal growth (Herrera and Ortega-Senovilla 2010), which gives a possible 
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explanation for the increase in foetal growth in ICP. On the contrary, a meta-analysis 
found ICP to be associated with a lower birth weight compared to controls (Li et al. 
2017). Compared to controls, the risk for a lower infant birth weight in mothers with 
ICP was increased in a Finnish study (Turunen et al. 2010). 
The onset of cholestasis of pregnancy is linked to pregnancy outcome. Early-
onset ICP is associated with a higher incidence of preterm labour, foetal distress and 
foetal low birth weight compared to late-onset ICP (Lin et al. 2017, Li et al. 2017, 
Estiu et al. 2017). Women with ICP and dichorionic diamniotic twin pregnancies 
have been associated with adverse perinatal outcomes when the onset is before 30 
weeks of gestation, TBA is >40 μml/l, aspartate aminotransferase (ASAT) is >200 
U/l and AFOS is >400 U/l (Mei et al. 2017). 
2.6 Management and treatment of ICP 
2.6.1 Management and care of pregnancy 
When a suspicion of intrahepatic cholestasis of pregnancy arises, the pregnant 
mother is referred to an obstetric clinic. The management and follow-up are 
individual and based on case series and/or consensus. It is recommended that liver 
function tests are measured weekly during pregnancy (Royal College of Obstetricians 
& Gynaecologists 2011). Cardiotocography and ultrasound are monitored according 
to individual assessment. 
2.6.2 Medication 
2.6.2.1 Ursodeoxycholic acid 
Ursodeoxycholic acid (UDCA) is the most common treatment for ICP (Pataia et al. 
2017). It can be considered the first-line treatment (Bacq et al. 2017). UDCA is 
considered a safe treatment during pregnancy (Parizek et al. 2016). The treatment is 
quite well tolerated, and the most common side effects are nausea, vomiting and 
loose stools (Chappell et al. 2012).  
UDCA is a relatively hydrophilic bile acid, and it comprises 1–3% of human BAs 
(Pataia et al. 2017). The mechanism of UDCA treatment is suggested to have three 
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main aspects. Firstly, it stimulates BA transporter synthesis, targeting and insertion 
into the hepatocyte membrane, and thus promotes BA secretion from the 
hepatocytes. Secondly, UDCA prevents the apoptotic effects of more hydrophobic 
BAs on mitochondria. Thirdly, it affects micelle formation, buffers BA toxicity and 
decreases bile hydrophobicity (Beuers 2006).  
UDCA has been reported to ameliorate pruritus (Glantz et al. 2008). The relief 
of the symptoms was not correlated with a reduction in serum bile acid levels, but 
with changes in decreased progesterone disulphate excretion in the urine (Glantz et 
al. 2008). According to a meta-analysis that compared UDCA to placebo, UDCA 
was reported to improve pruritus and liver function tests and reduce bile acid levels 
(Kong et al. 2016). A double-blind randomized placebo-controlled trial was recently 
published that is five times larger than the largest previous trial. UDCA had no 
clinically meaningful effect on maternal itching symptoms nor did it reduce bile acid 
levels (Chappell et al. 2019).  
UDCA is shown partially to reverse the GLP-1 deficit (Martineau et al. 2015). 
After initiation of UDCA therapy, increased GLP-1 release and a decrease in plasma 
glucose levels have been reported (Murakami et al. 2013).  
The evidence suggests that the effect of foetal well-being is aggregative. An in 
vitro rat model involving UDCA found the treatment to have a protective 
antiarrhythmic role for the foetal heart (Miragoli et al. 2011). Additionally, an in vitro 
model of the human foetal heart showed the protective effect of UDCA via a 
reduction in fibroblast differentiation into myofibroblasts and the hyperpolarization 
of myofibroblasts (Schultz et al. 2016). In addition, UDCA restores T-type calcium 
in the foetuses of mothers with ICP and prevents ventricular conduction slowing 
and arrhythmia (Adeyemi et al. 2017). UDCA has been reported to protect neonatal 
rat cardiomyocytes from the arrhythmogenic effects of bile acid taurocholate 
(Gorelik et al. 2003). Studies report UDCA reducing bile acids in amniotic fluid and 
colostrum (Brites et al. 1997, Brites and Rodrigues 1998, Brites et al. 1998) and 
improving placental morphology and function (Serrano et al. 1998, Geenes et al. 
2011). 
A recent large double-blind randomized placebo-controlled trial showed that 
UDCA does not reduce adverse perinatal outcomes (Chappell et al. 2019). As there 
is new evidence of UDCA’s effect on maternal and perinatal outcomes, the treatment 
should be carefully reconsidered. 
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2.6.2.2 Other treatments 
UDCA is the most commonly used treatment for ICP, but not all women respond 
to it. The second-line treatment is rifampicin, which is an antibiotic with cholestatic 
properties. It can ameliorate pruritus and lower serum BA, especially when combined 
with UDCA (Geenes et al. 2015).  
Cholestyramine is an anion exchange resin. One study suggests that it is effective 
in ameliorating pruritus, but biochemical abnormalities do not improve 
(Kondrackiene et al. 2005). It may affect intestinal absorption of UDCA or fat-
soluble vitamins, and thereafter raise the risk of intrapartum or postpartum 
haemorrhage (Williamson and Geenes 2014). Thus, cholestyramine is not a first-line 
treatment.  
In a meta-analysis, UDCA decreased pruritus, TBA, ALAT levels and preterm 
delivery more effectively than S-adenosylmethionine (SAMe) (Zhang et al. 2016). 
SAMe is not recommended as a treatment because there is no evidence of it 
controlling maternal symptoms or improving foetal outcome (Royal College of 
Obstetricians & Gynaecologists 2011). SAMe should be given twice a day 
intravenously, which also makes it a less attractive treatment (Williamson and Geenes 
2014). 
Dexamethasone has been reported to have a beneficial effect (Hirvioja et al. 
1992). With a small study population, Asian and South American women in 
particular were more likely to respond to the treatment compared to Caucasians 
(Diac et al. 2006). In a randomized controlled trial, ursodeoxycholic acid was more 
effective in improving biochemical abnormalities and symptoms compared to 
dexamethasone (Glantz et al. 2005). Based on a rodent study, dexamethasone may 
have an antiarrhytmogenic effect (Gorelik et al. 2003). Nevertheless, dexamethasone 
treatment has been associated with lower birth weight (Bloom et al. 2001). Repeated 
antenatal glucocorticoid treatment is also associated with measurable differences in 
brain maturation (Modi et al. 2001). Due to these side-effects, dexamethasone is not 
recommended as a first-line treatment for cholestasis of pregnancy.  
Antihistamines may be used to reduce the sensation of pruritus, although they do 
not influence biochemical abnormalities (Williamson and Geenes 2014). This 
treatment may help insomnia in addition to the itching by causing drowsiness 
(Williamson and Geenes 2014).   
Some clinicians recommend women with ICP use vitamin K. The 
recommendation is more based on physiological than evidence-based reasons (Royal 
College of Obstetricians & Gynaecologists 2011). However, because of the risk for 
 25 
neonatal haemolytic anaemia, hyperbilirubinemia and kernicterus (British Medical 
Association, Pharmaceutical Society of Great Britain 2010) the usage of vitamin K 
is recommended only after individual assessment.   
Treatment of cholestasis of pregnancy is under continuous research. In a recent 
study, epigallocatechin-3-gallate was shown to improve ICP symptoms by inhibiting 
matrix metalloproteinase-2 and matrix metalloproteinase-9 (Zhang and Xu 2017). 
Likewise, a case report suggested a possible role of metformin in the management 
of ICP (Elfituri et al. 2016). 
Additionally, a low-fat diet and menthol may be used to relieve pruritus (Royal 
College of Obstetricians & Gynaecologists 2011). 
2.6.3 Timing and management of delivery 
It is widely accepted that cholestasis of pregnancy is associated with unpredictable 
stillbirths that occur after 37 weeks (Williamson et al. 2004). The fear of stillbirth is 
the main reason for iatrogenic preterm delivery. Preterm delivery may also have 
adverse effects, so the timing of the delivery must be balanced with the foetus’ risk 
from ICP. The timing of the delivery should be evaluated individually (Henderson 
et al. 2014). It has been suggested that gestation should be prolonged up to 37 weeks 
before selecting iatrogenic birth (Lin et al. 2017). Compared to controls, women with 
ICP have been found to have a seven-fold risk of delivery at less than 37 weeks of 
pregnancy (Turunen et al. 2010). In a review, no evidence was found to support the 
active management of ICP (Henderson et al. 2014). 
The induction of labour has been reported to be more common among women 
with ICP than among controls (Wikström Shemer et al. 2013, Turunen et al. 2010). 
Moreover, spontaneous and iatrogenic preterm labour have been shown to more 
likely occur in ICP pregnancies than in control pregnancies (Wikström Shemer et al. 
2013). 
2.6.4 Pregnancy outcome 
There is controversial evidence on the risk of stillbirths. Early reports have been 
interpreted to suggest that ICP is associated with an increased risk of stillbirth 
(Laatikainen and Ikonen 1975, Fisk and Storey 1988). Nevertheless, an increased risk 
of stillbirth was not reported in a large population-based Swedish study (Wikström 
Shemer et al. 2013). Furthermore, a Finnish cohort study did not find an association 
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between stillbirths and ICP (Turunen et al. 2010). The low rate of stillbirths is 
sometimes explained by the active management of ICP, although there are some 
critical views on the matter. In one review, stillbirth rates in early reports were found 
to be similar to the respective national stillbirth rate in those countries where the 
studies were performed (Henderson et al. 2014). Nowadays, the prevalence of 
stillbirths is 1–2%, and this may be due to the induction and active management of 
labour, not because of ICP (Bacq and Sentilhes 2014, Lee et al. 2008, Bacq et al. 
2012). 
Preterm delivery may be iatrogenic or spontaneous in ICP pregnancies. Preterm 
delivery causes adverse effects on the newborn. In addition, meconium staining of 
the amniotic fluid and foetal hypoxia has been connected to intrahepatic cholestasis 
of pregnancy (Geenes et al. 2014). Meconium staining correlates with the severity of 
the ICP (Glantz et al. 2004, Lee et al. 2008). In the Finnish population at least, ICP 
is not associated with low Apgar scores (Turunen et al. 2010). 
2.6.5 Postpartum follow-up 
Some international publications suggest that liver function tests should be performed 
after delivery (Bacq and Sentilhes 2014, Wikström Shemer et al. 2015). It has been 
the case in Finland that if the clinical picture is clear and symptoms resolve after 
delivery, liver function tests are not routinely checked. 
2.6.6 The path in the Finnish maternity health care system 
In Finland, the pregnant woman is referred to an obstetrician if there is a suspicion 
of intrahepatic cholestasis of pregnancy in primary care. After delivery, there is no 
routine check-up if the woman feels well and the symptoms resolve. 
2.7 Long-term aspects of intrahepatic cholestasis of pregnancy 
2.7.1 Health behaviour 
Only a few studies have examined health behaviour after intrahepatic cholestasis of 
pregnancy. Women with a history of ICP reported smoking less frequently compared 
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to controls. They also reported maintaining a gallbladder diet more often compared 
to controls (Turunen et al. 2013a). 
Oral contraceptives and hormone replacement therapy can be used safely by 
women with a history of ICP. Nevertheless, women should be informed about the 
possibility of pruritus. It is recommended that liver tests are carried out three and six 
months after initiating hormonal contraceptives (Bacq and Sentilhes 2014) because 
the history of ICP may predict an increased risk of developing cholestasis, especially 
with combined contraceptives (World Health Organization 2015). Progestogen-only 
contraceptives can be used safely (World Health Organization 2015). Nevertheless, 
women with a history of ICP have reported using oral contraceptives less commonly 
and they reported limiting their number of children for health reasons more often 
compared to controls (Mölsä et al. 2012). 
 Among women with a history of ICP, oral or transdermal hormone therapy does 
not seem to affect the levels of bile acids or liver transaminases (Tuomikoski et al. 
2008, Ropponen et al. 2005). In a questionnaire study, women with a history of ICP 
reported the same amount of hormone replacement therapy compared to the 
reference group (Turunen et al. 2013b). 
2.7.2 Heredity 
ICP is reported to be hereditary in 16% of cases (Savander et al. 2003). First-degree 
relatives seem to have a 6% risk of ICP delivery (Eloranta et al. 2001). Moreover, 
the first-degree relatives’ risk for liver dysfunction during pregnancy has been shown 
to be five-fold (Eloranta et al. 2001). Compared to controls, the risk of women with 
a history of ICP having mothers who also had ICP is nine-fold, and the risk is five-
fold for both sisters and daughters (Turunen et al. 2013c). In familial cases, the 
recurrence of ICP is reported to be 92% (Savander et al. 2003). 
2.7.3 Morbidity 
Co-morbidity with cholestasis of pregnancy has been under research in recent years, 
although there are only a few studies concerning this topic; they are introduced 
below. Higher rates of gestational diabetes and pre-eclampsia are associated with 
ICP (Wikström Shemer et al. 2013, Marathe et al. 2017, Martineau et al. 2014). On 
the other hand, previous gestational diabetes is associated with an increased risk of 
type 2 diabetes, hypertension and ischemic heart disease (Daly et al. 2018). In 
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addition, an increased risk of cardiovascular diseases is associated with pre-eclampsia 
(Brown et al. 2013). Perhaps due to combined morbidity or because of a separate 
pathway, a small increased risk of later cardiovascular disease has been found 
(Wikström Shemer et al. 2015). P-wave duration and P-wave dispersion in 
electrocardiographs were shown to be lower in women with ICP, so they can be used 
to screen for women with an increased cardiovascular risk in order to target lifestyle 
counselling (Biberoglu et al. 2015). However, women with a history of ICP have 
reported less diagnosed hypertension or high cholesterol requiring medication as 
well as less cardiac arrhythmia compared to controls (Turunen et al. 2012), which 
does not confirm the increased risk of cardiovascular diseases among women with a 
history of ICP. 
Alcohol consumption might affect morbidity and mortality. However, based on 
a questionnaire study, alcohol consumption was not remarkably different in mothers 
with a history of ICP compared to controls (Turunen et al. 2013a). Alcoholic 
cirrhosis has been noted to be less likely diagnosed in women with a history of ICP 
than in controls (Marschall et al. 2013). Nevertheless, women with a history of ICP 
have been shown to have an increased risk for liver fibrosis and cirrhosis (Marschall 
et al. 2013, Ropponen et al. 2006). Additionally, the risk for non-alcoholic 
pancreatitis has been reported to be increased among women with a history of ICP 
(Ropponen et al. 2006).  
ICP has been associated with hepatitis C (Locatelli et al. 1999, Paternoster et al. 
2002) before and after experiencing ICP (Marschall et al. 2013). Therefore, hepatitis 
serology testing is recommended for the diagnosis of ICP (Bacq and Sentilhes 2014). 
Pregnant women who have ICP and hepatitis C seem to have a higher hepatitis C 
viral load than those who do not have ICP (Belay et al. 2015).  
The first studies to report the association between ICP and a higher frequency of 
gallstones were published in the late 1990s (Glasinovic et al. 1996). A shared risk 
factor, mutations in the ABCB4 gene, may explain the positive association between 
ICP and hepatobiliary diseases (Jacquemin et al. 1999, Marschall et al. 2010, 
Wasmuth et al. 2007). The risk for cholelithiasis and cholecystitis has been reported 
to be three-fold among women who have experienced ICP compared to the controls 
(Ropponen et al. 2006, Marschall et al. 2013). Hepatobiliary disorders were more 
often reported by women with a history of ICP than by controls (Turunen et al. 
2012).   
One population-based study has been conducted to investigate the association 
between ICP and autoimmune diseases. These autoimmune diseases – such as 
diabetes mellitus, thyroid disease, psoriasis, inflammatory polyarthropathies, and 
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Crohn’s disease – were found to be more common among ICP patients than among 
the controls (Wikström Shemer et al. 2015). Previously, women with a history of ICP 
have reported more hypothyroidism compared to controls (Turunen et al. 2012).  
In a questionnaire, women with a history of ICP reported more breast cancer 
compared to the reference group (Turunen et al. 2012). In a registry-based study, 
this association could not be confirmed (Wikström Shemer et al. 2015). Instead, an 
association between ICP and liver and biliary tree cancer was found (Wikström 
Shemer et al. 2015). 
2.7.4 Mortality 
After delivery, the risk of death is low among women with ICP (Suresh et al. 2017). 
Nevertheless, there are no studies investigating long-term mortality among women 
with a history of intrahepatic cholestasis of pregnancy. 
2.7.5 Health of the offspring after ICP   
It is well accepted that there are consequences of programming. Permanent or 
harmful effects on the structure, physiology or metabolism of the offspring may be 
caused by a stimulus or insult at a sensitive period of early life (Gluckman et al. 2009).  
Only a few studies have been conducted concerning the health of the children of 
women with ICP. It has been reported that the 16-year-old offspring of mothers 
with a history of ICP have altered lipid profiles. In this study, the males had an 
increased BMI and the females increased waist and hip girth compared to controls 
(Papacleovoulou et al. 2013). In a questionnaire study, daughters of women with a 
history of ICP reported more epilepsy than the reference group, but generally the 
mother’s ICP does not seem to have an effect on the health of the daughter (Vimpeli 
et al. 2013). 
2.8 Summary of literature 
Intrahepatic cholestasis of pregnancy is a pregnancy-related liver disorder 
characterized by pruritus on the soles and palms. In Finland, it manifests in 
approximately 1% of pregnancies. ICP typically occurs after 30 gestational weeks. 
 30 
For the diagnosis of ICP, pruritus and a rise in liver function parameters, typically 
ALAT and/or bile acids, is required. 
The aetiology and pathogenesis of ICP is complex. Genetic factors are 
undoubtably associated with ICP. Mutations in canalicular transporter ABCB4 in 
particular have been found. In addition to genetic susceptibility, the hormonal 
component during pregnancy and environmental factors have also been suggested. 
The risk of ICP has been shown to be increased among first-degree relatives. 
An increased risk of adverse pregnancy outcomes is associated with obstetric 
cholestasis. When maternal bile acid concentrations are ≥40 μmol/l, the risk for 
adverse foetal outcome has been shown to increase. Stillbirths are feared, but recent 
studies do not support a link between ICP and increased rates of stillbirth. The most 
common treatment for cholestasis of pregnancy is ursodeoxycholic acid, but the 
benefits of the treatment are controversial and deficient. 
 Only a few studies concerning the long-term aspects of ICP have been published. 
Higher rates of gestational diabetes and pre-eclampsia are associated with ICP. 
Additionally, a small increased risk of later cardiovascular disease has been found. 
Nevertheless, women with a history of ICP have reported less diagnosed 
hypertension or high cholesterol requiring medication as well as less cardiac 
arrhythmia compared to controls.  
Women with a history of ICP have been found to have an increased risk for some 
gastrointestinal diseases. An increased risk for liver fibrosis and cirrhosis has been 
found to be linked to ICP. Additionally, the risk for non-alcoholic pancreatitis has 
been found to be increased among women with a history of ICP. Intrahepatic 
cholestasis of pregnancy has been associated with hepatitis C before and after 
experiencing ICP. Therefore, hepatitis serology testing is recommended for the 
diagnosis of ICP.  
An increased risk for autoimmune diseases has been linked to ICP. One 
questionnaire study and one registry-based study have studied the association of ICP 
with cancers. In the questionnaire, women with a history of ICP announced more 
breast cancer compared to the reference group. This association was not confirmed 
in the registry-based study. Instead, an association between ICP and liver and biliary 
tree cancer was found. 
There are no studies investigating long-term mortality among women with a 
history of intrahepatic cholestasis of pregnancy. Moreover, little is known about the 
health of the offspring of mothers with a history of ICP. It has been reported that 
the 16-year-old offspring of mothers with a history of ICP have altered lipid profiles. 
In a questionnaire study, the daughters of mothers with a history of ICP reported 
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more epilepsy than the reference group, but generally the mother’s ICP does not 
seem to affect the health of the daughter. 
As ICP is the most common liver disease during pregnancy, it is important to 
study the long-term effects of the disease. There are only a few studies concerning 
women’s health after an ICP pregnancy, so there is a need to investigate this 
phenomenon. 
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3 AIMS OF THE STUDY 
The aims of the study were: 
1. to investigate what kind of guidelines have been given to the physicians 
who treat women with ICP; 
2. to obtain information about the co-morbidity of women with a history 
of ICP; 
3. to study whether there is an association between the occurrence of 
cancers and a history of ICP; 
4. to explore the survival of women with ICP from their birth and from 
their ICP delivery; 
5. to investigate the underlying causes of death among women with a 
history of ICP; 
6. to investigate the health of the sons of women with a history of ICP.  
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4 MATERIAL AND METHODS 
4.1 Study design 
A long follow-up time is required to investigate the association between a disease 
suffered during pregnancy and co-morbidity, mortality and survival from birth and 
from ICP delivery later in life. Consequently, a study population was obtained for a 
20-year period from Tampere University Hospital (TUH). The hospital discharge 
register contains diagnostic codes (ICD-8 for 1969–1986 and ICD-9 for 1987–1988), 
so the data were appropriate for the study. 
To explore the association between cancer morbidity and ICP, all diagnosed 
cancers were obtained from the Finnish Cancer Registry. The study included all 
reported cancers in the cohort for 1953–1960, all registered cancers for 1961–2013, 
and the location and malignancy of the cancer. 
To study the association between ICP and mortality and survival, causes of death 
were obtained from Statistics Finland. The cohort’s causes and dates of death were 
obtained for 1971–2015. 
In addition, to study the association between ICP and co-morbidity, the cohort’s 
hospital discharge diagnoses were accessed. The diagnoses were obtained from the 
Finnish Hospital Discharge Register (FHDR), which contains every hospital 
discharge diagnosis in Finland. The data gathered for this study included all hospital 
discharge diagnoses from 1969 up to the end of 2013 as well as diagnoses from 
specialized outpatient care for 1998–2013. The diagnoses were extrapolated to ICD-
10 as in a previous Swedish study (Wikström Shemer et al. 2015). More accurate 
analyses were made with diagnosis codes that had not been used in previous ICP 
studies. If the code in ICD-8 or -9 was less accurate than in ICD-10, the diagnostic 
classification was made by the superior code heading. The possibility of misdiagnosis 
can be considered low. 
To increase Finnish doctors’ knowledge about ICP, a review of the literature and 
a search of PubMed and Scopus was performed. In addition, a questionnaire was 
conducted to study the subjective health of the sons of mothers with a history of 
ICP. 
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The study was approved by the Regional Ethics Committee of Tampere 
University Hospital (R02149), the National Institute for Health and Welfare in 
Finland (THL/1051/5.05.00/2014) and Statistics Finland (TK53-740-15). 
4.2 Study population 
All ICP pregnancies at TUH from 1969 to 1988 were collected from the patient 
records. ICD-8 was used at TUH from 1969 to 1986. Because ICD-8 did not include 
a precise code for ICP, all the obstetric codes that might contain ICP were checked: 
637.9 Toxicosis NUD, 639.00 Pruritus, 639.01 Icterus gravis, 639.09 Necrosis acuta 
et subacuta hepatis, and 639.98 Aliae definitae. The code was verified by analysing 
the written diagnosis, and if it involved ICP, the case was included. ICD-9 was used 
between 1987 and 1988, and it contained the appropriate codes 6467A Hepatosis 
gravidarum and 6467X Hepatopathia alia. Every case was established from the 
patient records. For an ICP diagnosis, itching was required along with at least one of 
the following laboratory test results: ASAT >35 U/l, ALAT >40 U/l, or bile acids 
≥6 μmol/l.  
Altogether, 687 ICP deliveries were obtained from the patient records. The 
control group comprised the previous and subsequent women from the maternity 
ward diary for each ICP case. In total, the control group consisted of 1,374 women. 
Because the cohort included some women with repeated ICP deliveries, every 
woman was studied only once. Thereby, the cohort contained 575 women with a 
history of ICP. Personal identity codes were missing for four women in the ICP 
group and 41 in the control group, hence they were excluded. The final cohort 
constituted 571 women with ICP and 1,333 women in the control group (Figure 1). 
The details of the sons of the women in the ICP group (n=394) and the sons of 
women in the control group (n=705) were collected from TUH. The mothers of 
these sons were the same mothers used in the registry studies. Excluded from the 
cohort were 8 stillborn, 27 deceased, and 82 with missing addresses. Altogether, 982 
questionnaires were sent. The men’s postal addresses were accessed from the Finnish 
Population Register Centre and the postal survey was conducted in autumn 2010. 
Identical questionnaires were sent to both groups. The response rate was 37.8% 
(n=138) for the sons of the ICP group and 36.6% (n=226) for the sons of the control 
group. 
The women in the ICP and the control groups were found to be comparable 
regarding age, educational level, and body mass index in a previous questionnaire 
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study where the response rate was good, at over 65% (Turunen et al. 2012). The 
cohort was comparable regarding age at labour, age at death, and age of those still 
alive at the end of 2015 (Table 1). Mothers with ICP delivered in earlier gestational 
weeks than the controls did (Turunen et al. 2010) and they more often had a single 
child compared to the controls (Mölsä et al. 2012). 
 
     Suspected ICP patients 
             971                                             OMISSIONS 
                                                                   
                                                            Delivery not in TUH 
                                                                       49 
 
                                                          Additional visits during 
                                                             the same pregnancy 
                                                                       117 
 
                                                           Diagnostic criteria of  
                                                              ICP not fulfilled 
                                                                       118 
 
 
         ICP CASES                                        CONTROL CASES 
              687                                                         1,374 
 
                                   Each woman as 
                                    individual case 
                                           112 
               
                                 Missing personal 
                                    identity codes 
 
                                4                         41                       
 
         ICP GROUP                                      CONTROL GROUP      
               571                                                        1,333 
Figure 1.  Flow chart of the ICP and control groups. 
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Table 1.  Patients’ median age at labour, age at death, and age when still alive at the end of 
2015. 
4.3 Questionnaire and measurements 
For Study VI, a postal survey was conducted in autumn 2010 to study the health of 
the male offspring of women with a history of ICP and the controls. The men’s 
mean age was 30 years (range: 21–40 years). The age of 30 years was set as a cut-off 
point to categorize the respondents’ age. Education was classified as “high” for those 
who had finished high school and “low” for those who had not. The body mass 
index (BMI) of respondents was categorized, and a cut-off point was set at 25 kg/m². 
The groups were comparable regarding age and BMI. On the other hand, the groups 
were not comparable with respect to education. Sons of the ICP group were more 
often in the higher education group (63.0%) than the sons of the control group 
(46.2%) (p=0.002). Identical questionnaires were sent to both groups. The 
questionnaire comprised 39 items. The main aspects relevant to this study were 
present health, symptoms and complaints, diseases diagnosed by a doctor, use of 
medicines and mental health. Smoking and alcohol usage were also enquired. 
The respondents were asked to assess their present health by choosing one of the 
following choices: good, fairly good, moderate, rather poor or poor. Questions 
concerning symptoms and complaints during the previous 12 months were included 
in the query. In addition, the questions addressed diseases diagnosed by a doctor, 
and there were further questions focusing on the gastrointestinal, endocrine and 
metabolic systems, the urinary tract, heart and circulatory systems; respiratory 
diseases; the musculoskeletal system and connective tissue disorders. Furthermore, 
respondents were requested to state whether they had been diagnosed with cancer, 
migraine, urticaria, epilepsy or some significant injury or disease. Questions 
concerning whether the respondents had undergone any major surgery or had ever 
suffered hip, wrist or vertebral fractures were also included. 
The use of medicines, natural health drugs and vitamins during the previous year 
was enquired. Two mental health-related questions and the Depression Scale were 
used to evaluate mental health. The questions included whether the respondent had 
 Mothers with ICP Control group 
 n age age range n age age range 
At labour 571 27.6 16.9 – 41.1 1,333 27.1 15.0 – 46.4 
At death 39 56.7 34.1 – 78.5 111 55.9 28.1 – 83.8 
Alive at the end of 2015 532 63.7 48.0 – 80.8 1,222 63.3 46.3 – 85.0 
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suffered from or had undergone treatment for a mental health disorder. A validated 
Finnish test screening for the risk of present clinical depression, the Depression 
Scale, was included in the questionnaire (Salokangas, Poutanen, and Stengård 1995). 
The results of the Depression Scale vary from 0 to 30. The probability of depression 
is clinically relevant with a result of ≥9 and depression is quite probably diagnosed 
if the result is ≥12 points. 
4.4 Statistical analysis 
The SPSS System for Windows (Versions 22.0, 23.0 and 24.0) was used to analyse 
the data. Frequencies and percentages were used to present the results. The chi-
squared test was used to evaluate statistical significance. Odds ratios (OR) and 95% 
confidence intervals (CI) were conducted with binary logistic regression analysis. 
“ICP or not” was the dependent variable. The T-test was carried out to investigate 
the age at the time of cancer diagnosis. The Kaplan-Meir method was used to explore 
the survival of the mothers in the ICP and control groups. 
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5 RESULTS 
5.1 Review of the literature (Study I) 
This study was conducted to increase Finnish doctors’ knowledge about intrahepatic 
cholestasis of pregnancy and the route of these patients in the Finnish healthcare 
system. Information about the long-term aspects of ICP is accumulating. Women 
with a history of ICP should be encouraged to live normally after experiencing ICP. 
5.2 Co-morbidity of women with a history of ICP (Study II) 
In this 44-year follow-up study, the most common diseases group among the ICP 
and control groups were diseases of the genitourinary system, the nervous system 
and sense organs, and the musculoskeletal system and connective tissue. Diseases of 
the digestive system (ICP not included) were diagnosed in over a half of the ICP 
group, but in only a third of references (p<0.001).  
At least one disease of the thyroid gland was diagnosed in 7.0% (n=40) of the 
ICP group and 4.6% (n=61) of the controls (p=0.030) (Table 2). Arterial diseases 
were diagnosed in 0.9% (n=5) of the ICP group and 2.3% (n=30) of the controls 
(p=0.041, OR=0.38, 95% CI 0.15−0.99). 
When looking closer at the individual diagnoses from the ICD-10 classification 
groups, hypothyroidism was more common in the ICP group than in the controls. 
Some 3.5% (n=20) of the ICP group and 1.5% (n=20) of the controls were 
diagnosed with hypothyroidism (OR=2.38, 95% CI 1.27–4.46).  
Hepatobiliary diseases (ICP not included, K00–K99) were found in 35.2% 
(n=201) of the ICP group and in 11.6% (n=155) of the controls (p<0.001). Diseases 
of the digestive system other than hepatobiliary diseases were found in 28.4% 
(n=162) of the ICP group and in 27.5% (n=366) of the controls (p=0.683). 
Cholecystitis and/or cholelithiasis (OR 2.88, 95% CI 2.17–3.84) and diseases of the 
pancreas (OR 2.26, 1.20–4.27) were found significantly more often in the ICP group 
than in the control group (Table 3). The results include all subjects who have at least 
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one diagnosis among certain disease groups, although some subjects might have had 
several diagnoses regarding the same ICD-10 disease groups. 
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Table 2.  The occurrence (%) of neoplasms; disorders of the thyroid gland; and immune-
mediated, cardiovascular and pregnancy-associated diseases in the ICP group and 
the references. 
 
ICD-10 
code 
ICP 
N=571 
Controls 
N=1,333 
Difference 
  n % n % %-
units 
p-
value 
Neoplasms        
    Breast cancer C50 36 6.3 66 5.0 1.3 0.30 
    Liver and biliary tree cancer C22–C24 0 0.0 0 0.0 0.0 - 
Malignant diseases other than the 
aforementioned 
C00–D48 216 37.8 458 34.4 3.4 0.15 
Diseases of the thyroid gland E00–E07 40 7.0 61 4.6 2.4 0.03 
Immune-mediated diseases        
    Diabetes mellitus E10–E14 34 6.0 97 7.3 -1.3 0.30 
    Sarcoidosis D86 2 0.4 5 0.4 0.0 0.94 
    Crohn’s K50 3 0.5 5 0.4 0.1 0.64 
    Ulcerative colitis K51 6 1.1 10 0.8 0.3 0.51 
    Coeliac disease K90.0 6 1.1 13 1.0 0.1 0.88 
    Inflammatory polyarthropathies M05–M09 20 3.5 46 3.5 0.0 0.96 
    Systemic connective tissue disorders M32 1 0.2 3 0.2 0.0 0.83 
    Asthma J45 28 4.9 72 5.4 -0.5 0.66 
    Psoriasis L40 8 1.4 27 2.0 -0.6 0.35 
Cardiovascular diseases        
   Hypertensive disease I10–I15 67 11.7 178 13.4 -1.7 0.33 
   Coronary heart disease I21–I25 27 4.7 65 4.9 -0.2 0.89 
   Pulmonary heart disease I26 8 1.4 18 1.4 0.0 0.93 
   Cerebrovascular disease I27–I28 
G45 
22 3.9 56 4.2 -0.3 0.73 
   Arterial diseases I70–I79 5 0.9 30 2.3 -1.4 0.04 
Pregnancy-associated diseases        
   Pre-eclampsia O14.0–
O14.2 
23 4.0 72 5.4 -1.4 0.21 
   Gestational diabetes O24.4 9 1.6 24 1.8 -.02 0.73 
*The results include all subjects who have at least one of these diagnoses. 
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Table 3.  Risk (OR with 95% CI) for at least one mentioned hepatobiliary disease or disease of 
the pancreas in the ICP and control groups. 
Hepatobiliary disease ICD-10  N % OR 95% CI 
Cholecystitis and/or 
cholelithiasis 
K80–K81 Controls 106 8.0 1  
 ICP 114 20.0 2.88 2.17–3.84 
Diseases of the 
pancreas 
K85–K86 Controls 20 1.5 1  
 ICP 19 3.3 2.26 1.20–4.27 
Cirrhosis of the liver  
K70.2, 
K76.1,K70.3,P78.
8, K71.7,K74 
Controls 8 0.6 1  
ICP 7 1.2 2.06 0.74–5.70 
5.3 Occurrence of cancers among women with a history of ICP 
(Study III) 
This follow-up study considered cancers in a 50-year follow-up. At least one cancer 
was diagnosed in 16.8% (n=96) of the ICP group and in 13.9% (n=185) of the 
control group (p=0.098). A slightly higher risk for cancer (OR 1.26, 95% CI 0.96–
1.64) was found in the ICP group than in the controls. Malignant cancers were the 
main form of cancer in both groups (nearly 90%) (p=0.758).   
The most common cancer in both groups was breast cancer (Table 4). A slightly 
higher risk for breast cancer was found in the ICP group (OR 1.36, 95% CI 0.91–
2.03) than in the control group, but the finding was not statistically significant. 
Regarding other neoplasms, there were no statistically significant differences 
between the groups. One mother in the ICP group had been diagnosed with 
hepatobiliary cancer, but this diagnosis was not found among the controls. 
The mean age of mothers at the time of diagnosis was 53.0 years in the ICP group 
and 51.8 years in the control group (p=0.315). As of 31 December 2013, the mean 
age of those who had not been diagnosed with cancer was 61.5 years in the ICP 
group and 61.3 years in the control group. 
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Table 4.  The occurrence of cancers in the ICP and control groups. 
ICD-10 
code 
Cancer Mothers 
with ICP 
n=571 
Controls 
mothers 
n=1,333 
Difference 
  n % n % %-
units 
p-
value 
C50 Breast 40 7.0 70 5.3 1.7 0.133 
C73–
C75 
Thyroid and other endocrine 
glands 
6 1.1 5 0.4 0.7 0.075 
C64–
C68 
Urinary tract 4 0.7 3 0.2 0.5 0.116 
C42 Haematopoietic and 
reticuloendothelial systems 
2 0.4 2 0.2 0.2 0.382 
C30–
C39 
Respiratory and intrathoracic 
organs 
1 0.2 3 0.2 0.0 0.827 
C40–
C41 
Bone and articular cartilage 1 0.2 3 0.2 0.0 0.827 
C80 Unknown primary site 1 0.1 1 0.1 0.0 – 
C00–
C14 
Lip, oral cavity and pharynx 0 0.0. 1 0.1 -0.1 0.513 
C15–
C26 
Digestive organs 7 1.2 19 1.4 -0.1 0.731 
C45–
C49 
Mesothelial and soft tissue 0 0.0 1 0.1 -0.1 0.513 
 
C43–
C44 
Melanoma and other 
malignant neoplasms of skin 
18 3.2 38 2.9 -0.1 0.721 
C51–
C58 
Female genital organs 14 2.5 35 2.6 -0.1 0.826 
C69–
C72 
Eye, brain and other parts of 
central nervous system 
3 0.5 8 0.6 -0.1 0.844 
C77 Lymph nodes 2 0.4 7 0.5 -0.1 0.610 
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5.4 Survival analysis (Study IV) 
This study followed-up the cohort for 27–46 years. Nearly 7% (n=39) of the ICP 
group and 8% (n=111) of the control group had died by the end of 2015. The mean 
survival time from birth was 77.4 years in the ICP group and 79.2 years in the 
reference group (p=0.288) (Figure 2). The mean survival time after labour was 45.0 
years in the ICP group and 44.8 years in the control group (p=0.259).  
 
Figure 2.  Survival in the ICP and reference groups in terms of age. The censored line indicates the 
subjects who are alive at the end of the follow-up time. (Reprinted with permission from 
Elsevier.) 
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5.5 Underlying causes of death in women with a history of ICP 
(Study V) 
During this 44-year follow-up, the women of the cohort most commonly died of 
neoplasms – 46% (n=18) in the ICP group and 41% (n=46) in the control group 
(p=0.609) (Table 5). Statistically significant differences between the groups were not 
found concerning hepatobiliary neoplasms or malignant neoplasms of the digestive 
system as the underlying cause of death. 
Diseases of the circulatory system were the second most common underlying 
cause of death among the controls. These underlying causes accounted for 13% 
(n=5) of deaths in the ICP group and 26% (n=29) of deaths in the control group 
(p=0.088).  
Diseases of the digestive system were the second common underlying cause of 
death in the ICP group. These were more often the underlying cause of death in the 
ICP group than in the control group (15% (n=6) vs 4% (n=4), p=0.011). The risk 
of dying due to a gastrointestinal cause was nearly five-fold greater in the ICP group 
than in the control group (OR=4.85, 95% CI 1.29–18.18). Hepatobiliary diseases 
were the underlying cause of death in 67% (n=4) of those in the ICP group and 75% 
(n=3) of the controls (p=0.778) within the subset of gastrointestinal disease deaths. 
Alcoholic liver diseases were found in four mothers in the ICP group and in two 
mothers in the control group. Cirrhosis of the liver was found in one control. 
Diseases of the pancreas and alcohol-induced chronic pancreatitis were the 
underlying causes of death in two women in the ICP group. Gastro-oesophageal 
laceration-haemorrhage syndrome was the underlying cause of death in one control. 
In total, diseases of the digestive system and malignant neoplasms of the digestive 
system were the underlying causes of death in 28% (n=11) of the ICP group and 
14% (n=16) of the controls (p=0.054). Diseases of the other organ systems were 
rare in both groups. 
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Table 5.  Underlying causes of death among women with and without a history of ICP. 
Underlying cause of death 
(ICD-10) 
Mothers with ICP 
n=39 
Controls 
n=111 
Difference 
 n % n % %  
units 
p-
value 
Neoplasms (C00–D48) 18 46 46 41 5 0.609 
Diseases of the digestive system  
(K00–K93) 
6 15 4 4 11 0.011 
External causes of morbidity and mortality, injury, 
poisoning and certain consequences of external causes 
(V01–Y98, S00–T98) 
5 13 17 15 -2 0.705 
Diseases of the circulatory system (I00–I99) 5 13 29 26 -13 0.088 
Endocrine, nutritional and metabolic diseases (E00–
E90) 
2 5 5 5 0 0.874 
Diseases of the nervous system (G00–G99) 2 5 5 5 0 0.874 
Diseases of the musculoskeletal system and connective 
tissue (M00–M99) 
1 3 1 1 2 0.420 
Diseases of the respiratory system (J00–J99) 0 0 4 4 -4 0.230 
5.6 Health of the sons of women with a history of ICP (Study VI) 
In a postal survey conducted in 2010, there were no differences between the sons of 
the ICP group and the sons of the control group in the majority of the aspects 
examined. There was no difference in self-evaluated current health status. Health 
was rated as good or fairly good by 89% of the sons of the ICP group and 88% of 
the sons of the control group. 
Most commonly, backache, neck and shoulder pain, headache and coughing were 
reported in both groups. Coughing during the previous 12 months was reported by 
27% of the sons of the ICP group and 38% of the sons of the control group 
(p=0.034). The groups did not differ with respect to other symptoms (Table 6). 
Some 52% of the sons of the ICP group and 66% of the sons of the control 
group had smoked at least once in their lifetime (p=0.021). Current smoking was 
reported by 30% of the sons of the ICP group and 42% of the sons of the control 
group (p=0.023). Calculating smoking pack years, there were no significant 
differences between the groups. No differences were found in terms of the number 
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of doses of alcohol used or whether the respondent had ever considered reducing 
alcohol consumption.  
Concerning diagnosed diseases, only minor differences between the groups were 
found. Acute hepatitis and cholelithiasis were diagnosed in 1% (n=2) of the sons of 
the ICP group but in none of the sons of the control group (p=0.070). Nearly 9% 
of the sons of the ICP group and 11% of the sons of the control group suffered 
from migraine, which was the most common disease among both groups. Urticaria 
was reported by 2% (n=3) of the sons of the ICP group, but by none of the sons of 
the control group (p=0.026). Diseases of the circulatory system were less common 
among the sons of the ICP group, although the findings were not statistically 
significant.  
In the Depression Scale results, approximately 12% scored ≥9 points in both 
groups. Some 5% of the sons of the ICP group and 6% of the sons of the control 
group scored >12 points in the Depression Scale. There were no differences 
regarding mental health disorders. Wrist, back or hip fractures were reported by 10% 
of the sons of the ICP group and by 9% of the sons of the control group.  
There were no statistically significant differences in the usage of medicines. The 
most commonly used medicines among the sons of the ICP group were painkillers 
(89%), vitamins or trace elements (62%), asthma and antiallergic medication (24%) 
and gastric acid inhibitors (23%).  
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Table 6.  Symptoms and complaints during the previous 12 months among the sons of the ICP 
group and the sons of the control group. 
Symptoms and complaints Sons of the ICP 
group, 
n =138 (%) 
Sons of the 
controls, 
n = 226 (%) 
Difference in 
percentage points 
Difference 
(p-value) 
Heart palpitation 14.5 8.4 6.1 0.069 
Blushing 10.1 4.9 5.2 0.053 
Neck and shoulder pain 37.7 33.6 4.1 0.432 
Dryness of the eyes and 
mouth 
13.0 10.2 2.8 0.401 
Insomnia 21.7 19.0 2.7 0.531 
Rheumatic pains 5.1 2.7 2.4 0.228 
Headache 31.9 29.6 2.3 0.653 
Urinary problems 5.8 3.5 2.3 0.308 
Nausea 7.2 6.2 1.0 0.695 
Foot and/or leg swelling 3.6 3.1 0.5 0.785 
Dyspnoea 8.7 8.4 0.3 0.924 
Depression 13.0 12.8 0.2 0.953 
Dizziness 10.1 10.2 -0.1 0.992 
Chest pain 8.7 8.8 -0.1 0.960 
Itching of the palms and soles 3.6 4.0 -0.4 0.863 
General itching of the skin 14.5 17.3 -2.8 0.488 
Backache 38.4 42.0 -3.6 0.494 
Arthralgia, joint pain 14.5 19.0 -4.5 0.267 
Nervousness 15.2 20.8 -5.6 0.185 
Recurring stomach problems 9.4 15.0 -5.6 0.121 
Sweating 14.5 20.4 -5.9 0.159 
Coughing 26.8 37.6 -10.8 0.034 
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6 DISCUSSION 
6.1 Main results of the study 
Over a 44-year follow-up, diseases of the digestive system (ICP not included) were 
more common among mothers with a history of ICP when compared to the 
controls. Over a half of the ICP group were diagnosed with diseases of the digestive 
system, compared to only one third of the controls. Hepatobiliary diseases (ICP not 
included) were also more common in the ICP group compared to the control group. 
Over one third of the ICP group and one tenth of the controls were diagnosed with 
hepatobiliary diseases. The risk for cholecystitis and/or cholelithiasis was nearly 
three-fold and the risk for diseases of the pancreas was two-fold in the ICP group. 
Diseases of the thyroid gland were more common in the ICP group than in the 
control group. The risk for hypothyroidism was more than two-fold in the ICP 
group. However, arterial diseases were less common in the ICP group compared to 
the controls.  
There were no statistically significant differences in the occurrence of cancer 
between the ICP group and the controls in the 50-year follow-up. In this study, the 
risk for cancer – especially breast cancer, the most common cancer in both groups 
– was not statistically significantly higher in the ICP group. 
The mean survival time from birth and from labour did not differ significantly 
when comparing the ICP and control groups in the 27–46-year follow-up. During 
the 44-year follow-up, neoplasms were the most common underlying cause of death 
in both groups. Regarding hepatobiliary neoplasms, no significant differences were 
found between the ICP and control groups. Diseases of the circulatory system were 
the second most common underlying cause of death in the controls. The occurrence 
was two-fold in the controls when compared to the ICP group, but the finding was 
not statistically significant. In mothers with a history of ICP, the second most 
common underlying cause of death was diseases of the digestive system. These 
underlying causes of death were more common in the ICP group when compared 
to the control group. The risk of death from a gastrointestinal cause was nearly five-
fold in ICP group when compared to the controls. Deaths due to diseases of the 
digestive system and malignant neoplasms of the digestive system were twice as 
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common in the ICP group when compared to the controls, the difference being 
close to statistically significant. 
A postal questionnaire was conducted in 2010 to study the health of the male 
offspring of mothers with a history of ICP and mothers with no history of ICP. 
Generally, there were only minor differences between the groups in terms of health. 
The self-evaluated current health status was similar in the groups, and backache, neck 
and shoulder pain, headache and coughing were the most common symptoms in 
both groups. The sons of the ICP group reported less coughing during the previous 
12 months compared to the sons of the controls. With respect to other symptoms, 
no significant differences between the sons of women with ICP and the sons of the 
controls were found. Sons of the ICP group had smoked at least once in their lifetime 
less frequently. Additionally, the sons of the ICP group reported currently smoking 
less frequently. Nevertheless, there were no differences between the groups in 
smoking pack years or alcohol usage. Migraine was the most common disease in 
both groups. Acute hepatitis and cholelithiasis were slightly more common in the 
sons of the ICP group compared to the sons of the controls, although the difference 
was not statistically significant. Urticaria was comparatively more common in the 
sons of the ICP group. The groups did not differ in terms of the Depression Scale 
score, nor were there differences in the occurrence of mental health disorders or 
wrist, back or hip fractures. The use of medicines was similar in both groups, with 
painkillers being the most commonly used drugs. 
6.2 Reflections on the study setting, material and methods 
The study population included all pregnancies complicated with intrahepatic 
cholestasis of pregnancy during a twenty-year period at Tampere University Hospital 
(TUH). The study population can be regarded as extensive. TUH is a university 
hospital in the “million range”, and both normal and risky deliveries are carried out 
there. The prevalence of ICP was similar in the investigated period to the overall 
ICP prevalence in Finland (Turunen et al. 2010). There is a possibility that some 
controls may have had an ICP delivery in another hospital district. In addition, it is 
possible that some of the mothers may have had a delivery before 1969. The data 
collected from the cohort were based on personal identity codes, which makes the 
data more reliable. The cohort’s follow-up time was long.  
The ICP diagnoses were obtained and verified from the patient records: itching 
and laboratory test abnormalities were required as confirmation. The bile acid values 
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considered diagnostic for ICP were the standard for TUH at that time, but nowadays 
the diagnostic values for ICP are generally higher. The upper limit of normal bile 
acids can be reduced to between 6 and 10 μmol/l in fasted women, although many 
studies use an upper limit of normal between 10 and 14 μmol/l (Williamson and 
Geenes 2014). In our studies, the results can be considered similar, even though the 
diagnostic criterion for ICP was a bile acid concentration ≥6 μmol/l instead of ≥10 
μmol/l. The diagnosis was made by an obstetrician, and the diagnosis was not 
questioned. 
The controls were chosen to be the next and previous deliveries from the patient 
records. There were no power calculations made and that may be the reason why 
not all the differences were statistically significant. The aim was to obtain a large 
cohort and to follow it up for a long time. The follow-up time can be considered 
long. However, to investigate survival from birth and from ICP delivery and the 
underlying causes of death in more detail, the follow-up should be so long that 
everyone in the cohort has died. 
A long follow-up is crucial to investigate long-term aspects. Despite the long 
follow-up time, the cohort represents those who have died or been diagnosed with 
a disease at a relatively young age. An even longer follow-up time would confirm the 
results, as a wider diagnosis range would be able to be analysed due to the increase 
in statistical power. Although the follow-up time is long, the power for analysing rare 
diseases is weak. For these reasons, the analysis of rare diseases was not successful 
in this study material. 
The completeness and accuracy of the Finnish Hospital Discharge Register 
(FHDR) vary from satisfactory to very good (Sund 2012). A limitation of the FHDR 
is its inclusion of only those patients treated on an inpatient ward or in hospital. 
From 1998, information is available on outpatient visits to specialized healthcare. 
The prevalence of diseases typically treated in primary health care might have been 
greater if information had been available on diagnoses in primary health care. For 
instance, diabetes mellitus 2 and hypertension are typically treated in primary health 
care. Thus, these diagnoses are in the FHDR only if the condition is extraordinarily 
complicated or the patient is hospitalized for another reason. The ICD-8 and ICD-
9 diagnoses were extrapolated to ICD-10, and this did not cause any significant 
problems. In Study II, the aim was to compare morbidity between women with a 
history of ICP and the controls, and an analysis of the time from ICP to the diagnosis 
of the certain diseases was not included.  
The underlying causes and dates of death were obtained from Statistics Finland. 
The coverage of this information is practically 100% (Official Statistics of Finland 
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2013). The data for the deceased of the cohort can be considered reliable. However, 
one limitation of the study is the small number of death cases. 
The completeness of the Finnish Cancer Registry has been shown to be over 99% 
(Teppo et al. 1994). The accuracy of the registry has been found to be high, but there 
is a delay in the collection of registry data (Korhonen et al. 2002). Nevertheless, this 
delay did not cause major problems.  
The questionnaire for the sons of the cohort was sent via mail. Postal addresses 
were found for most of the sons, and the response rate was moderate. The response 
rate for the sons of the ICP group and the sons of the controls was 37.8% and 36.6%, 
respectively. The questionnaire was filled in at home. The respondents did not 
receive any payment for responding, but a prepaid return envelope was included with 
the questionnaire so there was no financial cost for answering. Had the questionnaire 
been online, the response rate might have been better. The response rate was lower 
for the sons of the cohort in comparison to a quite similar questionnaire sent to the 
daughters or mothers (Turunen et al. 2012, Vimpeli et al. 2013). 
The questionnaire study had some limitations. Since the men were quite young, 
some of the diseases usually detected in later life would not yet have been diagnosed. 
The sample size could also have been even larger. Furthermore, questionnaire studies 
always include a risk of recall bias. There was no connection between the severity of 
the mother’s ICP, the trimester of clinical presentation, peak bile acid levels 
(percentage of mothers with levels >40 μml/l), the presence of jaundice, average 
gestation at delivery, the percentage of males delivered before 37 weeks or the 
presence of other perinatal complications. 
6.3 Discussion of the results 
As intrahepatic cholestasis of pregnancy is hereditary in one in six cases (Savander 
et al. 2003) and the liver is crucial for maintaining the homeostasis of the human 
body, it was logical to investigate whether ICP has long-term effects. The registries 
used provided objective information on the long-term aspects of ICP. The health of 
the cohort’s sons was evaluated by questionnaire. 
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6.3.1 Co-morbidity of women with a history of ICP 
In the 44-year follow-up study, some differences were found in co-morbidity 
between the ICP group and the controls. Hepatobiliary diseases were 
overrepresented in the ICP group. Moreover, there was a higher occurrence of 
thyroid gland diseases in the ICP group, especially goitre and hypothyroidism. 
Cholelithiasis and/or cholecystitis and diseases of the pancreas were more common 
in the ICP group than in the control group. By contrast, the occurrence of arterial 
diseases was lower in the ICP group. In respect to other diseases, no differences 
were found between the ICP group and the controls. 
Hepatobiliary diseases were more common among in the ICP group than in the 
reference group. Over half of the ICP group had been diagnosed with diseases of 
the digestive system. In addition, women in the ICP group had an increased risk for 
cholecystitis and cholelithiasis. The findings are congruent with previous studies 
(Turunen et al. 2012, Ropponen et al. 2006, Marschall et al. 2013). Diseases of the 
pancreas were overrepresented in the ICP group compared to the control group. 
Non-alcoholic pancreatitis was found to be more common among women with a 
history of ICP than among controls (Ropponen et al. 2006). Patients with 
pancreatitis may also have cholecystitis, and it is plausible that only one of the 
diagnoses had been noted down in the medical records. However, the records of 
women with ICP presumably have the same weakness as the records of the 
references. 
A population-based study found an increased risk for later cardiovascular disease 
in women with a history of ICP, and the occurrence of cardiovascular diseases was 
lower than in our study (Wikström Shemer et al. 2015). In a previous questionnaire 
study, women who had experienced ICP reported less cardiac arrhythmia, high 
cholesterol and high blood pressure requiring medication compared to controls 
(Turunen et al. 2012). The difference might be explained by our cohort’s older age 
at the end of the follow-up. In this study, arterial diseases were less common among 
mothers with a history of ICP compared to the references. 
Hypothyroidism was more often found in the ICP group than in the control 
group. Congruent findings have been made regarding hypothyroidism in a 
questionnaire study (Turunen et al. 2012) and overall thyroid disease in a population-
based study (Wikström Shemer et al. 2015). It is commonly noted that the 
autoimmune pathogenesis has a remarkable effect on hypothyroidism. There might 
also be an autoimmune aspect in the pathogenesis of ICP. Mutations in gene ABCB4 
in ICP and cholelithiasis (Jacquemin et al. 1999, Marschall et al. 2010, Wasmuth et 
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al. 2007) might be an example of the shared risk factors possibly influencing the 
pathogenesis of ICP and other diseases of the digestive system. 
6.3.2 Occurrence of cancers among women with a history of ICP 
In the 50-year follow-up study, there were minor differences among the ICP and 
control groups regarding cancer occurrence. There was no statistically significant 
association between ICP and overall cancer. The finding is coherent with a previous 
study (Wikström Shemer et al. 2015). This same previous study found an association 
between ICP and hepatobiliary cancer. Nevertheless, the occurrence was small in the 
ICP group (0.1%), so the expectation of finding hepatobiliary cancers among our 
ICP group was low. However, one hepatobiliary cancer was found in the ICP group. 
The phenomenon could also be explained by the higher risk of chronic hepatitis, 
cholelithiasis and chronic cholangitis among women with a history of ICP 
(Ropponen et al. 2006, Marschall et al. 2013). The first may lead to liver cirrhosis 
and that may be complicated by hepatocellular cancer (Fattovich et al. 2004). 
Cholelithiasis and chronic cholangitis are associated with gallbladder and 
cholangiocellular cancer (Kim et al. 2015, Hundal and Shaffer 2014). Cholelithiasis 
has been associated with pooled gastrointestinal and right-side colon cancers 
(Shabanzadeh et al. 2017). 
In a previous questionnaire study, women with a history of ICP reported more 
breast cancer compared to controls (Turunen et al. 2012). There was a need to 
investigate whether the reported information could be confirmed using objective 
data sources. A recent study found no association between ICP and breast cancer 
(Wikström Shemer et al. 2015). In the present study, no statistically significant 
increase in the risk for breast cancer was found in the ICP group compared to the 
controls. The occurrence of breast cancer was in accordance with the known breast 
cancer risk for Finnish women (Engholm et al. 2016). Delivery before 37 weeks of 
gestation seems to increase the mother’s risk for breast cancer later in life (Hsieh et 
al. 1999). With the same cohort, ICP has been associated with premature delivery 
(Turunen et al. 2010), and thus this could increase the number of breast cancer cases 
among women with a history of ICP. 
A multifactorial genetic base has been found to influence the pathogenesis of 
ICP, and ICP might be one expression of a larger group of genetic diseases. 
Furthermore, the same hormonal factors influencing ICP may have an impact on 
the pathogenesis of certain cancers. 
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6.3.3 Survival analysis 
The ICP and control groups did not significantly differ in terms of survival from 
birth or ICP delivery in the 27–46-year follow-up. ICP is associated with a certain 
genetic profile (Williamson and Geenes 2014, Ozkan et al. 2015), and the same 
profile may influence the survival of patients with ICP from birth. Indeed, ICP itself 
might not affect survival, but the specific genetic profile may do so. This research 
provides new insights on the long-term aspects of ICP by studying survival from 
birth and from ICP delivery over such a long follow-up time. No statistically 
significant differences in survival from the birth or from ICP delivery were found 
between the ICP group and the control group during the follow-up time. Based on 
this study, ICP does not seem to be associated with women’s survival in middle age 
or in earlier life. 
The known risk for certain diseases after ICP (Marschall et al. 2013, Ropponen 
et al. 2006, Turunen et al. 2012, Wikström Shemer et al. 2015) may have an impact 
on the survival of women with a history of ICP. Hepatobiliary cancer has been found 
to be more common among women with a history of ICP than among controls 
(Wikström Shemer et al. 2015). In a questionnaire study, women with a history of 
ICP reported more breast cancer compared to controls (Turunen et al. 2012), but 
this finding was not confirmed by a registry-based study (Wikström Shemer et al. 
2015). The occurrence of cancer might have an effect on survival from birth. 
Furthermore, health behaviour has a crucial influence on survival. Women with a 
history of ICP reported less smoking compared to a control group, but no 
differences in recent alcohol consumption or physical activity were reported 
(Turunen et al. 2013a).  
Hepatitis C is associated with an increased risk of the occurrence of coronary 
atherosclerosis (Olubamwo et al. 2016), and it is also associated with ICP (Locatelli 
et al. 1999, Marschall et al. 2013, Paternoster et al. 2002). There were no differences 
in our cohort in terms of hepatitis C incidence. Thus, it can be considered that 
hepatitis C has a similar effect on the survival of the groups. 
6.3.4 Underlying causes of death among women with a history of ICP 
In this study, the underlying causes of death were examined in a 44-year follow-up. 
Gastrointestinal diseases were overrepresented as an underlying cause of death 
among women with a history of cholestasis of pregnancy. On the other hand, 
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diseases of the circulatory system were more common in the controls than in the 
ICP group.  
ICP has previously been associated with circulatory diseases (Wikström Shemer 
et al. 2015). However, women with a history of ICP reported less cardiac arrhythmia, 
high cholesterol and high blood pressure requiring medication compared to controls 
in a questionnaire study (Turunen et al. 2012). Among Finnish women over 15 years 
old, diseases of the circulatory system were the underlying cause in 38% of deaths 
(Official Statistics of Finland 2016). Over one of four underlying causes of death 
were diseases of the circulatory system in our control group. In the ICP group, 
diseases of the circulatory system accounted for only slightly more than one in ten 
deaths. ICP has been associated with gestational diabetes and pre-eclampsia 
(Wikström Shemer et al. 2013, Marathe et al. 2017). Gestational diabetes increases 
the risk of type 2 diabetes, hypertension and ischemic heart disease (Daly et al. 2018). 
An increased risk for cardiovascular diseases has been linked to pre-eclampsia 
(Brown et al. 2013). Nevertheless, in our study no association was found between 
ICP and an increased rate of diseases of the circulatory system as the underlying 
cause of death.    
The increased occurrence of gastrointestinal diseases as the underlying cause of 
death may be considered clinically relevant. The increased occurrence of 
hepatobiliary disease (Ropponen et al. 2006, Marschall et al. 2013, Turunen et al. 
2012) might increase the number of deaths from gastrointestinal diseases among 
women with a history of ICP. Hepatobiliary neoplasms were not underlying causes 
of death in either of the groups. An association between ICP and liver and biliary 
cancer has been reported, but the incidence was found to be rather low, at 0.1% 
(Wikström Shemer et al. 2015). The low incidence explains why none of these 
cancers were found in the cohort as an underlying cause of death. 
Alcohol consumption may influence the underlying cause of death. In a 
questionnaire study, there was no difference between women who had experienced 
ICP and the controls regarding risky consumption of alcohol (Turunen et al. 2013a). 
Another study found that alcohol cirrhosis was less likely to be diagnosed in women 
with a history of ICP than in controls (Marschall et al. 2013). Additionally, the 
increased risk of liver fibrosis and cirrhosis (Ropponen et al. 2006, Marschall et al. 
2013) among women with a history of ICP may explain the increased amount of 
hepatobiliary diseases among the underlying causes of death. 
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6.3.5 Health of the sons of mothers with a history of ICP 
Only minor differences manifested for most of the aspects addressed in the 
questionnaire survey conducted in 2010. Compared to the controls’ sons, the sons 
of the ICP group reported less coughing during the previous 12 months, and more 
had never smoked. The latter may have an impact on the former and partially explain 
the finding. The smoking habit may be influenced by the difference in the 
educational level of the two groups. The observation that mothers with a history of 
ICP tend to restrict their number of children (Mölsä et al. 2012) may have an impact 
on this. Hypothetically, parents in families with one child encourage their offspring 
to strive towards higher education. 
The sons of the ICP group reported more urticaria compared to the sons of the 
controls. Because the frequencies were low, this finding can be considered clinically 
irrelevant. A higher education level may have an impact on health consciousness, 
and this could influence the number of appointments with a doctor. 
Concerning epilepsy, there were no differences in the groups, although daughters 
of mothers with a history of ICP have reported more epilepsy. Instead, a trend was 
found of the sons of the ICP group having more physician-diagnosed acute hepatitis 
or cholelithiasis.  
The reported frequencies of the diseases in our cohort were quite similar to those 
for the average population in Finland. Migraine was found among 11% of working-
age men (Rantala et al. 2007), and asthma was reported in 8% of men in the Health 
2011 survey (Koskinen et al. 2012). Respiratory diseases may affect the frequency of 
cough. Slightly more than 20% of 30–44-year-old men reported an infectious 
respiratory disease during the previous two months in the Health 2000 survey 
(Aromaa and Koskinen 2004). The Health 2000 survey also revealed that 
approximately 30% of men in the same age range as our sample reported backache 
during the previous month. Roughly 80% of men had had back pain at some time 
(Aromaa and Koskinen 2004). The results of the study can be considered congruent 
with previous findings. 
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7 CONCLUSIONS AND FUTURE IMPLICATIONS 
This thesis includes the first Finnish registry studies with broad aspects investigating 
the health of women with a history of ICP. Some of these aspects were unique also 
from an international perspective.  
Intrahepatic cholestasis of pregnancy is associated with a certain genetic profile. 
This same genetic background may also influence co-morbidity and survival. The 
explanation for the differences found between the ICP and the reference groups may 
stem from genetic predisposition rather than the history of ICP itself.  
ICP was found to be associated with an increased risk for cholelithiasis and/or 
cholecystitis, diseases of the pancreas and hypothyroidism compared to the control 
group. Arterial diseases were less common in the ICP group compared to the control 
group. Extending the follow-up time might show whether co-morbidity converges 
as the cohort gets older. In further studies, the period from ICP to the diagnosis of 
various diseases might be of great interest. This was the first study to show the 
association between ICP and hypothyroidism based on registries. 
In the present study, the incidence of breast cancer was not statistically 
significantly higher in women with ICP compared to the controls. This study could 
not reinforce the previously found association between ICP and liver and biliary 
cancer. There is no need to change treatment strategies or cancer screening due to a 
history of ICP. 
Based on this study, intrahepatic cholestasis of pregnancy does not seem to 
influence survival from birth or from ICP delivery. Studying the survival of women 
with a history of ICP is unique. It is necessary to further extend the follow-up time 
of the cohort to verify these findings. 
Compared to the controls, women who had experienced ICP died more often of 
gastrointestinal diseases. This study is the first to study the survival of such women 
from birth and from ICP delivery and their underlying causes of death. 
Consequently, the results can be regarded as unique.  
In the future, an even larger cohort and longer follow-up time would confirm the 
results, as a wider diagnosis range might be analysed because of the increase in the 
statistical power. The follow-up time is long, but the power for analysing rare 
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diseases is weak. Thus, the analysis of rare diseases was not successful in this study 
material. 
The sons of the ICP group did not have remarkable long-term health 
consequences as a result of their mother’s pregnancy-related disorder. This finding 
can be considered a relief. From a public health perspective, there are numerous 
women with a history of ICP and the sons of such women, so it is meaningful to 
further study their health from a long-term perspective. 
Women with a history of ICP require special attention from general practitioners 
to detect co-morbidity. In the future, it would be worthwhile to examine the 
association between ICP, hepatobiliary diseases and alcohol consumption. This 
could lead to special guidance for women with a history of ICP regarding alcohol 
consumption. Additionally, the survival of women who have experienced ICP from 
birth and from delivery needs to be studied further, as it might transpire to be 
meaningful in the clinical context. 
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APPENDICES 
Appendix 1  Information to the recipient 
  Translated from Finnish by Kristiina Helander, MA. 
Appendix 2 Questionnaire 
  Translated from Finnish by Kristiina Helander, MA.  
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VERTAISARVIOITU 
Tieteessä | katsaus
Raskaushepatoosi  
– hankala, mutta ohimenevä vaiva
IXjbXlj_\gXkffj``ejX`iXjkllef`e(jpeepkka`jk%
KXlk`gl_b\XXkXmXcc`j\jk`*'%iXjbXljm``bfeacb\\e%
Kppg`cc`j\ef`i\\eXfe`_feblk`eX%DXbjXg\i`jk\ekiXejXd`eXXj`\eaXjXgg`_Xggfa\ekX`dfc\dg`\ekXjfk
bf_fXmXk%
<ee\eX`bX`j\ejpeepkpbj\e#j`b`eX_[`ebfk`cXeaXbf_klblfc\dXei`jb`kfmXkjlli\ekle\\k%
v`k`c_\k\kee\lmfcXjkX`k`pjgfc`bc`e`bXcc\aXkbfklkb`dlbj``eaXj\liXekXXe%
Jpeepkpbj\eacb\\eiXjbXlj_\gXkffj`gXiXe\\kpj`e%F`i\\k_m`mkgXi`jjXg`mjjaXcXYfiXkfi`fXimfk
efidXXc`jklmXkbX_[\ebllbXl[\eblcl\jjX%
Gfk`cXXccXfejlli\eklelkdXbjX$#_X`dXaXjXgg`jX`iXlbj`\e\c`e`b`e\ei`jb`%
Äitiysneuvola tavoittaa lähes kaikki raskaana 
olevat naiset. Neuvolalääkärin ja terveydenhoi-
tajan tehtävänä on seuloa hyvin sujuvista ras-
kauksista ne, joissa tarvitaan lisätutkimuksia ja 
-hoitoja. Raskaudenaikainen ihon kutina on 
yleinen ongelma. Kutinasta kärsivien äitien jou-
kosta on tunnistettava raskaushepatoosi, johon 
sairastuu noin 1–1,5 % synnyttäjistä. Hepatoo-
sin myöhäisvaikutusten vuoksi naisille ja hei-
dän lapsilleen saattaa tulla kysymyksiä useiden 
erikoisalojen lääkärien vastaanotoilla.
Epidemiologia, etiologia ja patogeneesi
Vuosina 2013–2015 raskaushepatoosin esiinty-
vyys oli Tampereen yliopistollisessa sairaalassa 
synnyttäneiden keskuudessa 1,1–1,5 %, kun taas 
Keski-Euroopassa esiintyvyys on vähäisempää, 
0,2–1,0 % (1). Raskaushepatoosin etiolo giaa ei 
ole pystytty osoittamaan aukottomasti. Luultavas-
ti siihen vaikuttavat monet eri tekijät. Sen on 
 ajateltu johtuvan maksan hormonaalisesta yli-
kuormituksesta geneettisesti alttiilla naisilla. 
Myös ympäristötekijöitä on ehdotettu taudin 
syyksi (2,3).
Raskaushepatoosi uusiutuu 50–70 prosentis-
sa seuraavista raskauksista. Riski on suurin 
(92 %) niillä, joilla esiintyy MDR3-geenissä mu-
taatio (4). Useat geenit tai geenimutaatiot voivat 
osallistua taudin monimutkaiseen patogenee-
siin (5). Raskaushepatoosiin sairastuneella nai-
sella on useammin lähisuvussa maksan toimin-
tahäiriötä raskauden aikana (6).
Hormonaaliset tekijät ovat olennaisia ras-
kaushepatoosin patogeneesissa. Taudin on aja-
teltu aiheutuvan riittämättömästä maksan kapa-
siteetista metaboloida suuria määriä istukan 
tuottamia steroidihormoneja raskauden aikana 
(7,8). Maksasoluissa sappihappoja poistavan 
pumpun toimimattomuus tai hepatosyyttien 
kyvyttömyys erittää istukan tuottamien steroi-
dien hajoamistuotteita sappeen voivat aiheuttaa 
turvotusta maksassa ja sapen salpauksen. Mo-
nisikiöraskaudessa istukan tuottamien steroi-
dihormonien määrä on suurempi kuin yksi-
sikiöisessä raskaudessa. Raskaushepatoosin riski 
saattaa tästä syystä olla 2,5–5-kertainen (9,10).
Ympäristötekijät mahdollisesti vaikuttavat 
raskaushepatoosin ilmaantumiseen. Raskaus-
hepatoosi näyttää olevan talvisin yleisempi ja 
vaikeampi (3). Lisäksi ravintotekijöillä, esimer-
kiksi seleenin vähäisyydellä, voi olla merkitystä 
taudin kehittymisessä (2). Raskaushepatoosia 
sairastavilla äideillä on keskiraskaudessa tai 
synnyttäessä matalampi D-vitamiinitaso kuin 
verrokeilla (11). D-vitamiinitason on todettu 
olevan käänteisesti verrannollinen lapsiveden 
lapsenpihkalla värjääntymiseen (12). Veren ko-
honneen glukoositason (13) ja lipidiarvon (14) 
on havaittu olevan yhteydessä raskaushepatoo-
siin. Koeputkihedelmöityshoidolla alkaneisiin 
raskauksiin liittyy lähes nelinkertainen tauti-
riski (15). Yli 35 vuoden ikä saattaa lisätä ras-
kaushepatoosin riskiä (7).
Raskaushepatoosin pääasiallisen oireen, kuti-
nan, on ajateltu johtuvan seerumin sappihappo-
jen suurentuneesta määrästä ja ihon liiallisesta 
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TAULUKKO 1. 
Raskaushepatoosin erotusdiagnostiikka.
Tyypillisin  
raskauskolmannes
Kutina Maksa-arvot B Sappihapot B Keltaisuus Muita oireita tai löydöksiä
Raskaushepatoosi 3. + + + (+)
Sappikivitauti – (+) (+) + +
Hepatiitit – + + + + Virusantigeeni  löydettävissä
Raskaudenaikainen akuutti 
rasvamaksa
3. + + (+) (+) Pahoinvointi
Oksentelu
Oikean kylkikaaren kipu
Hypoglykemia
Vuodot
20 % äidin kuolleisuus
Pre-eklampsia 3. – + – – Hypertensio
Proteinuria
Päänsärky
Näköhäiriöt
Vatsakipu
Alkuraskauden pahoinvointi 1. – (+) (+) (+)
Raskaudenaikainen atooppinen 
ihottuma
2. + – – – Ihottuman tyypillinen ulkonäkö  
ja tyyppipaikat
Gestationaalinen pemﬁgoidi 2. tai 3. + – – – Rakkulat
Sikiön riski pienikokoisuuteen  
ja ennenaikaisuuteen
Monimuotoinen raskausihottuma 3. + – – – Läiskäinen ihottuma
Rakkulat mahdollisia
– = ei tyypillistä raskauskolmannesta/ei oiretta tyypillisesti; + = tyypillinen oire; (+) = mahdollinen oire, mutta ei tyypillisin
sappihappopitoisuudesta. Sappihappojen mer-
kitys on kuitenkin kyseenalaistettu, sillä se ei 
näytä olevan ainoa kutinaa selittävä tekijä 
(16,17). Kutina voi alkaa jo ennen maksa-arvo-
jen nousua tai vasta sen jälkeen (16). Steroidit 
ja niiden hajoamistuotteet välittävät sapen sal-
paukseen liittyvää (kolestaattista) kutinaa (18). 
Kohonneita histamiinitasoja on havaittu kole-
staasipotilailla (19), mutta histamiinilla ei luul-
tavasti ole olennaista merkitystä kutinan välittä-
jänä. Potilaille, joilla on kolestaattinen kutina, 
ei kehity samanlaisia ihoreaktioita kuin niille, 
joilla on kohonnut histamiinitaso. Kaikki hepa-
toosipotilaat eivät hyödy antihistamiineista kuti-
nan hoidossa (20), mutta voivat hyötyä öisin an-
tihistamiinien väsyttävästä vaikutuksesta (21).
Oireet ja diagnostiikka
Raskaushepatoosi alkaa yleensä 30. raskausvii-
kon jälkeen. Myös varhaisemmin alkavia tauti-
muotoja, jopa raskausviikolla 8, on kuvattu (3).
Terveen ihon kutina on pääasiallinen oire, 
 joka herättää epäilyn raskaushepatoosista. Pit-
kään kestävä ja voimakas kutina voi ilmetä raa-
pimisesta aiheutuvina ihorikkoina. Tyypillisesti 
kutina on voimakkainta kämmenissä, jalkapoh-
jissa ja vatsalla. Se voi olla erityisen häiritsevää 
öisin ja aiheuttaa unettomuutta ja väsymystä.
Jossakin maissa on todettu keltaisuutta jopa 
noin 10–15 prosentilla hepatoosia sairastavista 
äideistä, joskin se on suurimmaksi osaksi lie-
vää (1). Vaihtelevia kliinisiä kuvia on kuvattu: 
693 raskaushepatoosipotilaan kohortissa ei yh-
delläkään ollut kliinistä keltaisuutta (22). Suo-
messa hepatoosipotilaiden keltaisuus on hyvin 
harvinaista.
Jos kliininen epäily hepatoosista herää, var-
mistetaan asia laboratoriokokeilla. Neuvolassa 
tarkistetaan P-ALAT ja sappihapot. Jos laborato-
riokokeissa (ALAT, ASAT, bilirubiini ja sappi-
hapot) on poikkeavuutta, lähetetään odottaja 
erikoissairaanhoitoon äitiyspoliklinikalle. Diag-
noosiin vaaditaan kutinaoire ja ainakin yhden 
maksantoimintakokeen suurentunut arvo. 
Maksabiopsiassa näkyy lievä kolestaasi, jossa on 
intrasellulaarisia sappipigmenttejä ja kanavissa 
sapen salpausta, mutta ei nekroosia (23). Mak-
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sabiopsiaa ei kuitenkaan tarvita tyypillisen ras-
kaushepatoosin diagnostiikassa.
Raskaushepatoosi on yleensä helppo erottaa 
muista maksan toimintahäiriöistä. Oireiden 
varhainen alkamisajankohta tai maksa-arvojen 
pysyminen koholla synnytyksen jälkeen antavat 
aiheen pohtia muiden maksasairauksien mah-
dollisuutta (24).
Tärkeimpiä erotusdiagnostisia sairauksia 
kuvataan taulukossa 1. Niistä tärkeimpiä ovat 
sappikivitauti ja hepatiitit. Sappikivitaudin 
vahvistaa kaikututkimuksessa löydetyt sappi-
kivet. Ne oireilevat kuitenkin raskaana olevilla 
yllättävän harvoin, minkä selittänee raskauden 
aikainen suuri progestiinipitoisuus (25). He-
patiitit aiheuttavat systeemisiä oireita, ja virus-
antigeeni on löydettävissä.
Transaminaasiarvot voivat nousta myös 
 vaikeassa pre-eklampsiassa, erityisesti HELLP-
oireyhtymässä (hemolysis, elevated liver enzy-
mes, low platelets), mutta siihen ei liity kole-
staasia eikä kutinaa. Akuutti raskaudenaikainen 
rasvamaksa (AFLP) puhkeaa tyypillisesti äkilli-
sesti loppuraskaudessa ja johtaa nopeasti mak-
san toimintavajaukseen. Se on kuitenkin harvi-
nainen (1/10 000–13 000). Hyperemesis gravi-
darum eli alkuraskauden pahoinvointi voi myös 
aiheuttaa lievää hyperbilirubinemiaa ja trans-
aminaasitasojen kohoamista. Alkuraskauden 
pahoinvointiin ei tyypillisesti liity kutinaa. Ras-
kaushepatoosin varhainen alku ensimmäisellä 
kolmanneksella on hyvin harvinaista (21).
Raskauden aikana puhkeava atooppinen ihot-
tuma, urtikarinen tai gestationaalinen pemfi-
goidi ja virusinfektiot, kuten Ebstein-Barrin tai 
sytomegalovirus, voivat joskus aiheuttaa erotus-
diagnostisia haasteita. Näissä esiintyy kuitenkin 
taudille tyypillisiä ihottumia. 
Seuranta ja hoito
Hepatoosiraskaus lisää ennenaikaisen synny-
tyksen riskiä (12–44 %) (8,22,26), sikiön ahdin-
koa (10–44 %) (8,22,27,28) ja kohdunsisäisen 
kuoleman vaaraa (1–3 %). Näiden sikiöhaittojen 
aiheuttajana pidetään sappihappoja (22,29). Nii-
den on osoitettu aiheuttavan istukan laskimoi-
den vasokonstriktiota ja lisäävän myomet-
riumin herkkyyttä oksitosiinille (30,31). Niiden 
on myös osoitettu vaikuttavan useilla eri tavoilla 
istukkaan ja sikiön sydämen sykkeeseen 
(32,33). Kohdunsisäisen kuoleman riski on yh-
distetty sappihappoihin, jotka aiheuttavat sikiöl-
le rytmihäiriöitä (34).
Raskaushepatoosin seuranta ja hoito tapahtu-
vat äitiyspoliklinikalla. Maksan toimintakokeita, 
joista ALAT ja sappihapot tärkeimpinä, tarkkail-
laan kerran tai kaksi viikossa. Sikiön vointia 
tarkkaillaan yksilöllisesti kardiotokografian 
(KTG) ja ultraäänen avulla. Sikiön kuolema on 
äkillinen tapahtuma, ja käytettävissä olevilla 
seurantamenetelmillä sitä on vaikea ennustaa 
(35). Toisinaan päädytään käynnistämään syn-
nytys tai tekemään keisarileikkaus. Kuitenkin 
tutkimusnäyttö keisarileikkauksen tai varhaisen 
käynnistämisen eduista puuttuu (36).
Synnytyksen jälkeen maksa-arvot palautuvat 
normaaleiksi. Niiden seurannan tarpeellisuudes-
ta synnytyksen jälkeen vallitsee erilaisia käsityk-
siä. Suomessa maksa-arvoja ei yleensä ole seu-
rattu, jos synnyttäjä on parantunut oireettomaksi 
ja kliininen kuva on ollut tyypillinen. Jos oireet 
jatkuvat synnytyksen jälkeen, tutkitaan maksa-
kokeet perusterveydenhuollossa (kuvio 1).
Lääkkeettömistä hoidoista vähärasvaista ruo-
kavaliota voidaan suositella vähentämään mak-
san metabolista taakkaa (37). Oireenmukaisena 
hoitona voidaan kutinaan käyttää antihista-
miineja, vaikkakin niiden tehoa on epäilty kuti-
nan syyteorioiden perusteella (17). Myös viilen-
tävää mentolivoidetta on suositeltu lieventä-
mään ihon kutinaa (24).
Ursodeoksikoolihappoa (UDCA) pidetään 
raskaushepatoosin tehokkaimpana hoitona. Se 
vaikuttaa tehokkaalta vähentämään kutinaa ja 
parantamaan maksa-arvoja, ja se voi myös eh-
käistä sikiön ahdinkoa (38). Ursodeoksikooli-
happo vähentää ja korvaa sapen endogeenisiä 
sappihappoja, normalisoi maksaentsyymien ta-
soja kaikissa intrahepaattisissa kolestaattisissa 
tiloissa ja pienentää bilirubiinipitoisuuksia. Se 
myös parantaa sappihappojen kuljetusta pois 
 istukasta ja siten voisi vähentää tautiin liittyviä 
sikiön riskejä (38,39). Tuoreessa kotimaisessa 
tutkimuksessa ursodeoksikoolihappo helpotti 
äidin kokemaa kutinaa ja paransi maksan toi-
mintakokeita vaikuttamatta kuitenkaan sikiöön 
ja istukan estrogeenituotantoon (40). Tarvitaan 
kuitenkin lisää tutkimusta sen vaikutuksista 
 sikiöön (21).
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Terveen ihon kutina on pääasiallinen oire,  
joka herättää epäilyn raskaushepatoosista.
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Myös muita valmisteita on käytetty raskaus-
hepatoosin hoidossa, joskaan yhtä tehokasta ja 
turvallista kuin ursodeoksikoolihappo ei ole tois-
taiseksi löytynyt. Aiemmin on käytetty muun 
muassa barbituraatteja, rifampisiinia, kolestyra-
miinia ja deksametasonia (41). Rifampisiini on 
antibiootti, jolla on vaikutuksia sapen erittymi-
seen. Sitä käytetään primaarisen biliaarisen kir-
roosin hoidossa. On esitetty, että ursodeoksikoo-
lihappo yhdistettynä rifampisiiniin olisi tehok-
kaampi kuin kumpikaan monoterapiana, mutta 
satunnaistettuja tutkimuksia ei tästä ole. Kolesty-
ramiini voi heikentää ursodeoksikoolihapon ja 
rasvaliukoisten vitamiinien imeytymistä suolis-
tosta ja lisätä verenvuodon riskiä synnytyksen 
 aikana tai sen jälkeen. Siksi sitä ei suositella 
 ensilinjan hoidoksi (21). Joissakin tapauksissa 
deksametasoni lievittää tehokkaasti hepatoosin 
oireita ja alentaa seerumin sappihappotasoja 
(42,43,44). Deksametasonin toistuvat suuret an-
nokset on kuitenkin yhdistetty pieneen syntymä-
painoon (45) ja poikkeavaan hermoston kehityk-
seen (46), minkä vuoksi sitä ei suositella raskaus-
hepatoosin ensilinjan hoidoksi.
Ennuste
Raskaushepatoosi lisää ennenaikaisen synny-
tyksen ja vastasyntyneen erityishoidon tarvetta 
(7). Havaintoja syntyneiden lasten matalammis-
ta Apgar-pisteistä on julkaistu (7), mutta kaikki 
tutkimukset eivät ole vahvistaneet tällaista 
 havaintoa (47).
Raskaushepatoosilla on hyvä ennuste. Synny-
tyksen jälkeen kutina häviää parissa päivässä 
(1). Jos keltaisuutta on ollut, se häviää puoles-
taan parissa viikossa. Laboratoriokokeet norma-
lisoituvat 2–8 viikon aikana. Jos oireet jatkuvat 
synnytyksen jälkeen, on etsittävä taustalta piile-
vää maksasairautta (48). Seuraavassa raskaudes-
sa hepatoosi on yleinen (4), mutta raskauden 
seuranta voi tapahtua normaalisti neuvolassa. 
Kutinan ilmaantuessa ohjelmoidaan maksa- 
arvojen tutkimukset.
Pitkäaikaisvaikutukset
Raskaushepatoosiin liittyy useiden maksa-, sap-
pi- ja haimasairauksien lisääntynyt riski. Koti-
maisessa suuressa tutkimuksessa todettiin kol-
minkertainen hepatiitti C:n riski ja kahdeksan-
kertainen alkoholiin liittymättömän maksakir-
roosin riski. Sappikivien ja sappirakon tuleh-
duksen riski oli lähes nelinkertainen. Alko-
holiin liittymättömän haimatulehduksen riski 
oli puolestaan kolminkertainen, mutta riskin 
kasvua voi selittää myös sappikivien suurempi 
esiintyvyys (48). Toisessa kotimaisessa tutki-
muksessa on lisäksi hypotyreoosin ja rintasyö-
vän havaittu olevan yleisempiä hepatoosiin sai-
rastuneilla naisilla (49).
Suomalaisessa potilasryhmässä taudin ei ole 
todettu vaikuttavan juurikaan naisten terveys-
tottumuksiin pidemmällä aikavälillä (50). Ras-
kaushepatoosin sairastaneet naiset ovat har-
vemmin käyttäneet yhdistelmäehkäisypillereitä, 
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 KUVIO 1.
Raskaushepatoosin hoito, seuranta ja lähettämisindikaatiot.
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ja heidän on havaittu rajoittaneen lapsilukuaan 
terveyssyistä useammin kuin verrokkien (51). 
Hormonikorvaushoitojen määrään ei taudin ole 
todettu kotimaisessa väestöryhmässä vaikutta-
van, mutta naiset ovat muita useammin koh-
danneet kieltoja niiden käyttämisestä (52).
Nykyisten matalahormonisten yhdistelmä-
ehkäisypillerien käyttö näyttää turvalliselta ras-
kaushepatoosin jälkeen. On kuitenkin ehdotettu, 
että potilaalle kerrotaan kutinan mahdollisuu-
desta ja testattaisiin rutiinimaisesti maksakokeet 
kolmen ja kuuden kuukauden jälkeen yhdistel-
mäehkäisypillerien aloituksesta (53). Progestiinia 
sisältävien minipillerien käyttö on turvallista eikä 
laboratoriokontrolleja tarvita (54).
Raskaushepatoosiin liittyy geneettinen teki-
jä, mutta tietoa lasten myöhemmästä tervey-
destä on vähän. Kahdessa suomalaistutkimuk-
sessa päätulos oli, ettei hepatoosin sairastanei-
den äitien tyttärien tai poikien terveys eronnut 
verrokeista (55,56). Tyttärien riski sairastua 
raskaushepatoosiin omassa raskaudessaan on 
suurentunut (6).
Oraalisen tai transdermaalisen hormonikor-
vaushoidon ei ole havaittu haittaavan maksan 
toimintaa hepatoosin sairastaneilla naisilla 
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(57), joten nykytiedon valossa se näyttää ole-
van turvallista.
Raskaushepatoosin sairastaminen lisää jonkin 
verran joidenkin sairauksien riskiä (58), mutta 
hepatoosi on kuitenkin äidille varsin harmiton. 
Naisia tulee rohkaista elämään normaalia elä-
mää raskaushepatoosin sairastamisen jälkeen.
Lopuksi
Raskaushepatoosi on äidille varsin vaaraton 
tauti, mutta sikiön riskien vuoksi tila vaatii seu-
rantaa erikoissairaanhoidossa. Ursodeoksikooli-
happo on tällä hetkellä suositelluin lääkehoito. 
Tietoa tautiin mahdollisesti liittyvistä pitkä-
aikaisseurauksista on kertymässä. O
English summary | www.laakarilehti.fi | in english
Intrahepatic cholestasis of pregnancy
1063SUOMEN LÄÄKÄRILEHTI 15/2016 VSK 71
Intrahepatic cholestasis of pregnancy
@ekiX_\gXk`ZZ_fc\jkXj`jf]gi\^eXeZp@:G `jXc`m\i[`jfi[\in_\i\Y`c\Ôfn`j`dgX`i\[%K_\gi\mXc\eZ\f]@:G`j
Xggifo`dXk\cp(`e=`ecXe[%@:GljlXccpdXe`]\jkjX]k\i*'^\jkXk`feXcn\\bj#Xe[k_\dX`ejpdgkfd`j`kZ_`e^
\jg\Z`Xccpfek_\gXcdj#jfc\jXe[XY[fd\e%=fik_\[`X^efj`jf]@:GXcjfXi`j\`ec`m\i]leZk`fegXiXd\k\ij#
kpg`ZXccp8C8KXe[&fiY`c\XZ`[j#`jXcjfi\hl`i\[%
K_\\k`fcf^pXe[gXk_f^\e\j`jf]@:G`jZfdgc\o%@eX[[`k`fekfk_\^\e\k`ZjljZ\gk`Y`c`kpXe[k_\_fidfeXc
Zfdgfe\ek[li`e^gi\^eXeZp#\em`ifed\ekXc]XZkfij_Xm\XcjfY\\ejl^^\jk\[%K_\[`j\Xj\`jhl`k\efe$_Xid]lc
kfk_\dfk_\i#Xck_fl^_`kZ_`e^ZXeY\`ii`kXk`e^Xe[[`jkliY_\ijc\\g%=ifdgi`dXip_\Xck_ZXi\#k_\gi\^eXek
nfdXen`k_@:Gj_flc[Y\i\]\ii\[kfXefYjk\ki`ZZc`e`Z#n_\i\j_\n`ccY\ZXi\]lccpdfe`kfi\[YpcXYfiXkfip
k\jkj#:K>ZXi[`fkfZf^iXg_p Xe[lckiXjfle[Y\ZXlj\f]k_\]\kXci`jbj%@:G`eZi\Xj\jk_\i`jbf]gi\dXkli\
[\c`m\ip#Xe[]\kXc[`jki\jj[li`e^cXYfliXe[jk`ccY`ik_%K_\i\Zfdd\e[\[ki\Xkd\ek`jlijf[\fopZ_fc`ZXZ`[#
n_`Z_dXp`dgifm\c`m\i]leZk`fek\jkjXe[i\[lZ\]\kXci`jbj%@eZ\ikX`eZXj\j`e[lZk`fef]cXYflifiZX\jXi\Xe
j\Zk`fe`j`e[`ZXk\[%
@kZ_`e^jlYj`[\jn`k_`eXZflgc\f][XpjX]k\icXYfliXe[cXYfiXkfipk\jkjefidXc`q\n`k_`e\`^_kn\\bj%Nfd\e
n`k_X_`jkfipf]@:G_Xm\Xe`eZi\Xj\[i`jbf]c`m\i#gXeZi\Xk`ZXe[Y`c`Xip[`jfi[\ij%C`b\n`j\#_`^_\i]i\hl\eZ`\j
f]_pgfk_pif`[`jdXe[Yi\XjkZXeZ\i_Xm\Y\\ei\gfik\[%
English summary
SUVI HÄMÄLÄINEN
D%;%#I\j\XiZ_\i#Le`m\ij`kpf]
KXdg\i\
>\e\iXcGiXZk`fe\i#@bXXc`e\e
?\Xck_:\ek\i
jlm`%_XdXcX`e\e7lkX%]`
KAISA TURUNEN 
KARI J. MATTILA  
JUKKA UOTILA 
MARKKU SUMANEN
SUOMEN LÄÄKÄRILEHTI 15/2016 VSK 711063a
38%/,&$7,21
,,
,QWUDKHSDWLFFKROHVWDVLVRISUHJQDQF\DQGFRPRUELGLW\$\HDUIROORZXS
VWXG\
+lPlOlLQHQ677XUXQHQ.0DWWLOD.-.RVXQHQ(6XPDQHQ0
$FWD2EVWHW*\QHFRO6FDQG
3XEOLFDWLRQUHSULQWHGZLWKWKHSHUPLVVLRQRIWKHFRS\ULJKWKROGHUV

 







38%/,&$7,21
,,,
,QWUDKHSDWLF&KROHVWDVLVRI3UHJQDQF\DQG&DQFHU$&RKRUW6WXG\
+lPlOlLQHQ677XUXQHQ.0DWWLOD.-.RVXQHQ(6XPDQHQ0
)DP0HG0HG6FL5HV
3XEOLFDWLRQUHSULQWHGZLWKWKHSHUPLVVLRQRIWKHFRS\ULJKWKROGHUV

 







,QWUDKHSDWLF&KROHVWDVLVRI3UHJQDQF\DQG&DQFHU$&RKRUW6WXG\
6XYL7XXOLD+lPlOlLQHQ.DLVD7XUXQHQ.DUL-0DWWLOD(OLVH.RVXQHQDQG0DUNNX6XPDQHQ
'HSDUWPHQWRI*HQHUDO3UDFWLFH)DFXOW\RI0HGLFLQHDQG/LIH6FLHQFHV8QLYHUVLW\RI7DPSHUH7DPSHUH)LQODQG
-DQDNNDOD+HDOWK&HQWUH7XUHQNL)LQODQG
&HQWUHIRU*HQHUDO3UDFWLFH3LUNDQPDD+RVSLWDO'LVWULFW7DPSHUH)LQODQG
&RUUHVSRQGLQJDXWKRU6XYL7XXOLD+lPlOlLQHQ'HSDUWPHQWRI*HQHUDO3UDFWLFH)DFXOW\RI0HGLFLQHDQG/LIH6FLHQFHV8QLYHUVLW\RI7DPSHUH7DPSHUH)LQODQG7HO
(PDLOKDPDODLQHQVXYLW#VWXGHQWXWDIL
5HFHLYHGGDWH-XQH$FFHSWHGGDWH-XQH3XEOLVKHGGDWH-XO\
&RS\ULJKW   +lPlOlLQHQ 67 HW DO 7KLV LV DQ RSHQDFFHVV DUWLFOH GLVWULEXWHG XQGHU WKH WHUPV RI WKH &UHDWLYH &RPPRQV $WWULEXWLRQ /LFHQVH ZKLFK SHUPLWV
XQUHVWULFWHGXVHGLVWULEXWLRQDQGUHSURGXFWLRQLQDQ\PHGLXPSURYLGHGWKHRULJLQDODXWKRUDQGVRXUFHDUHFUHGLWHG
$EVWUDFW
2EMHFWLYH ,Q D SUHYLRXV TXHVWLRQQDLUH VWXG\PRUH EUHDVW FDQFHUVZHUH UHSRUWHG E\ZRPHQZLWK LQWUDKHSDWLF
FKROHVWDVLV RI SUHJQDQF\ ,&3 WKDQ E\ WKH FRQWUROV 7KH DLP RI WKLV VWXG\ ZDV WR HVWDEOLVK ZKHWKHU ,&3 LV
DVVRFLDWHGZLWKFDQFHU LQ WKH)LQQLVK&DQFHU5HJLVWU\GDWD WKHVWXG\SRSXODWLRQEHLQJWKHVDPHFRKRUWDV LQ WKH
TXHVWLRQQDLUHVWXG\
0HWKRGV7KHVWXG\SRSXODWLRQFRPSULVHGZRPHQZLWK ,&3 LQDW OHDVWRQHSUHJQDQF\DQGFRQWUROV
IURP7DPSHUH8QLYHUVLW\+RVSLWDO LQ)LQODQGGXULQJ±7KH FDQFHU GDWDZHUHREWDLQHG IURP WKH)LQQLVK
&DQFHU5HJLVWU\7KHFDQFHUVZHUHFODVVLILHGE\,&'2DQGGLDJQRVHGGXULQJWKHSHULRGí
5HVXOWV,QWKH,&3JURXSWKHRGGVUDWLRRIFDQFHUV25&,±DQGEUHDVWFDQFHULQSDUWLFXODU
25&,±ZDVVOLJKWO\KLJKHU WKDQ LQ WKHFRQWUROJURXS6HYHQSHUFHQWRI WKH ,&3JURXSDQG
RIWKHFRQWUROJURXSKDGEUHDVWFDQFHU
&RQFOXVLRQ %DVHG RQ WKLV VWXG\ WKHUH LV QRW D VLJQLILFDQW DVVRFLDWLRQ EHWZHHQ ,&3 DQG FDQFHU (DUOLHU
REVHUYDWLRQ LQWKHTXHVWLRQQDLUHVWXG\UHJDUGLQJDVVRFLDWLRQEHWZHHQ,&3DQGEUHDVWFDQFHUFDQQRWEHFRQILUPHG
E\WKLVUHJLVWU\EDVHGVWXG\
.H\ZRUGV,QWUDKHSDWLFFKROHVWDVLVRISUHJQDQF\,&3&DQFHU
,QWURGXFWLRQ
,QWUDKHSDWLF FKROHVWDVLV RI SUHJQDQF\ ,&3 LV D UHYHUVLEOH OLYHU
GLVRUGHUZLWKSUXULWXVDV WKHPDLQ V\PSWRPHVSHFLDOO\RQ WKHSDOPV
DQGVROHV$QHOHYDWHGVHUXPELOHDFLGDQGWUDQVDPLQDVHFRQFHQWUDWLRQ
LV DOVR UHTXLUHG IRU GLDJQRVLV >@ ,Q (XURSH WKH LQFLGHQFH RI ,&3 LV
DSSUR[LPDWHO\  EXW UDWHV YDU\ JHRJUDSKLFDOO\ >@ ,Q )LQODQG WKH
LQFLGHQFHLVDSSUR[LPDWHO\Ρ>@DQGLQ6ZHGHQWKHLQFLGHQFH
LV Ρ >@ +RUPRQDO IDFWRUV VHHP WR FRQWULEXWH WR WKH
SDWKRJHQHVLV RI ,&3 >@ (VWURJHQ PD\ SDUWLFLSDWH LQ WKH
GHYHORSPHQW RI FKROHVWDVLV >@ DQG SURJHVWHURQHPD\ LPSDLU KHSDWLF
ELOHKRPHRVWDVLV >@*HQHWLF IDFWRUVDUHNQRZQWREH LQYROYHGLQ WKH
SDWKRJHQHVLV ,&3 LV LQKHULWHG DV D VH[OLPLWHG GRPLQDQW SKHQRW\SH
DQG PXOWLSOH JHQHV DUH LQپXHQWLDO >@ 0XOWLGUXJUHVLVWDQW SURWHLQ 
0'5 LV DVVRFLDWHG ZLWK XS WR  RI ,&3 FDVHV >@
(QYLURQPHQWDOIDFWRUVPD\DOVRKDYHDUROHLQWKHSDWKRJHQHVLVRIWKH
GLVRUGHU >@ ,Q DGGLWLRQ D SRVLWLYH IDPLO\ KLVWRU\ >@ DQG WZLQ
SUHJQDQFLHVUDLVHWKHULVNRI,&3>@
([FHVVLYHH[SRVXUHRIHQGRJHQRXVHVWURJHQRYHUWKHOLIHWLPHPD\EH
D FDXVDWLYH IDFWRU RI EUHDVW FDQFHU >@ +RUPRQDO JHQHWLF DQG
HQYLURQPHQWDO IDFWRUV DUH NQRZQ WRKDYH DQ LPSDFW RQ WKH DHWLRORJ\
DQGSDWKRJHQHVLVRIFDQFHUVDQG,&3&DQFHUDQWLJHQ&$LV
DJO\FRSURWHLQFRPPRQO\IRXQGLQEUHDVWFDQFHUFHOOVDQGLWVOHYHOVLQ
VHUXP UHپHFW WKH DPRXQW RI EUHDVW FDQFHU FHOOV LQ WKH ERG\ &$
OHYHOV DUH UDLVHG GXULQJ SUHJQDQF\ LQ JHQHUDO EXW WKH\ DUH KLJKHU LQ
,&3SUHJQDQFLHV WKDQ LQ FRQWUROV >@ ,Q DQ H[WHQVLYH UHJLVWU\EDVHG
VWXG\,&3ZDVDVVRFLDWHGZLWKDQLQFUHDVHGULVNIRUODWHUKHSDWRELOLDU\
FDQFHU+HSDWLWLV&LQIHFWLRQZDVVWURQJO\DVVRFLDWHGZLWKOLYHUFDQFHU
EXW DіHU DGMXVWLQJ IRU WKLV GLDJQRVLV ZRPHQ ZLWK ,&3 ZHUH VWLOO DW
LQFUHDVHGULVN IRU OLYHUPDOLJQDQF\ ,QDGGLWLRQ LQDVHSDUDWHDQDO\VLV
H[FOXGLQJDOOZRPHQZLWKJDOOVWRQHGLVHDVHRUFKRODQJLWLVZRPHQZLWK
,&3KDGDQLQFUHDVHGULVNIRUELOLDU\WUHHPDOLJQDQFLHV>@
$ORZQXPEHURIFKLOGELUWKVKDVEHHQDVVRFLDWHGZLWKDQLQFUHDVHG
ULVNIRUEUHDVWFDQFHU6LQFHPRWKHUVZLWK,&3KDYHEHHQIRXQGWROLPLW
WKHLUFKLOGQXPEHUPRUHRіHQWKDQFRQWUROV>@LWPD\EHVSHFXODWHG
ZKHWKHU WKLV KDV LQFUHDVHG WKH LQFLGHQFH RI EUHDVW FDQFHUV 3ULPDU\
KHDOWKFDUH DUUDQJHV DOPRVW H[FOXVLYHO\ PDWHUQLW\ FDUH LQ WKH 1RUGLF
FRXQWULHV >@ ,Q )LQODQG KHDOWK FHQWUHV PDLQWDLQ PDWHUQLW\ KHDOWK
FOLQLFVZKHUHDQXUVHRUDPLGZLIHDQGD)DPLO\'RFWRUDUHUHVSRQVLEOH
IRU FDUH >@ НH PDWHUQLW\ KHDOWK FOLQLFV LQ SULPDU\ KHDOWK FDUH
XVXDOO\ GHWHFW ,&3 ,I D SUHJQDQW ZRPDQ FRPSODLQV RI SUXULWXV KHU
$/$7DQGELOHDFLGVYDOXHVDUHVFUHHQHG(LWKHURI WKHVHYDOXHVEHLQJ
HOHYDWHG WKHPRWKHU LV UHIHUUHG WR DQ REVWHWULFLDQ >@ ,I SUXULWXV LV
LQWROHUDEOHWKHPRWKHULVUHIHUUHGWRWKHREVWHWULFFOLQLFZLWKRXWZDLWLQJ
WKHUHVXOWVRIWKHEORRGWHVW
$TXHVWLRQQDLUHVWXG\REVHUYHGWKDW,&3PD\EHDVVRFLDWHGZLWKDQ
HOHYDWHGULVN IRUEUHDVWFDQFHU >@+RZHYHU WKHVWXG\ZDVEDVHGRQ
VXEMHFWLYH LQIRUPDWLRQ REWDLQHG IURP VHOIUHSRUWV НH DLP RI WKH
SUHVHQWVWXG\ZDVWRLQYHVWLJDWHXVLQJREMHFWLYHUHJLVWU\GDWDZKHWKHU
,&3KDVDQDVVRFLDWLRQZLWKEUHDVWFDQFHURURWKHUFDQFHUVZKHQXVLQJ
WKHVDPHFRKRUWDVWKHTXHVWLRQQDLUHVWXG\
+lPlOlLQHQHWDO)DP0HG0HG6FL5HV
'2,
5HVHDUFK$UWLFOH 2SHQ$FFHVV
)DP0HG0HG6FL5HVDQRSHQDFFHVVMRXUQDO
,661
9ROXPHͫ,VVXHͫ
Fa
m
ily
 M
ed
ici
ne
 & M
edical Science Research
ISSN: 2327-4972
Family Medicine & 
Medical Science Research
0DWHULDODQG0HWKRGV
$OO,&3SUHJQDQFLHVDW7DPSHUH8QLYHUVLW\+RVSLWDO78+GXULQJ
͡ZHUHFROOHFWHGIURPWKHSDWLHQWUHFRUGV)URPWR
,&'ZDVXVHGDW78+%HFDXVH,&'GLGQRWLQFOXGHDSUHFLVHFRGH
IRU ,&3 ZH FKHFNHG DOO WKH REVWHWULF FRGHV WKDW PLJKW FRQWDLQ ,&3
 7R[LFRVLV 18'  3UXULWXV  ,FWHUXV JUDYLV 
1HFURVLV DFXWD HW VXEDFXWD KHSDWLV DQG  $OLDH GHٽQLWDH
НHUHDіHUZHFKHFNHGWKHZULWWHQGLDJQRVLVEHKLQGWKHFRGHDQGLILW
UHIHUUHGWR,&3ZHLQFOXGHGWKHFDVHIRUIXUWKHUVHOHFWLRQ,&'ZDV
XVHGEHWZHHQDQG DQG LW FRQWDLQHG WKH DSSURSULDWH FRGHV
$ +HSDWRVLV JUDYLGDUXP DQG ; +HSDWRSDWKLD DOLD НH
GLDJQRVLVZDV YHULٽHG IURP HDFK SDWLHQW UHFRUGZLWK WKH SUHVHQFH RI
WKHPDLQV\PSWRPRILWFKLQJDQGDEQRUPDOODERUDWRU\WHVWUHVXOWV$W
OHDVWRQHRIWKHIROORZLQJZDVUHTXLUHG$6$7!8O$/$7!8O
RUELOHDFLGVƗPROORUPRUH
НH VWXG\ SRSXODWLRQ FRPSULVHG  ,&3 GHOLYHULHV НH GDWD
LQFOXGHGVRPHZRPHQZLWKUHSHDWHG,&3GHOLYHULHVDQGHDFKRIWKHVH
ZRPHQ ZDV VWXGLHG DV DQ LQGLYLGXDO FDVH НH ,&3 JURXS WKXV
FRQWDLQHG ZRPHQНH SURFHHGLQJ DQG IROORZLQJ VXEMHFWV LQ WKH
PDWHUQLW\ZDUGGLDU\ZHUH WDNHQDVFRQWUROV IRUHDFK,&3FDVHНHUH
ZHUH  FRQWUROV LQ WRWDOНH JURXSV ZHUH FRPSDUDEOH UHJDUGLQJ
DJHHGXFDWLRQDOOHYHODQGERG\PDVVLQGH[НHGHOLYHULHVRIPRWKHUV
ZLWK ,&3 WRRN SODFH DW HDUOLHU JHVWDWLRQDO ZHHNV WKDQ WKRVH RI WKH
FRQWUROV)RXUZRPHQZHUHUXOHGRXWIURPWKH,&3FDVHVDQGIURP
WKHFRQWUROVEHFDXVHRIDPLVVLQJSHUVRQDOLGHQWLW\FRGHНHٽQDOGDWD
FRPSULVHGZRPHQZLWK,&3DQGFRQWUROV
НHFDQFHUGDWDZHUHREWDLQHGIURPWKH)LQQLVK&DQFHU5HJLVWU\LQ
-DQXDU\  EDVHG RQ SHUVRQDO LGHQWLW\ FRGHV $OO SK\VLFLDQV
KRVSLWDOV DQG RWKHU UHOHYDQW LQVWLWXWLRQV KDYH KDG DQ REOLJDWLRQ WR
UHSRUW HYHU\ FDQFHU WR WKH )LQQLVK &DQFHU 5HJLVWU\ VLQFH НH
GDWDEDVH FRQWDLQV DOO WKH GLDJQRVHG FDQFHUV DQG FDQFHU GHDWKV LQ
)LQODQG VLQFH  DQG WKH PRVW RI FDQFHUV VLQFH  ZKHQ
V\VWHPDWLF FDQFHU UHJLVWUDWLRQ ZDV VWDUWHG >@НH )LQQLVK &DQFHU
5HJLVWU\ DOVR FRQWDLQV LQIRUPDWLRQ RQ DOO GHDWK FHUWLٽFDWHV WKDW
PHQWLRQ FDQFHU НH 5HJLVWU\ WDNHV QRWLFH RI WKH FRPSOHWHQHVV DQG
DFFXUDF\RI LWVGDWD DQG LWV FRPSOHWHQHVVKDVEHHQ VKRZQ WREHRYHU
 >@НH5HJLVWU\ LVXSKHOGE\ WKH1DWLRQDO ,QVWLWXWH IRU+HDOWK
DQG:HOIDUHRI)LQODQGНHVWXG\GDWDLQFOXGHGDOOUHSRUWHGFDQFHUVRI
WKHFRKRUWGXULQJ͡DOOUHJLVWHUHGFDQFHUVGXULQJ͡
DQG WKH ORFDWLRQ DQG EHKDYLRXU RI WKH FDQFHU НH FDQFHUV ZHUH
UHSRUWHGE\,&'2WRSRJUDSKLFDOFRGHV>@:RPHQZKRKDGKDG
PRUH WKDQ RQH FDQFHU ZHUH DOVR LQFOXGHG LQ WKH VWXG\НH FDQFHUV
ZHUH FODVVLٽHG E\ ,&'2 FRGHV LQWR ODUJHU VXEJURXSV &DQFHU
EHKDYLRXU ZDV FODVVLٽHG DV EHQLJQ XQFOHDU EHKDYLRXU FDUFLQRPD LQ
VLWXRUPDOLJQDQW
НHGDWDZHUHDQDO\VHGXVLQJWKH63666\VWHPIRU:LQGRZV9HUVLRQ
 НH UHVXOWV DUH SUHVHQWHG DV IUHTXHQFLHV DQG SHUFHQWDJHV
6WDWLVWLFDO VLJQLٽFDQFH ZDV WHVWHG ZLWK D FKLVTXDUHG WHVW %LQDU\
ORJLVWLF UHJUHVVLRQDQDO\VLVZDVSHUIRUPHG WRREWDLQRGGVUDWLRV 25
DQGFRQٽGHQFH LQWHUYDOV &,НHGHSHQGHQW YDULDEOHZDV ͦ,&3
RUQRW ͧ7WHVWZDVSHUIRUPHGWRH[SORUHGLٶHUHQFHUHJDUGLQJDJHDWWKH
GLDJQRVH PRPHQW RI FDQFHU НH FRKRUW GLG QRW REWDLQ LQIRUPHG
FRQVHQWEHFDXVHWKHVWXG\LVUHWURVSHFWLYHDQGGRHVQRWKDYHDQHٶHFW
RQ WUHDWPHQW НH VWXG\ KDV WKH DSSURYDO RI WKH 5HJLRQDO (WKLFV
&RPPLWWHHRI7DPSHUH8QLYHUVLW\+RVSLWDO5DQGWKH1DWLRQDO
,QVWLWXWHIRU+HDOWKDQG:HOIDUHLQ)LQODQG7+/
5HVXOWV
,Q WKH ,&3 JURXS ZRPHQ  KDG EHHQ GLDJQRVHGZLWK DW
OHDVWRQHFDQFHUFRPSDUHGWRZRPHQLQWKHFRQWUROJURXS
НHGLٶHUHQFHZDVQRWVWDWLVWLFDOO\VLJQLٽFDQWS 0RWKHUVZLWK
,&3KDGDVOLJKWO\KLJKHUULVNIRUFDQFHU25&,͡
WKDQ WKH FRQWUROPRWKHUV1RQH RI WKHPRWKHUVZLWK ,&3 DQGٽіHHQ
RIWKHFRQWUROVKDGEHHQGLDJQRVHGZLWKWZRRUPRUHVHSDUDWH
FDQFHUVS 2QHRIWKHFRQWUROVKDGKDGWKUHHVHSDUDWHFDQFHUV
НUHHZRPHQKDGEHHQGLDJQRVHGZLWKDFDQFHUEHIRUHODERXUDQGDOO
RIWKHPZHUHFRQWUROV
НHRFFXUUHQFHRIFDQFHUVLVSUHVHQWHGLQ7DEOH%UHDVWFDQFHUZDV
WKHPRVWFRPPRQFDQFHULQERWKJURXSVНHPRWKHUVZLWK,&3KDGD
VOLJKWO\KLJKHUULVNIRUEUHDVWFDQFHU25&,͡WKDQ
WKHFRQWUROPRWKHUV%UHDVWFDQFHUZDVGLDJQRVHGDWDVOLJKWO\ROGHUDJH
LQWKH,&3JURXSWKDQLQWKHFRQWUROJURXSEXWWKHGLٶHUHQFHZDVQRW
VWDWLVWLFDOO\VLJQLٽFDQW
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7DEOH  НH RFFXUUHQFH RI FDQFHUV LQ PRWKHUV ZLWK ,&3 DQG WKH
FRQWUROV
&LWDWLRQ +lPlOlLQHQ677XUXQHQ.0DWWLOD.-.RVXQHQ(6XPDQHQ0,QWUDKHSDWLF&KROHVWDVLVRI3UHJQDQF\DQG&DQFHU$&RKRUW
6WXG\)DP0HG0HG6FL5HVGRL
3DJHRI
)DP0HG0HG6FL5HVDQRSHQDFFHVVMRXUQDO
,661
9ROXPHͫ,VVXHͫ
0HODQRPD DQG RWKHU PDOLJQDQW QHRSODVPV RI WKH VNLQ DV ZHOO DV
FDQFHUV RI WKH IHPDOH JHQLWDO RUJDQV ZHUH DPRQJ WKHPRVW FRPPRQ
FDQFHUV LQ ERWK JURXSV &DQFHUV RI WKH WK\URLG DQG RWKHU HQGRFULQH
JODQGV DQG XULQDU\ WUDFW FDQFHU ZHUHPRUH FRPPRQ LQ WKHPRWKHUV
ZLWK,&3WKDQLQWKHFRQWUROVEXWWKHGLٶHUHQFHVZHUHQRWVWDWLVWLFDOO\
VLJQLٽFDQW 2I WKH GLJHVWLYH RUJDQ FDQFHUV KHSDWRELOLDU\ FDQFHU ZDV
DOVR H[DPLQHG VHSDUDWHO\ +HSDWRELOLDU\ FDQFHU ZDV IRXQG LQ RQH
PRWKHU ZLWK ,&3 DQG DPRQJ QRQH RI FRQWUROV 0RVW RI WKH FDQFHUV
QHDUO\ZHUHPDOLJQDQW LQERWKJURXSV7DEOHНHGLٶHUHQFH
EHWZHHQWKHJURXSVZDVQRWVWDWLVWLFDOO\VLJQLٽFDQWS 
&DQFHUEHKDYLRXU 0RWKHUVZLWK,&3Q  &RQWUROPRWKHUVQ 
0DOLJQDQW  
&DUFLQRPDLQVLWX  
8QFOHDUEHKDYLRXU  
%HQLJQ  
7DEOH&DQFHUEHKDYLRXUDFFRUGLQJWR,&'2DPRQJPRWKHUVZLWK,&3DQGWKHFRQWUROV
НHPRWKHUVZLWK,&3KDGEHHQGLDJQRVHGZLWKFDQFHUDWDVOLJKWO\
ROGHU DJH WKHPHDQ DJH EHLQJ  \HDUV LQ WKH ,&3 JURXS DQG 
\HDUVLQWKHFRQWUROJURXSНHGLٶHUHQFHZDV\HDUVS НH
PHDQ DJH RIPRWKHUV ZKR KDG QRW EHHQ GLDJQRVHG ZLWK FDQFHU ZDV
 \HDUV DPRQJ ,&3 PRWKHUV DQG  \HDUV DPRQJ FRQWUROV LQ

'LVFXVVLRQ
НH,&3JURXSDQGWKHFRQWUROJURXSHYLQFHGPLQRUGLٶHUHQFHVLQ
PRVW RI WKH VWXG\ RXWFRPHPHDVXUHVНH ٽQGLQJV DUH LQ DJUHHPHQW
ZLWKIRUPHUREVHUYDWLRQVRQWKHDVVRFLDWLRQRIFDQFHUDQG,&3,QWKH
FRQWUROJURXSWKHUHZHUHZRPHQZKRKDGEHHQGLDJQRVHGZLWKWZRRU
PRUHVHSDUDWHFDQFHUVEXWLQWKH,&3JURXSHDFKZRPDQZLWKFDQFHU
KDGEHHQGLDJQRVHGZLWKRQO\RQH FDQFHU ,&3ZDVDVVRFLDWHGZLWKD
VOLJKWO\KLJKHUULVNIRUFDQFHUHVSHFLDOO\EUHDVWFDQFHU
НH DLP RI WKH SUHVHQW VWXG\ ZDV WR HVWDEOLVK ZKHWKHU ,&3 LV
DVVRFLDWHGZLWKDQLQFUHDVHGULVNIRUFDQFHUVDQGHVSHFLDOO\IRUEUHDVW
FDQFHUZKLFKZDVWKHUHVXOWIRXQGIURPWKHHDUOLHUVWXG\EDVHGRQVHOI
UHSRUWV 'HVSLWH WKH VPDOO ORVV RI FDVHV WKH GDWD ZHUH DGHTXDWHНH
GDWD REWDLQHG IURP WKH )LQQLVK &DQFHU 5HJLVWU\ FDQ EH FRQVLGHUHG
UHOLDEOH
0HGLFDWLRQVPD\ KDYH DQ LPSDFW RQ WKH ULVN IRU FDQFHU2YHU WKH
SDVWGHFDGHVYDULRXVWUHDWPHQWVKDYHEHHQXVHGIRU,&3:HKDYHQRW
FROOHFWHG LQIRUPDWLRQDERXW WKHPHGLFDWLRQIRU,&3DPRQJRXUVWXG\
SRSXODWLRQDQGFRQVHTXHQWO\WKHUROHRIPHGLFDWLRQUHJDUGLQJWKHULVN
IRUFDQFHUFDQQRWEHHYDOXDWHG
$UHFHQW6ZHGLVK VWXG\GLGQRWٽQGDQ\FOHDUDVVRFLDWLRQEHWZHHQ
RYHUDOOFDQFHUDQG,&3>@ZKLFKLVLQDJUHHPHQWZLWKRXUٽQGLQJV
,Q WKH VDPH VWXG\ DQ LQFUHDVHG ULVN IRU ODWHU KHSDWRELOLDU\ FDQFHU LQ
ZRPHQ ZLWK ,&3 ZDV IRXQG OLYHU FDQFHU +5  DQG ELOLDU\ WUHH
FDQFHU +5  ,Q WKH DIRUHPHQWLRQHG VWXG\ WKH RFFXUUHQFH RI
KHSDWRELOLDU\FDQFHUVZDVVPDOOLQWKH,&3JURXS͡%DVHGRQ
WKHDERYHVWXG\WKHH[SHFWDWLRQYDOXHWRٽQGDQ\KHSDWRELOLDU\FDQFHUV
LQ RXU VWXG\ZDV YHU\ VPDOO +RZHYHU RQH KHSDWRELOLDU\ FDQFHUZDV
IRXQGLQRXU,&3JURXSZKLFKH[FHHGVWKHH[SHFWDWLRQYDOXH
НHUHLVKLJKHUULVNRIKHSDWRELOLDU\GLVHDVHDQGSDUWLFXODUO\FKURQLF
KHSDWLWLV DPRQJ ZRPHQ ZLWK D KLVWRU\ RI ,&3 >@ НH ODWWHU
GLVHDVHFDXVHVOLYHUFLUUKRVLVDQGLVRіHQFRPSOLFDWHGE\KHSDWRFHOOXODU
FDQFHU>@ $OVR FKROHOLWKLDVLV DQG FKURQLF FKRODQJLWLV DUH DVVRFLDWHG
ZLWK ,&3 >@ DQG DUH DVVRFLDWHG ZLWK JDOOEODGGHU DQG
FKRODQJLRFHOOXODUFDQFHU>@
НH 6ZHGLVK UHJLVWU\ VWXG\ GLG QRW ٽQG DQ\ DVVRFLDWLRQ EHWZHHQ
EUHDVWFDQFHUDQG,&3+5,QRXUVWXG\PRWKHUVZLWK,&3KDGD
VOLJKWO\ KLJKHU ULVN IRU EUHDVW FDQFHU WKDQ WKH FRQWURO PRWKHUV 25
 DOWKRXJK WKH GLٶHUHQFH ZDV QRW VWDWLVWLFDOO\ VLJQLٽFDQW НH
RFFXUUHQFH RI EUHDVW FDQFHU ZDV ORZHU LQ WKH 6ZHGLVK SRSXODWLRQ
WKDQLQRXU)LQQLVKSRSXODWLRQ:RPHQVͤULVNIRUKDYLQJEUHDVW
FDQFHUEHIRUHWKHDJHRILVLQ)LQODQGDQGLQ6ZHGHQ>@
2XU ORQJHU IROORZXS WLPH DQG WKH \RXQJHU DJH RI PRWKHUV LQ WKH
6ZHGLVK VWXG\PLJKW H[SODLQ WKH GLٶHUHQFH1HYHUWKHOHVV WKH FRKRUW
VKRXOG EH IROORZHG HYHQ ORQJHU EHFDXVH QRZ WKH FRKRUW UHSUHVHQWV
WKRVHZKRKDGEHHQGLDJQRVHGZLWKFDQFHUDWDIDLUO\\RXQJDJH
3UHPDWXUH GHOLYHU\ JHVWDWLRQ ZHHNV  VHHPV WR LQFUHDVH WKH
PRWKHU Vͤ ULVN IRUEUHDVWFDQFHU ODWHU LQ OLIH >@)RUPHUO\ LWKDVEHHQ
IRXQG WKDW ,&3 LV DVVRFLDWHG ZLWK DQ HOHYDWHG ULVN IRU GHOLYHU\ LQ
JHVWDWLRQ ZHHNV XQGHU  >@ ,W FDQ EH FRQVLGHUHG WKDW SUHPDWXUH
GHOLYHU\PD\ LQFUHDVH WKH QXPEHU RI EUHDVW FDQFHU FDVHV DPRQJ ,&3
ZRPHQ
$TXHVWLRQQDLUHVWXG\REVHUYHGWKDWWKHZRPHQZLWK,&3UHSRUWHG
PRUHEUHDVWFDQFHUYVS >@,QRXUVWXG\EUHDVW
FDQFHUZDV IRXQG DPRQJ LQ WKH ,&3JURXS DQG DPRQJ LQ
WKH FRQWURO JURXS WKH FRKRUW EHLQJ WKH VDPH DV LQ WKH TXHVWLRQQDLUH
VWXG\ ,Q WKLV UHJLVWU\ VWXG\ KRZHYHU WKH GLٶHUHQFH EHWZHHQ WKH
JURXSVLVQRWVWDWLVWLFDOO\VLJQLٽFDQW
,&3 KDV IRXQG WR KDYH D PXOWLIDFWRULDO JHQHWLF EDVH ,W PD\ EH
VSHFXODWHG WKDW ,&3 LV RQH H[SUHVVLRQ RI D ODUJHU JURXS RI JHQHWLF
GLVHDVHV+RUPRQDOIDFWRUVPD\EHUHOHYDQWLQWKHSDWKRJHQHVLVRI,&3
DQG EUHDVW FDQFHU >@ ,W PD\ EH VSHFXODWHG ZKHWKHU WKH VDPH
KRUPRQDOIDFWRUVKDYHDQHٶHFWRQERWKGLVHDVHV
НLV LV WKH ٽUVW )LQQLVK UHJLVWU\ VWXG\ RQ WKH SRWHQWLDO DVVRFLDWLRQ
EHWZHHQ,&3DQGFDQFHU$FFRUGLQJWRWKHZULWHUVͤNQRZOHGJHWKHUHLV
RQO\ RQH UHJLVWU\ EDVHG VWXG\ LQYHVWLJDWLQJ WKH DVVRFLDWLRQ EHWZHHQ
,&3DQGFDQFHU >@ DQG WKHUHIRUH WKHٽQGLQJV LQ WKLV VWXG\PD\EH
FRQVLGHUHG XQLTXH +RZHYHU IRUPHU REVHUYDWLRQV UHJDUGLQJ WKH
DVVRFLDWLRQEHWZHHQ,&3DQGEUHDVWFDQFHU LQWKHTXHVWLRQQDLUHVWXG\
FRXOGQRWEHFRQٽUPHGE\WKLVUHJLVWU\EDVHGVWXG\$ODUJHUQXPEHU
RI ,&3 ZRPHQ DQG D ORQJHU IROORZXS WLPH RI WKH FRKRUW PLJKW EH
QHHGHGWRFRQٽUPWKHUHVXOWV%DVHGRQWKLVVWXG\GRFWRUVGRQRWKDYH
WRFKDQJHWKHLUWUHDWLQJVWUDWHJLHVDQGVFUHHQFDQFHUVEHFDXVHDZRPDQ
KDVDKLVWRU\RI,&3
&LWDWLRQ +lPlOlLQHQ677XUXQHQ.0DWWLOD.-.RVXQHQ(6XPDQHQ0,QWUDKHSDWLF&KROHVWDVLVRI3UHJQDQF\DQG&DQFHU$&RKRUW
6WXG\)DP0HG0HG6FL5HVGRL
3DJHRI
)DP0HG0HG6FL5HVDQRSHQDFFHVVMRXUQDO
,661
9ROXPHͫ,VVXHͫ
$FNQRZOHGJPHQWV
НH&HQWUHIRU*HQHUDO3UDFWLFHRIWKH3LUNDQPDD+RVSLWDO'LVWULFW
IXQGHG WKH VWXG\ E\ VHWWOLQJ WKH GXHV IURP WKH1DWLRQDO ,QVWLWXWH IRU
+HDOWKDQG:HOIDUHLQ)LQODQGDQGWKH)LQQLVK&DQFHUUHJLVWU\:HDUH
JUDWHIXOWRWKH1DWLRQDO,QVWLWXWHIRU+HDOWKDQG:HOIDUHLQ)LQODQGDQG
WKH)LQQLVK&DQFHU5HJLVWU\IRUWKHLUFRQVHQWWRXVHWKHUHJLVWU\GDWD
&RQپLFWRI,QWHUHVW
НHDXWKRUVKDYHQRFRQپLFWVRILQWHUHVW
5HIHUHQFHV
 :LOOLDPVRQ & *HHQHV 9  ,QWUDKHSDWLF FKROHVWDVLV RI SUHJQDQF\
2EVWHW*\QHFRO
 *HHQHV 9 :LOOLDPVRQ &  ,QWUDKHSDWLF FKROHVWDVLV RI SUHJQDQF\
:RUOG-*DVWURHQWHURO
 /DDWLNDLQHQ77XOHQKHLPR$0DWHUQDOVHUXPELOHDFLGOHYHOVDQG
IHWDOGLVWUHVVLQFKROHVWDVLVRISUHJQDQF\,QW-*\QDHFRO2EVWHW
 :LNVWU¸P6KHPHU(0DUVFKDOO+8/XGYLJVVRQ-)6WHSKDQVVRQ2
,QWUDKHSDWLF FKROHVWDVLV RI SUHJQDQF\ DQG DVVRFLDWHG DGYHUVH SUHJQDQF\
DQGIHWDORXWFRPHVD\HDUSRSXODWLRQEDVHGFRKRUWVWXG\%-2*

 5H\HV+ 5HYLHZ ,QWUDKHSDWLF FKROHVWDVLV$SX]]OLQJGLVRUGHURI
SUHJQDQF\-*DVWURHQWHURO+HSDWRO
 5H\HV+6H[KRUPRQHVDQGELOHDFLGVLQLQWUDKHSDWLFFKROHVWDVLVRI
SUHJQDQF\+HSDWRORJ\
 6LPRQ )5 )RUWXQH - ,ZDKDVKL 0 *DUWXQJ & :RONRٶ $ HW DO
(WKLQ\O HVWUDGLRO FKROHVWDVLV LQYROYHV DOWHUDWLRQV LQ H[SUHVVLRQ RI OLYHU
VLQXVRLGDOWUDQVSRUWHUV$P-3K\VLRO*
 $EX+D\\HK 6 3DSDFOHRYRXORX * /RYJUHQ6DQGEORP $ 7DKLU 0
2GXZROH2 HW DO  ,QWUDKHSDWLF FKROHVWDVLV RI SUHJQDQF\ OHYHOV RI
VXOIDWHGSURJHVWHURQHPHWDEROLWHVLQKLELWIDUQHVRLG;UHFHSWRUUHVXOWLQJLQ
DFKROHVWDWLFSKHQRW\SH+HSDWRORJ\
 'L[RQ 3+ :LOOLDPVRQ &  НH SDWKRSK\VLRORJ\ RI LQWUDKHSDWLF
FKROHVWDVLVRISUHJQDQF\&OLQ5HV+HSDWRO*DVWURHQWHURO
 3DQ& 3HUXPDOVZDPL 39  3UHJQDQF\UHODWHG OLYHU GLVHDVHV &OLQ
/LYHU'LV
 3RXSRQ5,QWUDKHSDWLFFKROHVWDVLVRISUHJQDQF\ IURPEHGVLGH WR
EHQFKWREHGVLGH/LYHU,QW
 7XUXQHQ . +HODQGHU . 0DWWLOD .- 6XPDQHQ 0  ,QWUDKHSDWLF
FKROHVWDVLVRISUHJQDQF\LVFRPPRQDPRQJSDWLHQWV
ٽUVWGHJUHHUHODWLYHV
$FWD2EVWHW*\QHFRO6FDQG
 (ORUDQWD 0/ +HLQRQHQ 6 0RQRQHQ 7 6DDULNRVNL 6  5LVN RI
REVWHWULFFKROHVWDVLVLQVLVWHUVRILQGH[SDWLHQWV&OLQ*HQHW
 7XUXQHQ . 6XPDQHQ 0 +DXNLODKWL 5/ .LUNLQHQ 3 0DWWLOD . 
*RRGSUHJQDQF\RXWFRPHGHVSLWH LQWUDKHSDWLFFKROHVWDVLV6FDQG-3ULP
+HDOWK&DUH
 <DJHU-''DYLGVRQ1((VWURJHQFDUFLQRJHQHVLV LQEUHDVWFDQFHU
1(QJO-0HG
 6KDUPD-%6KDUPD68VKD%5*XSWD$.XPDU6HWDO$FURVV
VHFWLRQDO VWXG\ RI WXPRU PDUNHUV GXULQJ QRUPDO DQG KLJKULVN
SUHJQDQFLHV,QW-*\QDHFRO2EVWHW
 :LNVWU¸P 6KHPHU ($ 6WHSKDQVVRQ 2 НXUHVVRQ 0 НRUVHOO 0
/XGYLJVVRQ -) HW DO  ,QWUDKHSDWLF FKROHVWDVLV RI SUHJQDQF\ DQG
FDQFHU LPPXQHPHGLDWHG DQG FDUGLRYDVFXODU GLVHDVHV $ SRSXODWLRQ
EDVHGFRKRUWVWXG\-+HSDWRO
 0¸OV¦ $ 7XUXQHQ . 0DWWLOD .- 6XPDQHQ 0  8QQHFHVVDU\
FRQIXVLRQ DERXW IDPLO\ SODQQLQJ DіHU LQWUDKHSDWLF FKROHVWDVLV RI
SUHJQDQF\&RQWUDFHSWLRQ
 6LJXUGVVRQ -$  НH *3
V UROH LQ PDWHUQLW\ FDUH 6FDQG - 3ULP
+HDOWK&DUH
 /DHV(*LVVOHU0+HDOWK LQ)LQODQG+HDOWKRISUHJQDQWZRPHQ
0LQLVWU\RI6RFLDO$ٶDLUVDQG+HDOWK)LQODQG
 'XRGHFLP  (YLGHQFHEDVHG PHGLFLQH JXLGHOLQHV &KROHVWDVLV RI
SUHJQDQF\KHSDWRVLV
 7XUXQHQ.0¸OV¦$+HODQGHU.6XPDQHQ00DWWLOD.-+HDOWK
KLVWRU\ DіHU LQWUDKHSDWLF FKROHVWDVLV RI SUHJQDQF\$FWD2EVWHW*\QHFRO
6FDQG
 )LQQLVK &DQFHU 5HJLVWU\ KWWSZZZFDQFHUٽV\RSDUHNLVWHULHQ
UHJLVWUDWLRQ5HIHUUHG
 7HSSR/3XNNDOD(/HKWRQHQ0'DWDTXDOLW\DQGTXDOLW\FRQWURO
RIDSRSXODWLRQEDVHGFDQFHUUHJLVWU\([SHULHQFHLQ)LQODQG$FWD2QFRO

 :RUOG +HDOWK 2UJDQL]DWLRQ  KWWSZZZZKRLQW
FODVVLٽFDWLRQVLFGDGDSWDWLRQVRQFRORJ\HQ5HIHUUHG
 0DUVFKDOO+8:LNVWU¸P6KHPHU(/XGYLJVVRQ-)6WHSKDQVVRQ2
,QWUDKHSDWLF FKROHVWDVLV RI SUHJQDQF\ DQG DVVRFLDWHG KHSDWRELOLDU\
GLVHDVHDSRSXODWLRQEDVHGFRKRUWVWXG\+HSDWRORJ\
 5RSSRQHQ $ 6XQG 5 5LLNRQHQ 6 <OLNRUNDOD 2 $LWWRP¦NL . 
,QWUDKHSDWLFFKROHVWDVLVRISUHJQDQF\DVDQ LQGLFDWRURI OLYHUDQGELOLDU\
GLVHDVHV$SRSXODWLRQEDVHGVWXG\+HSDWRORJ\
 (QJKROP* )HUOD\ - &KULVWHQVHQ 1 .HMV $ +HUW]XP/DUVHQ 5 HW DO
125'&$1&DQFHU,QFLGHQFH0RUWDOLW\3UHYDOHQFHDQG6XUYLYDO
LQ WKH1RUGLF&RXQWULHV9HUVLRQ$VVRFLDWLRQRI WKH1RUGLF&DQFHU
5HJLVWULHV'DQLVK&DQFHU6RFLHW\
 +VLHK&&:XX - /DPEH07ULFKRSRXORV'$GDPL+2 HW DO 
'HOLYHU\RISUHPDWXUHQHZERUQVDQGPDWHUQDOEUHDVWFDQFHUULVN/DQFHW


&LWDWLRQ +lPlOlLQHQ677XUXQHQ.0DWWLOD.-.RVXQHQ(6XPDQHQ0,QWUDKHSDWLF&KROHVWDVLVRI3UHJQDQF\DQG&DQFHU$&RKRUW
6WXG\)DP0HG0HG6FL5HVGRL
3DJHRI
)DP0HG0HG6FL5HVDQRSHQDFFHVVMRXUQDO
,661
9ROXPHͫ,VVXHͫ
38%/,&$7,21
,9
/RQJWHUPVXUYLYDODIWHULQWUDKHSDWLFFKROHVWDVLVRISUHJQDQF\$IROORZXS
RIPRWKHUV
+lPlOlLQHQ677XUXQHQ.0DWWLOD.-.RVXQHQ(6XPDQHQ0
(-2*
3XEOLFDWLRQUHSULQWHGZLWKWKHSHUPLVVLRQRIWKHFRS\ULJKWKROGHUV

 







Full length article
Long-term survival after intrahepatic cholestasis of pregnancy:
A follow-up of 571 mothers
Suvi-Tuulia Hämäläinena,b,c,d,*, Kaisa Turunena, Kari J. Mattilaa, Elise Kosunena,c,d,
Markku Sumanena
aDepartment of General Practice, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland
b Janakkala Health Centre, Tapailanpiha 13 B, 14200 Turenki, Finland
c Science Center, Tampere University Hospital, 33521 Tampere, Finland
dCentre for General Practice, Pirkanmaa Hospital District, 33521 Tampere, Finland
A R T I C L E I N F O
Article history:
Received 7 April 2019
Accepted 11 June 2019
Available online xxx
Keywords:
Intrahepatic cholestasis of pregnancy
Death
Mortality
Survival
Women’s health issues
A B S T R A C T
Objective: Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder during
pregnancy. ICP has been associated with morbidity but little is known about women’s long-term survival.
Our aim was to determine whether ICP is associated with mothers’ long-term survival.
Study design: The study population comprised 571 women with ICP in at least one pregnancy seen at
Tampere University Hospital in Finland between 1969‒1988. The reference group comprised 1333
women: the previous and the following participant in the maternity ward diary. The data were obtained
from Statistics Finland in March 2017 containing deaths among the study participants between
1971‒2015. The follow-up time of the cohort was 27–46 years. The Kaplan-Meier method was used.
Results: Totally, 39 of the mothers with ICP (6.8%) and 111 of the reference group (8.3%) had died by the
end of 2015 (p = 0.267). The mean survival time of ICP women was 77.4 years and of the reference group
79.2 years (p = 0.288). The mean survival time from labour in the ICP group was 45.0 years and in the
reference group 44.8 years (p = 0.259).
Conclusions: Based on this study ICP does not seem to be associated with women’s survival. There is no
need to follow-up ICP mothers' health because of the nonexistent risk of premature death.
© 2019 Published by Elsevier B.V.
Introduction
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-
speciﬁc liver condition which occurs most often in the late second
or third trimester. The incidence is estimated to be between 0.2%
and 2% and it varies geographically [1,2]. The disease is more
common in South Asia, South America and Scandinavia. The
diagnosis requires the key symptom pruritus and a rise in serum
bile acids and transaminases [1]. During pregnancy the impor-
tance of ICP is related to its effects on the fetus [3]. Fetal
complications such as prematurity, fetal distress and stillbirth are
associated with ICP [4,5]. Within 48 h of delivery the mother’s ICP
symptoms usually resolve, and biochemical abnormalities resolve
within 2–8 weeks [6].
Genes, hormonal and environmental factors have an effect on
the pathogenesis of intrahepatic cholestasis of pregnancy. Several
gene mutations have an impact on its pathogenesis [7–14]. Family
clustering, the presence of ethnic and geographic variations, and
mutations in gene coding for hepatobiliary transport proteins refer
to genetic predisposition of ICP [1,2]. Progesterone and estrogen
seem to have an effect on the disease, and ICP patients have an
altered steroidogenesis [15]. Selenium deﬁciency and time of year
may be involved in ICP’s pathogenesis [16–18].
Recently, there has been growing interest in comorbidity
associated with intrahepatic cholestasis of pregnancy. Increased
risk for hepatobiliary diseases and cancers, some autoimmune
diseases, and cardiovascular diseases have been found [19–21].
Women who have experienced ICP seem to have more gestational
diabetes and pre-eclampsia than controls [22,23]. The disease
seems to be linked to hepatitis C infection [20,24–26]. ICP women
was found to have a higher HCV viral load [26].
Little attention has been paid to ICP women’s survival. The
condition being the most common pregnancy related liver disease,
it is important to know about ICP’s association regarding survival
and public health. According to the writers’ knowledge, ICP
mothers’ survival over such a long follow-up time has not been
studied prior to this study. As ICP is associated with speciﬁc genetic
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proﬁle and morbidity, the aim of this study was to determine
whether there is an association between ICP and survival.
Material and methods
The study population comprised all ICP pregnancies at
Tampere University Hospital, Finland, between 1969 and 1988.
Patients with ICP were identiﬁed in the hospital discharge
register using diagnosis codes. From 1969 to 1986, ICD-8 was used
at Tampere University Hospital. Because ICD-8 did not include a
precise code for ICP, we checked all the obstetric codes that might
contain ICP: 637.9 Toxicosis NUD, 639.00 Pruritus, 639.01 Icterus
gravis, 639.09 Necrosis acuta et subacuta hepatis, and 639.98
Aliae deﬁnitae. Thereafter, we checked the written diagnosis
behind the code, and if it referred to ICP, we included the case for
further selection. ICD-9 was used between 1987 and 1988, and it
contained the appropriate codes 6467A Hepatosis gravidarum
and 6467X Hepatopathia alia. The diagnosis was veriﬁed from
each patient record with the presence of the main symptom of
itching and abnormal laboratory test results. At least one of the
following was required: ASAT > 35 U/l, ALAT > 40 U/l, or bile acids
6 mmol/l or more. The study population comprised 687 ICP
deliveries [27]. The diagnosis of ICP was made in the special
health care of University Hospital.
The study population included some women with repeated ICP
deliveries, and each of these women was studied as an individual
case. The ICP group thus contained 575 women. The reference
group consisted of two women for each ICP delivery; the previous
and the next women in the maternity ward diary. It was veriﬁed
from the patient records that the women in the reference group
were not diagnosed with ICP. Altogether, the reference group
consisted of 1374 women. Four women were ruled out from the ICP
cases because of a missing personal identity code, as were 41
women from the reference group. The ﬁnal cohort comprised 571
women with ICP and 1333 women as a reference. Totally ﬁve
hepatitis cases were diagnosed among the cohort until 2013, and
two of them were hepatitis-C.
We collected the cohort’s dates of death from Statistics Finland.
The data contain all deaths to 2015. The follow-up time of the
cohort was 27–46 years. The data were analysed using SPSS for
Windows, version 22.0. The results were analysed with the
Kaplan-Meier method.
The patients' consent was not required for this registry study.
The study was approved by the Regional Ethics Committee of
Tampere University Hospital (R02149) and the National Institute
for Health and Welfare in Finland (THL/1051/5.05.00/2014).
Results
Totally, 39 of the mothers with ICP (6.8%) and 111 of the
reference group (8.3%) had died by the end of 2015 (p = 0.267).
There were no differences between the groups regarding age at
labour, at death and age of those who were living at the end of 2015
(Table 1).
The mean survival time from birth among ICP women was 77.4
years and among reference group 79.2 years, p-value being 0.288
(Fig. 1). The mean survival time after labour in the ICP group was
45.0 years and in the reference group 44.8 years, p-value being
0.259 (Fig. 2).
Discussion
Statistically signiﬁcant differences were not found in the
survival between the ICP and the reference groups.
The cohort includes all ICP cases detected in Tampere
University Hospital during 1969–1988. Practically 100 percent
of the deaths can be found in the data of Statistics Finland [28].
The strength of our study is the long follow-up time, 27–46 years
after delivery.
A weakness of the study is that it presents deaths at
relatively early ages. Even a longer follow-up time is needed to
examine whether ICP is associated with differences in survival
among those who die older. The levels of bile acids and/or
transaminases used for diagnosis of ICP were somewhat lower
than more recent criteria and this can be regarded as a
weakness of the study. The lack of knowledge of potential
confounding factors such as body mass index can be considered
weakness of the study.
Previously ICP has been associated with age over 35 years [29].
However, such an association was not found among this cohort.
Thus, the cohort can be considered comparable with reference
group regarding age. According to a questionnaire study with an
excellent response rate, the groups were comparable regarding
body mass index and education level [30]. In the cohort, ICP
women seem to have had fewer deliveries compared to the
reference group [31].
Within the same cohort, a questionnaire study showed that
smoking was less common among the ICP patients than in the
reference group [32]. No differences regarding recent alcohol
consumption or physical activity were found. Within the same
cohort, the women with a history of ICP reported less high
cholesterol and high blood pressure requiring medication [30].
However, aforementioned diseases and health behaviour had no
effect on survival.
Comorbidity has been recognized to be associated with ICP.
In the questionnaire study made within the same cohort, ICP
women reported more hypothyroidism and hepatobiliary
diseases [30]. Hepatobiliary diseases have shown to be
associated with ICP in registry-based studies [19,20]. Addi-
tionally, a registry-based study linked hypothyroidism and
some other autoimmune diseases to ICP and found also an
increased risk for cardiovascular diseases among ICP women
[21]. Moreover, gestational diabetes and pre-eclampsia have
been associated with ICP [22,23].
The association between intrahepatic cholestasis of pregnancy
and cancers has been studied. The questionnaire study suggested
an association between ICP and breast cancer [30]. In later registry-
based studies, the linkage was not found [21,33]. Instead, a
connection between ICP and hepatobiliary cancer has been found
[21]. As a summary, ICP increases the woman’s risk for certain
diseases. Although ICP is associated with certain comorbidity, the
survival seems to be similar compared to controls.
Table 1
Median ages and age ranges of the cohort at labour, at death, and those still living at the end of 2015.
Mothers with ICP Reference group
n median age age range n median age age range
At labour 571 27.6 16.9 – 41.1 1333 27.1 15.0 – 46.4
At death 39 56.7 34.1 – 78.5 111 55.9 28.1 – 83.8
Living at the end of 2015 532 63.7 48.0 – 80.8 1222 63.3 46.3 – 85.0
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Hepatitis C has been associated with increased risk of
occurrence of coronary atherosclerosis [34]. Although hepatitis
C has been associated with ICP [20,24,25], in our cohort there were
no differences in the hepatitis C incidence between ICP women and
the reference group. Thus, in our cohort hepatitis C comorbidity
does not have an effect on survival.
ICP is associated with a certain genetic proﬁle [1,2]. The same
proﬁle may have an inﬂuence on the survival among ICP patients.
Indeed, ICP itself might not have an effect on the survival but this
speciﬁc genetic proﬁle might have. This research brings a new
insight for long-term aspects of ICP as studying survival over such a
long follow-up time.
During the follow-up time no statistically signiﬁcant differ-
ences in the survival between the ICP and the reference group were
found. Based on this study ICP does not seem to be associated with
women’s survival in middle or younger age. This ﬁnding is relieving
for women with a history of ICP as it is not associated with their life
expectation. In addition, there is no need for the health care system
to follow-up ICP mothers' health because of the nonexistent risk of
premature death.
Fig. 1. Survival in the ICP and the control groups regarding age. The censored line indicates the subjects who are alive at the end of the follow-up time.
Fig. 2. Survival in the ICP and the control groups regarding years after labour. The censored line indicates the subjects who are alive at the end of the follow-up time.
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Intrahepatic cholestasis of pregnancy and
associated causes of death: a cohort study
with follow-up of 27–46 years
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Abstract
Background: The aim of this study was to determine whether intrahepatic cholestasis of pregnancy (ICP) is
associated with causes of death during on average 35 years follow-up after the delivery.
Methods: The study population comprised 571 women with ICP in at least one pregnancy seen at Tampere University
Hospital, Finland, between 1969 and 1988. ICP was verified from patient records. The previous and following subjects in
the maternity ward diary were taken as controls for each ICP case. In total, there were 1333 controls. All underlying
causes of death were obtained from Statistics Finland in March 2017. The deaths occurred during 1971–2015 and the
causes of death were classified according to ICD-10.
Results: Altogether, 39 of the mothers with ICP (6.8%) and 111 of the controls (8.3%) had died by the end of 2015
(p = 0.267). There were more underlying causes of death from gastrointestinal diseases (15%) in the ICP group than in
the control group (4%) (p = 0.011). The number of underlying causes of death due to diseases of the circulatory system
were lower in the ICP group (13%) than in the control group (26%), although the finding was not statistically significant
(p = 0.088). Moreover, neoplasms were the underlying cause of death in 46% of cases among mothers with ICP and in
41% of cases among the controls (p = 0.609). Diseases of the other organ systems were rare in both groups.
Conclusion: Women with a history of ICP do not have an increased overall mortality. However, deaths from
gastrointestinal diseases are overrepresented among women with a history of ICP.
Keywords: Intrahepatic cholestasis of pregnancy, Causes of death, Mortality
Background
Intrahepatic cholestasis of pregnancy (ICP) is a revers-
ible liver dysfunction during pregnancy. It is character-
ized by otherwise unexplained pruritus, especially on the
palms of the hands, soles of the feet, and the abdomen.
The diagnosis also requires a rise in serum bile acids
and transaminases [1]. ICP is associated with perinatal
complications, for example meconium staining of the
amniotic fluid, stillbirth and preterm delivery [2, 3].
Ursodeoxycholic acid is the primary treatment used for
ICP [4]. The mother’s ICP symptoms usually resolve
within 48 h of delivery and biochemical abnormalities
resolve within 2–8 weeks [5].
Mutations of several genes may influence the patho-
genesis of ICP [6–13]. In addition, hormonal factors, es-
pecially estrogen and progesterone, may be involved in
the pathogenesis of ICP [14]. Genetic predisposition to
ICP is revealed by family clustering, the presence of
ethnic and geographic variations, and mutations in gene
coding for hepatobiliary transport proteins [1, 14].
Intrahepatic cholestasis has been associated with hepato-
biliary cancers, some autoimmune diseases, and cardio-
vascular diseases [15]. Also increased risk for gestational
diabetes and pre-eclampsia has been reported among
women with a history of ICP [16, 17].
To examine factors influencing causes of death, a long
follow-up is required. Due to the genetic background
and higher occurrence of some diseases, the objective
was to determine whether ICP is associated with causes
of death during on average 35 years follow-up after the
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delivery. To the authors’ knowledge, this is the first
study to investigate this association over such a long
follow-up time.
Methods
Data source and study population
The study population comprised all ICP pregnancies at
Tampere University Hospital (TUH) between 1969 and
1988. Patients with ICP were identified in the hospital
discharge register using diagnosis codes. From 1969 to
1986, ICD-8 was used at TUH. Because ICD-8 did not
include a precise code for ICP, we checked all the obstet-
ric codes that might contain ICP: 637.9 Toxicosis NUD,
639.00 Pruritus, 639.01 Icterus gravis, 639.09 Necrosis
acuta et subacuta hepatis, and 639.98 Aliae definitae.
Thereafter, we checked the written diagnosis behind the
code, and if it referred to ICP, we included the case for
further selection. ICD-9 was used between 1987 and
1988, and it contained the appropriate codes 6467A
Hepatosis gravidarum and 6467X Hepatopathia alia. The
diagnosis was verified from each patient record with the
presence of the main symptom of itching and abnormal
laboratory test results. At least one of the following was
required at that time at Tampere University Hospital:
ASAT > 35 U/l, ALAT > 40 U/l, or bile acids 6 μmol/l or
more. The study population comprised 687 ICP
deliveries.
The study population included some women with re-
peated ICP deliveries, and each of these women were
studied as an individual case. The ICP group thus con-
tained 575 women. Two controls for each ICP delivery
were taken; these controls were the previous and the
next subjects in the maternity ward diary. Altogether,
there were 1374 controls. The groups were comparable
regarding age, educational level, and body mass index
[18]. Four women were ruled out from the ICP cases
because of a missing personal identity code, as were 41
women from the controls. The final cohort comprised
571 women with ICP and 1333 controls. The groups
were comparable regarding the participants’ age at
labour, age at death, and age of those living at the end of
2015 (Table 1).
For the deceased in the cohort, we obtained the under-
lying causes of their death from 1971 to 2015 from Sta-
tistics Finland. The coverage of the underlying cause of
death statistics is practically 100% [19]. The follow-up
time of the cohort’s mothers was 27–46 years. The
causes of death were classified using ICD-10 [20], and
the older ICD-8 and ICD-9 codes were changed to the
corresponding ICD-10 codes.
Statistical analysis
The data were analysed using SPSS for Windows, ver-
sion 22.0. The results are presented as frequencies and
percentages. From cross tabulation, p-values were calcu-
lated using the Chi-squared test, and values of 0.05 or
lower were considered statistically significant. Binary
logistic regression analysis was performed to obtain odds
ratio (OR) and 95% confidence intervals (CI). The
dependent variable was “ICP or not”.
Results
Altogether, 39 of the mothers with ICP (6.8%) and 111
of the controls (8.3%) had died by the end of 2015 (p =
0.267). The underlying causes of death are presented in
Table 2. Each deceased has one underlying cause of
death.
The most common underlying causes of death were
neoplasms, 46% of cases among mothers with ICP and
in 41% of cases among the controls (p = 0.609). There
were no hepatobiliary neoplasms in the ICP group and
only one in the control group. Malignant neoplasms of
digestive system were the underlying causes of death in
28% (n = 5) of ICP women and in 26% (n = 12) of con-
trols (p = 0.890). In the ICP group the malignant neo-
plasms were colon (n = 2), small intestine (n = 1) and
stomach (n = 2) cancers. Respectively, malignant
neoplasms in the control group were pancreas (n = 3),
ampulla of Vater (n = 1), colon (n = 6) and stomach
(n = 2) cancers.
Diseases of the circulatory system were the underlying
cause of death in 13% of cases among mothers with ICP
and in 26% of cases among the controls (p = 0.088). Dis-
eases of the circulatory system were the second common
underlying cause of death among the controls.
Diseases of the digestive system were more often the
underlying cause of death in the ICP group than in the
control group (15% vs. 4%, p = 0.011). The risk to have a
gastrointestinal cause of death was nearly 5-fold in ICP
group compared to controls (OR = 4.85, 95% CI 1.29–
18.18). Diseases of the digestive system were the second
common underlying cause of death among mothers with
Table 1 Median ages of patients at labour, at death, and those still living at the end of 2015
Mothers with ICP Controls
n age age range n age age range
At labour 571 27.6 16.9–41.1 1333 27.1 15.0–46.4
At death 39 56.7 34.1–78.5 111 55.9 28.1–83.8
Living at the end of 2015 532 63.7 48.0–80.8 1222 63.3 46.3–85.0
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ICP. Within gastrointestinal diseases, hepatobiliary
diseases were the underlying cause of death among 67%
(n = 4) of ICP mothers and 75% (n = 3) of controls (p =
0.778). Alcoholic liver diseases were found in four ICP
mothers and in two controls and cirrhosis of liver in one
control. Diseases of pancreas and alcohol-induced
chronic pancreatitis were the underlying causes of death
among two women with ICP. Gastro-oesophageal
laceration-haemorrhage syndrome was the underlying
cause of death in one control. In total, diseases of the
digestive system and malignant neoplasms of the di-
gestive system were the underlying causes of death in
28% (n = 11) of ICP women and 14% (n = 16) of
controls (p = 0.054).
Diseases of the other organ systems were rare in both
groups.
Discussion
The main finding was that women with a history of ICP
do not have an increased overall mortality. There were
more deaths from gastrointestinal diseases in the ICP
group than in the control group. Diseases of the circula-
tory system were twice as frequently the underlying
cause of death in the control group than in the ICP
group.
Strengths and limitations
The data in our study were relevant and the methods
were valid and reliable. One limitation of the study was
the small number of death cases. Nevertheless, the
follow-up time of this study was long, 27–46 years, com-
prising all ICP cases at TUH during the 1969–1988
period. A long follow-up time is required when investi-
gating the causes of death of mothers. Although the
follow-up time was long, the deaths represent those who
died relatively young. Life expectancy of Finnish women
at the age of 65 years was 21 years in 2014 [21]. The life
expectancy of ICP mothers (n = 532) living at the end of
the follow-up in 2015 is over 20 years. An extended
follow-up time would show whether causes of death are
the same for the mothers who die older.
A weakness of the study is that the levels of bile acids
and/or transaminases used for diagnosis of ICP were
somewhat lower than more recent criteria. There is a
possibility of existing liver disease at the time of ICP
diagnosis. However, the diagnosis of ICP requires exclu-
sion of other reasons and the diagnosis was made by an
obstetrician.
Comparison with existing literature
It seems that the mothers with ICP die of cardiovascular
diseases less frequently than expected and the controls
more frequently than expected. The number of deaths
from circulatory diseases seems to be lower in the ICP
group, even though ICP has been associated with circu-
latory diseases [15]. On the other hand, women with
ICP have reported less cardiac arrhythmia, high choles-
terol, and high blood pressure requiring medication [22].
In 2015, diseases of the circulatory system were the
underlying cause of nearly 38% of deaths among Finnish
women over 15 years old [23]. In our study, diseases of
the circulatory system were the underlying cause of
death among 26% of the controls. Our cohort represents
those who died younger, and the proportions of the
causes of death might change if the cohort would be
followed even longer. Although there were fewer deaths
due to diseases of the circulatory system in the ICP
group, it cannot be concluded that ICP protects from
diseases of the circulatory system. ICP has been
associated with gestational diabetes and pre-eclampsia
[16, 17]. Gestational diabetes increases risk of type 2
diabetes, hypertension and ischemic heart disease [24].
An increased risk in cardiovascular diseases have been
associated with pre-eclampsia [25]. Nevertheless, the
mortality to circulatory system diseases was not higher
in our study.
Despite the rather small number of deaths, statistically
significant differences were found. The findings may be
Table 2 Underlying causes of death among women with and without a history of ICP
Underlying cause of death
(ICD-10)
Mothers with ICP
n = 39
Controls
n = 111
Difference
n % n % % units p-value
Neoplasms (C00–D48) 18 46 46 41 5 0.609
Diseases of the digestive system (K00–K93) 6 15 4 4 11 0.011
External causes of morbidity and mortality, injury, poisoning
and certain consequences of external causes (V01–Y98, S00–T98)
5 13 17 15 -2 0.705
Diseases of the circulatory system (I00–I99) 5 13 29 26 −13 0.088
Endocrine, nutritional and metabolic diseases (E00–E90) 2 5 5 5 0 0.874
Diseases of the nervous system (G00–G99) 2 5 5 5 0 0.874
Diseases of the musculoskeletal system and connective tissue (M00–M99) 1 3 1 1 2 0.420
Diseases of the respiratory system (J00–J99) 0 0 4 4 −4 0.230
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considered clinically relevant. Increased risk of hepato-
biliary diseases has been reported among women who
experience ICP [15, 22, 26, 27]. The increased occur-
rence of hepatobiliary diseases may be reflected in the
increase of deaths from gastrointestinal diseases among
the ICP group.
Hepatobiliary neoplasms as underlying causes of death
were not detected in this study among ICP mothers.
Previously an association between ICP and liver cancer
and biliary tree cancer has been reported [15]. Neverthe-
less, the incidence of these cancers has been found to be
0.1% so that the expected number of these rare cancers
in our cohort is rather low. In this study, we did not
investigate the incidence of different cancers but the
underlying causes of death in the cohort.
Risk consumption of alcohol was not remarkably dif-
ferent among ICP mothers compared to controls in a
questionnaire study of the same cohort [28]. According
to a large Swedish study alcoholic cirrhosis was less
likely to be diagnosed with women with ICP compared
to controls [27]. Alcohol consumption might have an ef-
fect on the underlying causes of death, particularly on
hepatobiliary diseases. Women with a history of ICP
have an increased risk of liver fibrosis and cirrhosis
which might be caused by hepatitis C infection [24].
This finding may reflect on the increased risk of deaths
from gastrointestinal diseases in ICP women.
Many genetic mutations have been found to be associ-
ated with ICP [6–13]. Our hypothesis is that ICP is a
manifestation of a genetic background that exposes the
individual to certain diseases and causes of death.
Conclusion
Women with a history of ICP do not have an increased
overall mortality. However, gastrointestinal diseases are
overrepresented in the underlying causes of death
among women with a history of ICP. This is the first
study to examine the association between ICP and
underlying causes of death over such a long follow-up
time. An even longer follow-up time is required to
investigate further the association between ICP and
gastrointestinal causes of death. This would confirm
whether the phenomenon found in our study continues
among those who die older.
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Male Maternal Health Issues
Introduction
Men’s health is affected by genetic, environmental and 
exposure agents, and their health behavior. Factors during 
pregnancy and labor are associated with men’s health in 
adulthood (Curhan et al., 1996). Intrahepatic cholestasis 
of pregnancy (ICP) is a reversible liver disorder during 
pregnancy, where the bile flow is impaired (Lammert, 
Marschall, Glantz, & Matern, 2000). ICP usually mani-
fests in the third trimester of pregnancy and is character-
ized by mother’s pruritus, especially on the palms and 
soles and an increase in serum bile acid and transami-
nases (Reyes, 1997). The incidence of ICP varies geo-
graphically and is 0.1% to 1.5% in Europe, United States, 
Canada, and Australia (Geenes & Williamson, 2009). In 
Finland, the incidence is approximately 1.0% to 1.5% 
(Laatikainen & Tulenheimo, 1984).
The etiology of ICP remains unknown, but the disor-
der seems to be related to hormonal factors (Reyes, 1997, 
2008). It has been proposed that ICP may be inherited by 
the X-chromosome or is autosomal-linked, and a variety 
of genes influence its pathogenesis (Eloranta et al., 2003; 
Karlsen & Hov, 2010; Mullenbach et al., 2005; Noe et al., 
2005; Pauli-Magnus et al., 2004; Reyes, Ribalta, & 
Gonzalez-Ceron, 1976). Adenosine triphosphate binding 
cassette, subfamily B, member 4 (ABCB4/abcb4) gene is 
associated in up to 15% of the ICP cases. This gene, also 
known as multidrug resistant protein 3 (MDR3), encodes 
a transporter for phospholipids across the canalicular 
membrane of liver hepatocytes (Pan & Perumalswami, 
2011; Poupon, 2005). Environmental factors may also be 
involved (Lammert et al., 2000; Reyes, 2008).
ICP does not cause severe problems for a mother dur-
ing pregnancy, although itching can cause insomnia and 
use of medications (Geenes & Williamson, 2009). ICP 
increases the risk of stillbirth, fetal distress, and preterm 
delivery (Alsulyman, Ouzounian, Ames-Castro, & 
Goodwin, 1996; Glantz, Marschall, & Mattsson, 2004), 
although Apgar scores have been only slightly lower for 
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Abstract
Little is known about the effects of mother’s intrahepatic cholestasis of pregnancy (ICP) on the health of sons born to 
these mothers. The purpose of the present study was to explore the health of sons born to mothers with ICP. The 
study design was a retrospective study of ICP mothers’ sons. In the region of Tampere University Hospital in Finland, 
365 sons of mothers with ICP during 1969 to 1988 and 617 sons of mothers without ICP were sent a questionnaire 
in 2010. The response rates were 37.8% (n = 138) and 36.6% (n = 226), respectively. Only minor differences were 
reported between the two groups. Self-evaluated health was similar. There were no significant differences between 
the groups regarding symptoms and complaints, diagnosed diseases, mental health, and use of medicines. Cough was 
10.8 percentage points less common among ICP mothers’ sons than among controls (p = .034). Urticaria was more 
common among ICP mothers’ sons, the difference in percentage points being 2.2 (p = .026). In general, a mother’s 
ICP does not affect her son’s health.
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ICP mothers’ newborns (Turunen, Sumanen, Haukilahti, 
Kirkinen, & Mattila, 2010).
ICP appears to have some effects on the mothers’ 
long-term health. Women with ICP have been observed to 
more often have hypothyroidism and liver, biliary, and 
pancreatic diseases (Ropponen, Sund, Riikonen, 
Ylikorkala, & Aittomäki, 2006; Turunen, Mölsä, 
Helander, Sumanen, & Mattila, 2012). Likewise, more 
breast cancer is reported (Turunen et al., 2012). Epilepsy 
has been more frequent among the daughters of ICP 
mothers than among controls (Vimpeli, Turunen, 
Helander, Mattila, & Sumanen, 2013). The health of ICP 
mothers’ sons has not been studied previously.
In terms of clinical presentation, from the maternal 
viewpoint, the main consideration is intense pruritus, 
which may become so intolerable that delivery is consid-
ered as early as 35 to 37 weeks (Pathak, Sheibani, & Lee, 
2010). For the fetus, there is concern for meconium stain-
ing of the amniotic fluid, fetal respiratory distress, intra-
uterine fetal demise, and sudden death postnatally. Due to 
increased incidence of cardiac, adrenal, and neurologic 
disorders perinatally, one might expect an increased inci-
dence of diseases for men. In view of the genetic back-
ground and the fetal and obstetric risks associated with 
ICP, the present study sought to establish whether there is 
a connection between a mother’s ICP and her son’s health.
Material and Method
In autumn 2010, a postal survey was conducted among 
sons of women who had suffered from ICP. The cohort 
comprised 982 men, 365 of whom were sons of ICP 
mothers and 617 sons of control mothers. The diagnoses 
in the hospital discharge register that referred to ICP were 
verified. Criteria for ICP diagnosis were the main symp-
toms, itching and abnormal laboratory tests, and at least 
one of the following: aspartate aminotransferase >35 
U/L, alanine aminotransferase >40 U/L, or bile acids t6 
μmol/L. The mothers had been diagnosed with ICP dur-
ing pregnancy in the obstetric department of Tampere 
University Hospital during the period 1969 to 1988, and 
two control women were chosen for each, namely, the 
previous and following parturient in the maternity ward 
diary (Turunen et al., 2012). Once these criteria were ful-
filled, there were no more inclusion or exclusion criteria. 
Because this study only deals with men’s (not women’s) 
questionnaires, the cohort size is not fully 2:1.
Postal addresses were obtained from the Population 
Register Centre in Finland. Eight stillborns and 27 deceased 
sons were excluded together with 82 whose addresses were 
not found. Of ICP mothers’ sons 138 (37.8%) and of con-
trols’ 226 (36.6%) responded (Figure 1).
Men’s mean age was 30 years, the minimum being 
21 years and maximum 40 years. In categorizing the 
respondents’ age, 30 years was set as a cutoff point. 
Education was classified as “high” for those who had 
completed high school and “low” for those who had not. 
The respondents’ body mass index (BMI) was catego-
rized and 25 kg/m² was set as a cutoff point. With respect 
to age and BMI, the two groups were comparable. The 
groups were not comparable as to education. There were 
more in the higher education group among sons of ICP 
mothers (63.0%) than of controls (46.2%; p = .002; see 
Table 1).
The two groups received identical questionnaires. The 
questionnaire was composed of 39 items; the main 
aspects relevant to this study being present health, symp-
toms and complaints, diseases diagnosed by a doctor, use 
of medicines, and mental health. Smoking and alcohol 
usage were assessed.
The respondents were asked to evaluate their present 
health by choosing one of the following alternatives: 
good, fairly good, moderate, rather poor, and poor. 
There were questions concerning symptoms and com-
plaints during the past 12 months. Questions regarding 
diseases diagnosed by a doctor were asked, which 
focused on gastrointestinal, endocrine and metabolic, 
urinary tract, heart and circulatory system, respiratory 
diseases, musculoskeletal system, and connective tissue 
disorders. It was further asked if the respondent had 
been diagnosed with cancer, migraine, urticaria, epi-
lepsy, or some significant injury or disease. Respondents 
were also asked whether they had undergone any major 
surgery or had ever suffered hip, wrist, or vertebral 
fractures.
Cohort n = 1 099
ICP mothers’ sons n = 394 
control mothers’ sons n = 705 
Controls’ sons
n = 617
Respondents
n = 138
37.8%
Respondents
n = 226
36.6%
ICP mothers’ sons
n = 365
Questionnaires
n = 982
Excluded sons in 2010 
8 stillborn
27 deceased
82 missing address etc.
Figure 1. Flow chart of the survey population.
Note. ICP = intrahepatic cholestasis of pregnancy.
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Use of medicines, natural health drugs, and vitamins 
during the past year was assessed. Mental health was 
evaluated by two mental health-related questions and the 
Depression Scale. The questions concerned whether the 
respondent had suffered from a mental health disorder or 
had undergone treatment for a mental health disorder. 
The Depression Scale is a validated Finnish test screen-
ing for the risk of present clinical depression (Salokangas, 
Poutanen, & Stengård, 1995). Points in the Depression 
Scale differ from 0 to 30. If the result is 9 or more points, 
the probability of depression is clinically relevant and 12 
or more points refers to quite probably a depression 
diagnosis.
This study had the consent of the Ethics Committee of 
Pirkanmaa Hospital District (R02149). Responding to the 
questionnaire was regarded as consent to the survey and 
the subjects were not compensated for responding. 
Statistical analyses were made using the SPSS System for 
Windows, release 22.0. Results are presented as frequen-
cies and percentages. Statistical significance was tested 
by the chi-square test.
Results
The number of respondents was 365 in the group of ICP 
mothers’ sons and 617 in the group of controls’ sons. 
These were the base figures in percentage calculation. 
Table 2 presents symptoms and complaints during the 
past 12 months, Table 3 presents diagnosed diseases, and 
Table 4 presents medications used.
In general, there were only minor differences between 
the two groups. The two groups did not differ in respect 
to self-evaluated current health status. Of ICP mothers’ 
sons, 89.1% and of controls’ sons, 87.6% rated their 
health as good or fairly good.
The most common symptoms in both groups were 
backache, neck and shoulder pain, headache, and cough-
ing. Of ICP mothers’ sons, 26.8% and of controls’ sons, 
37.6% reported coughing during the past 12 months, the 
difference being 10.8 percentage points (p = .034). 
Otherwise, there were no significant differences between 
the groups with respect to other symptoms. Blushing, pal-
pitation, and neck and shoulder pain were more common 
among ICP mothers’ sons in percentage points. In turn, 
nervousness, recurring stomach problems, sweating, and 
cough were more common among controls’ sons. Only 
concerning coughing was there a statistically significant 
difference, although the difference concerning blushing 
was close to significant (p = .053; see Table 2).
Among sons of ICP mothers, 52.2% and 65.9% of 
controls had smoked at least once in their life-time (p = 
.021). Currently, 29.7% of the ICP mothers’ sons smoked 
and 41.6% of controls’ sons, the difference being statisti-
cally significant (p = .023). There were no significant dif-
ferences between the groups concerning smoking 
calculated in pack years. Of the ICP mother’s sons, 39.1% 
and 46.9% of controls’ sons smoked or had smoked regu-
larly (p = .147). There was no difference between the 
groups regarding use of alcohol, number of used alcohol 
doses, or whether the respondent had ever considered 
reducing alcohol consumption.
There were only minor differences between the groups 
in respect to diagnosed diseases (see Table 3). Acute hep-
atitis and cholelithiasis were 1.4 percentage points more 
common among ICP mothers’ sons (p = .07). Migraine 
was the most common disease among ICP mothers’ sons 
with a prevalence of 8.7%. Some significant injury 
(6.5%), rise in liver function test results (6.5%), asthma 
(5.1%), kidney or urinary tract infection (5.1%), and car-
diac arrhythmia (4.3%) were fairly common among ICP 
mothers’ sons. However, there were no significant differ-
ences between the groups.
Urticaria was the only disorder which was more com-
mon among ICP mothers’ sons. Altogether, 2.2% (n = 3) 
of ICP mothers’ sons and 0.0% (n = 0) of controls reported 
urticaria. The difference was statistically significant (p = 
Table 1. Characteristics of Sons of ICP Mothers and Controls.
ICP group, n = 134-138 
(%)
Controls, n = 218-226 
(%)
Difference in percentage 
points Difference (p value)
Age (years) .933
 <30 42.0 42.5 −0.5  
 t30 58.0 57.5 0.5  
Education .002
 Low 37.0 53.8 −17.0  
 High 63.0 46.2 17.0  
Body mass index .181
 BMI < 25.0 44.0 51.4 −7.4  
 BMI t 25.0 56.0 48.6 7.4  
Note. ICP = intrahepatic cholestasis of pregnancy; BMI = body mass index.
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.026). Diseases of the circulatory system were less com-
mon among ICP mothers’ sons, the findings not being 
statistically significant.
Of sons of ICP mothers, 12.3% and of controls, 12.4% 
had 9 or more points in the Depression Scale. ICP moth-
ers’ sons, 5.1% and controls’, 6.2% had more than 12 
points in the Depression Scale. Of the ICP mothers’ sons, 
17.4% and 18.1% of controls had suffered from some 
mental health disorder or had have treatment for it, the 
difference being not statistically significant. Wrist, back, 
or hip fractures were reported by 10.1% of sons of ICP 
mothers and 9.3% of controls, the difference not being 
statistically significant.
The most used medicines among sons of ICP mothers 
were painkillers (89.1%), vitamins or trace elements 
(62.3%), asthma and antiallergic medication (23.9%), as 
well as gastric acid inhibitors (23.2%; see Table 4). 
Slightly more commonly, sons of ICP mothers had used 
painkillers (2.4 percentage points) and sleeping pills (2.3 
percentage points) compared with sons of controls. A few 
more sons of controls had used dermatologic drugs (5.9 
percentage points) and natural health drugs (4.7 percent-
age points). However, the differences were not statisti-
cally significant.
Discussion
The two groups evinced only minor differences in most 
of the survey questions. The main findings were a lower 
frequency of cough during the past 12 months and ever-
smoking among ICP mothers’ sons and a higher incidence 
of urticaria among ICP mothers’ sons. A trend for 
increased blushing and heart palpitation complaints dur-
ing the prior 12 months was reported. Moreover, there 
was a trend for increased incidence of physician-diag-
nosed acute hepatitis or cholelithiasis, although this can-
not be regarded as clinically relevant.
The material received was relevant and sufficient for 
this kind of analysis. Postal addresses were found for 
most sons and response activity was fairly good; 37.8% 
of ICP mothers’ sons and 36.6% of controls’ sons 
responded. The response rates did not differ markedly 
between the groups. Data were collected by a question-
naire filled in at home. The respondents were fairly young 
and the response rate might have been higher if the ques-
tionnaire had also been available on the Internet.
The two groups were not comparable in respect of 
education levels. This may be linked to the observation 
that ICP mothers’ more often have only one child in their 
families (Mölsä, Turunen, Mattila, & Sumanen, 2012). It 
Table 2. Symptoms and Complaints During the Past 12 Months Among Sons of ICP Mothers and Controls.
Symptoms and complaints
ICP mothers’ sons, 
n = 138 (%)
Controls’ sons,  
n = 226 (%)
Difference in 
percentage points
Difference 
(p value)
Heart palpitation 14.5 8.4 6.1 .069
Blushing 10.1 4.9 5.2 .053
Neck and shoulder pain 37.7 33.6 4.1 .432
Dryness of eyes and mouth 13.0 10.2 2.8 .401
Insomnia 21.7 19.0 2.7 .531
Rheumatic pains 5.1 2.7 2.4 .228
Headache 31.9 29.6 2.3 .653
Urinary problems 5.8 3.5 2.3 .308
Nausea 7.2 6.2 1.0 .695
Foot and/or leg swelling 3.6 3.1 0.5 .785
Dyspnea 8.7 8.4 0.3 .924
Depression 13.0 12.8 0.2 .953
Dizziness 10.1 10.2 −0.1 .992
Chest pain 8.7 8.8 −0.1 .960
Itching of palms and soles 3.6 4.0 −0.4 .863
General itching of skin 14.5 17.3 −2.8 .488
Backache 38.4 42.0 −3.6 .494
Arthralgia, joint pain 14.5 19.0 −4.5 .267
Nervousness 15.2 20.8 −5.6 .185
Recurring stomach problems 9.4 15.0 −5.6 .121
Sweating 14.5 20.4 −5.9 .159
Coughing 26.8 37.6 −10.8 .034
Note. ICP = intrahepatic cholestasis of pregnancy.
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Table 3. Diseases Diagnosed by a Doctor Among Sons of ICP Mothers and Controls.
ICP mothers’ 
sons, n = 138 (%)
Controls’ sons, 
n = 226 (%)
Difference in 
percentage points
Difference 
(p value)
Diseases of the digestive system
 Acute hepatitis 1.4 0.0 1.4 .070
 Cholelithiasis 1.4 0.0 1.4 .070
 Colitis ulcerosa 1.4 0.4 1.0 .303
 Crohns’ disease 0.7 0.0 0.7 .200
 Chronic choledochitis 0.0 0.0 0.0 —
 Liver cirrhosis 0.0 0.0 0.0 —
 Chronic hepatitis 0.0 0.4 −0.4 .434
 Pancreatitis 0.0 0.4 −0.4 .434
 Rise in liver function test results 6.5 7.1 −0.6 .838
 Helicobacter pylori infection 0.0 0.9 −0.9 .268
 Fatty liver 0.7 1.8 −1.1 .406
 Gastric catarrh, gastric or duodenal ulcer 2.2 4.0 −1.8 .348
 Celiac disease 0.0 2.2 −2.2 .079
Endocrine and metabolic diseases
 Goiter 0.7 0.0 0.7 .200
 Hyperthyroidism 0.0 0.0 0.0 —
 Diabetes on medication 0.0 0.9 −0.9 .268
 Diabetes on diet therapy 0.0 0.9 −0.9 .268
 Hypothyroidism 0.0 1.3 −1.3 .174
Diseases of the respiratory system
 Bronchitis 2.2 0.4 1.8 .124
 Pulmonary tuberculosis 0.0 0.0 0.0 —
 Chronic obstructive pulmonary disease (COPD) 0.0 0.4 −0.4 .434
 Asthma 5.1 8.0 −2.9 .290
Diseases of the circulatory system
 High blood pressure on medication 2.2 5.3 −3.1 .144
 High cholesterol on medication 1.4 1.8 −0.4 .816
 Pulmonary embolus 0.0 0.4 −0.4 .434
 Cardiac failure 0.0 0.4 −0.4 .434
 Cardiac arrhythmia 4.3 5.3 −1.0 .681
 Myocardial infarction 0.0 0.0 0.0 —
 Angina pectoris 0.0 0.0 0.0 —
 Deep venous thrombosis 0.0 1.3 −1.3 .174
 Blood clot with inflammation in lower extremity 0.0 0.4 −0.4 .434
Urinary tract diseases
 Kidney or urinary tract infection 5.1 3.1 2.0 .342
 Kidney stones 0.0 0.0 0.0 —
 Renal failure or kidney failure 0.7 0.4 0.3 .724
Diseases of the musculoskeletal system and connective tissue
 Other chronic inflammatory joint disease than 
rheumatoid arthritis
2.9 2.2 0.7 .683
 Osteoporosis 0.0 0.0 0.0 —
 Osteoarthrosis 2.2 4.0 −1.8 .348
 Rheumatoid arthritis 0.0 0.4 −0.4 .434
Other diseases
 Some significant injury 6.5 10.6 −4.1 .186
 Urticaria 2.2 0.0 2.2 .026
 Anemia 2.9 1.8 1.1 .476
 Epilepsy 2.2 1.8 0.4 .785
 Cancer 0.0 1.3 −1.3 .174
 Migraine 8.7 10.6 −1.9 .551
Note. ICP = intrahepatic cholestasis of pregnancy.
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may be speculated that in families with one child parents 
encourage the child to aspire to a higher education. As the 
groups differed in education level, it may be concluded 
that the two might evince differences in lifestyle diseases, 
which might explain the difference in smoking and cough.
Although it has been presented that daughters of ICP 
mothers have a higher frequency of epilepsy (Vimpeli et 
al., 2013), this was not reported among the sons. The 
methodologies in the studies of the daughters and the 
sons were basically the same, and consequently the two 
studies and their results are comparable. Women with a 
history of ICP show higher frequencies of several liver, 
biliary and pancreatic diseases, breast cancer, and hypo-
thyroidism, but this was not the case among the sons. The 
sons being relatively young, not all diseases may have 
been detected. Nevertheless, hypothyroidism often 
emerges at a relatively young age, albeit more rarely 
among men than women.
The frequencies of the diseases noted in our cohort are 
quite similar to those in the average population in Finland. 
The prevalence of migraine among working-age men in 
Finland is 11% (Rantala, Sumanen, & Mattila, 2007). 
Previously, the cough symptom of chronic bronchitis has 
been reported by 12% (Aromaa & Koskinen, 2004) and 
asthma was reported in 8% of men in the Health 2011 
survey (Koskinen, Lundqvist, & Ristiluoma, 2012). In 
our study, the frequency of cough symptoms may have 
been higher due to respiratory diseases. Infectious respi-
ratory disease were reported by 22% of 30- to 44-year-old 
men in the Health 2000 survey (Aromaa & Koskinen, 
2004). In the Health 2000 survey, backache was reported 
during the previous month by an average of 30% of men 
of the same age as in this study. On average, 80% of men 
had had back pain at some time. In our study, back pain 
during the past year was assessed and the results can thus 
be considered congruent. A permanent injury or disability 
caused by an accident was reported by 13% to 18% of 
men under 55 years old (Aromaa & Koskinen, 2004). 
This rate was lower in our cohort. The rise in liver func-
tion tests may be caused by obesity, medication, and alco-
hol consumption. There was no significant difference 
between the groups in this context, although ICP mani-
fests as a rise in liver function tests.
Urticaria was more common among ICP mothers’ sons 
than controls. This finding can be considered clinically 
irrelevant as the frequencies were low. It may be specu-
lated that ICP mothers’ sons are conscious of their health 
and make appointments with a doctor more often as they 
have a higher education level.
ICP has a genetic background, and consequently it 
may be speculated whether the genome of the sons of ICP 
mothers is different from that of control mothers’ sons. 
The treatment of ICP mothers and the fetal outcome did 
not appear to be associated with sons’ health in the long 
term. The current study limitations were the young age of 
the men limiting detection of diseases that would occur 
with aging, small sample size, likelihood of recall bias, 
unclear on severity of ICP which likely affects the chances 
of long-term sequela, the trimester of clinical presenta-
tion, peak bile acid levels (percentage of mothers with 
levels greater than 40), presence of jaundice, average ges-
tation at delivery, percentage of men delivered before 37 
weeks, and presence of other perinatal complications 
since those are likely to affect long-term health.
To our knowledge, this is the first survey to explore 
whether a mother’s ICP has effects on her son’s health in 
the long term. The health of women with a history of ICP 
and their daughters’ health has previously been studied 
Table 4. Used Medications During the Past 12 Months Among Sons of ICP Mothers and Controls.
Medication
ICP mothers’ sons, 
n = 138 (%)
Controls’ sons, n = 226 
(%)
Difference in percentage 
points
Difference 
(p value)
Painkillers 89.1 86.7 2.4 .499
Sleeping pills 9.4 7.1 2.3 .424
Heart medication 1.4 0.4 1.0 .303
Vitamins or trace elements 62.3 61.5 0.8 .877
Sedatives 5.1 4.9 0.2 .930
Lipid lowering drugs 1.4 1.8 −0.4 .816
Gastric acid inhibitors 23.2 23.9 −0.7 .878
Asthma or antiallergic medication 23.9 25.7 −1.8 .708
Antidepressants 4.3 7.1 −2.8 .289
Antihypertensive medication 2.9 6.2 −3.3 .159
Eye drops 15.9 19.5 −3.6 .397
Natural health drugs 13.0 17.7 −4.7 .239
Dermatologic drugs 10.9 16.8 −5.9 .119
Note. ICP = intrahepatic cholestasis of pregnancy.
Hämäläinen et al. N77
(Turunen et al., 2012; Vimpeli et al., 2013). Based on our 
findings, a mother’s ICP does not affect her son’s health 
later in life, and mothers’ concerns may be relieved with 
this information.
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